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PART A 
 
ABSTRACT 
 
Cancer causes over eight million deaths per year, more than any other disease in the world, 
underlining the need for improved treatments. Recent years have provided the first breakthroughs 
of cancer immunotherapy. Cancer gene therapy with oncolytic adenoviruses is a potent form of 
immunotherapy, where targeted tumor-lytic viruses are used to direct patients’ own immune 
system against their cancer. With over 1,000 trials carried out and more than 5,000 cancer patients 
treated, cancer gene therapy is appearing safe and promising approach for solid tumors, 
highlighted by the first positive phase-III trial results in the Western countries in 2013. 
Nevertheless, numerous other oncolytic immunotherapy trials have failed due to low efficacy. The 
aim of this thesis is to improve efficacy while maintaining low toxicity by combining oncolytic 
immunotherapy with conventional treatment modalities, and to identify resistance mechanisms 
and biomarkers for oncolytic immunotherapy. 
 
Radiotherapy is widely used to treat solid tumors such as prostate and breast cancer, but large 
curative doses carry the risks for side-effects. Cancer cells can be sensitized to ionizing radiation by 
adenovirus replication per se, but the mechanisms remain unknown. Adenoviral proteins E1B55K, 
E4orf3 and E4orf6 might play a role in radiosensitation by targeting the Mre11-Rad50-NBS1 (MRN) 
protein complex, which is essential for DNA double-strand break repair. We showed in vitro that 
E4orf3 and E4orf6, but not E1B55K, expressing recombinant adenoviruses are effective 
radiosensitizers that enhance DNA damage accumulation and cell killing after radiotherapy. 
Moreover, the combination treatment significantly inhibited tumor growth in mice bearing 
prostate cancer xenografts. This intrinsic ability of adenoviruses to radiosensitize cells could be 
harnessed against cancer cells by selective targeting. Combination treatment with radiotherapy 
and oncolytic adenoviruses is therefore a promising way to increase efficacy, optimize the curative 
irradiation dose, and consequently reduce the harmful side-effects. 
 
Owing to the tremendous transforming capacity, advanced tumors can develop resistance to 
virtually any therapeutic modality. With regard to chemotherapy and targeted therapies, many 
resistance mechanisms have been identified, which has allowed development of countermeasures. 
For oncolytic adenoviruses, however, no such data is yet available. We established two ovarian 
cancer mouse models of acquired resistance, where initially sensitive tumors respond to the 
oncolytic virus but then relapse despite the presence of functional virus. Mouse models were 
utilized to study the phenomenon on gene expression, protein, and tissue levels. We identified 
interferon signaling upregulation in the tumors of acquired resistance by microarray. Pathway 
analyses suggested potential therapeutic targets in adenovirus-resistant cells, and myxovirus 
resistance protein A (MxA) was found a useful protein level indicator correlating with resistance to 
virus. Furthermore, transplantation studies suggested a role for tumor stroma in maintaining 
resistance. Improved understanding of the antiviral phenotype causing tumor recurrence is 
essential for developing countermeasures. Identified resistance pathways may be targeted for 
improving therapeutic efficacy, while the resistance marker MxA could serve as a clinical 
biomarker for oncolytic adenoviruses.  
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Combination of standard chemotherapy with oncolytic immunotherapy has the potential to 
increase antitumor efficacy in a synergistic manner. There is evidence that the cytopathic effect 
elicited by oncolytic adenoviruses is mediated via autophagy and is highly immunogenic. Similarly, 
certain chemotherapeutics and have been shown to induce immunogenic cell death, a prerequisite 
for antitumor T-cell responses, which is characterized by exposure of calreticulin on the cell 
surface, and release of adenosine triphosphate and a nuclear protein high-mobility group box 1 
(HMGB1). Meanwhile, low-dose chemotherapy with cyclophosphamide has been shown to inhibit 
the immunosuppressive regulatory T-cells. We demonstrated that oncolytic adenovirus together 
with an autophagy-inducing chemotherapeutic temozolomide and low-dose cyclophosphamide 
increased immunogenic cell death in vitro, and enhanced tumor growth inhibition that associated 
with increased autophagy in vivo. In the clinical part, combination therapy was found safe in 41 
treatments given to 17 cancer patients with refractory solid tumors, who were treated in the 
context of an advanced therapy access program (ATAP). Treatments were well-tolerated with 
mostly mild grade 1-2 clinical adverse reactions. Objective signs of possible efficacy and antitumor 
immune activations were observed: Disease stabilization or better was achieved in 67% of 
evaluable treatments, and post-treatment HMGB1 release seemed to correlate with antitumor T-
cell activity in blood. As an estimated effect on survival, combination-treated patients trended for 
increased overall survival over virus-only treated matched non-randomized control patients.  
 
With the emergence of effective immunotherapeutic modalities, biomarkers are urgently needed 
for identification of cancer patients likely to benefit. HMGB1 protein is emerging as a key player in 
immunomodulation and has been implicated prognostic for certain conventional therapies. We 
addressed the biomarker value of serum HMGB1 in a clinical-epidemiological cohort of 202 cancer 
patients with refractory solid tumors, who were treated with oncolytic adenoviruses in the ATAP. 
Patients with low HMGB1-baseline level (below median concentration) showed significantly 
improved overall survival and disease control rate as compared to high-baseline patients, while 
both patient groups showed good safety. Importantly, these observations held in multivariate 
models adjusted for confounding factors, indicating that low HMGB1-baseline status is an 
independent prognostic, and the best predictive factor for disease control. HMGB1-low patients 
seemed to benefit from immunogenic-transgene coding adenoviruses and antitumor T-cell activity 
in blood, suggesting an immune-mediated mechanism. We have thus identified a novel prognostic 
and predictive biomarker for oncolytic immunotherapy. Our results indicate that HMGB1-baseline 
may distinguish between immunologically responsive and suppressed cancer patients, and could 
help in selecting the right patients for oncolytic immunotherapy. 
 
Combination of oncolytic immunotherapy with conventional treatments has the potential to evoke 
durable responses and increase cure rates, particularly when based on basic scientific rationale. 
Our results provide evidence for combining oncolytic adenoviruses with radiotherapy, low-dose 
temozolomide and low-dose cyclophosphamide. In addition, we present novel insights into 
antiviral resistance mechanisms in vivo and biology underlying the combination treatments. 
Finally, we report safety, possible signs of efficacy, and immunological effects in altogether 238 
patient treatments, and introduce a promising prognostic and predictive biomarker for oncolytic 
immunotherapy. Hence, our results may prove useful when developing oncolytic adenovirus 
treatments, designing clinical trials, and selecting the right patients for each therapy. 
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TIIVISTELMÄ 
 
Syöpä nousi tilastoissa maailman yleisimmäksi kuolinsyyksi vuonna 2012, johtaen vuosittain 8.2 
miljoonan potilaan kuolemaan, huolimatta parantuneesta ennaltaehkäisystä, diagnostiikasta ja 
tavanomaisista hoidoista. Uusia hoitomuotoja tarvitaan etenkin levinneiden kasvainten hoitoon, 
joiden ennuste on usein heikko. Lupaava syövän immunoterapia tähtää potilaan hankinnaisen 
immuunijärjestelmän aktivoimiseen syöpäkasvaimia vastaan. Hyvin siedetyillä onkolyyttisillä 
adenoviruksilla voidaan tuhota kasvainsoluja selektiivisesti ja aikaansaada terapeuttisia 
immuunivasteita. Geneettisen manipuloinnin keinoin onkolyyttiset adenovirukset on muokattu 
tuhoamaan ja lisääntymään vain syöpäsoluissa, säästäen terveet solut – niiden turvallisuus on 
todettu jo lukuisissa kliinisissä kokeissa ympäri maailman. Väitöskirjatutkimukseni käsittelee 
onkolyyttisen immunoterapian yhdistämistä tavanomaisiin syöpähoitoihin, sädehoitoon ja 
solunsalpaajiin, joita vastaan kehittyvä kasvainresistenssi ja haittavaikutukset rajoittavat tehoa. 
Ensimmäisessä osajulkaisussa raportoimme kahden virusproteiinin herkistävän tehokkaasti 
eturauhassyöpää sädehoidolle estämällä DNA-korjausmekanismeja, sekä hidastavan 
tuumorikasvua hiirimallissa. Toisessa osajulkaisussa tutkimme onkolyyttisiä adenoviruksia vastaan 
kehittyvää kasvainresistenssiä, ja havaitsimme interferoni-vasteen yliaktivoituvan sekä 
identifioimme potentiaalisesti hyödyllisen markkeriproteiinin joka korreloi virus-resistenssin 
kanssa. Kolmas, translationaalinen tutkimus käsitteli onkolyyttisten adenovirusten ja matala-
annoksisen solunsalpaaja-hoidon, temotsolomidin ja syklofofamidin, yhteisvaikutuksia 
prekliinisesti eturauhassyövässä, sekä potilaiden levinneiden kasvainten kokeellisessa hoidossa. 
Prekliinisesti yhdistelmähoito oli synerginen teholtaan, lisäsi kuolevien syöpäsolujen autofagiaa 
sekä HMGB1-proteiinin vapautumista immunogeenisyyden merkkinä, ja hidasti tehokkaimmin 
tuumorikasvua hiirimallissa. 41 yhdistelmähoitoa annettuna 17 syöpäpotilaalle olivat hyvin 
siedettyjä, joskin gradus 1–2 flunssankaltaisia oireita ja pahoinvointia esiintyi yleisesti. 
Raportoimme viitteitä mahdollisista hoitovasteista kuvantamisessa ja tuumorimarkkereissa 
yhteensä 67%:lla arvioitavista potilaista. Lisäksi mittasimme HMGB1 proteiinin vapautumista 
vereen hoidon jälkeisesti, sekä samanaikaisia anti-tumoraalisia T-soluvasteita, sekä havaitsimme 
pitkittyneen elossaoloajan verrattuna ei-randomoituihin, virus-hoidettuhin kontrollipotilaisiin. 
Neljännessä tutkimuksessa syvennyimme havaintoomme seerumin HMGB1 proteiinin muutoksista 
virus-hoidetuissa potilaissa: Raportoimme onkolyyttisen adenovirushoidon terapeuttisen ja 
immunologisen vaikutuksen korostuvan 202 syöpäpotilaan aineistossa sillä osalla potilaista joiden 
veren HMGB1-taso oli alkutilanteessa matala. Raportoimme hoitojen olevan yhtä hyvin siedettyjä 
ja turvallisia molemmissa potilasryhmissä. Arvioimme matalan HMGB1-lähtötason ennustearvoa 
monimuuttuja-malleissa, ja osoitimme sen olevan itsenäinen prediktiivinen tekijä hoitovasteille 
kuvantamisessa, sekä prognostinen pidentyneelle elossaoloajalle verrattuna korkean lähtötason 
potilaisiin. HMGB1-matalat potilaat näyttivät hyötyvän erityisesti anti-tumoraalisten T-solujen 
aktivaatiosta, sekä hoidoista immuunijärjestelmää stimuloivilla adenoviruksista, viitaten 
biomarkkerin mekanismin olevan immuunivälitteinen. Tuloksemme osoittavat siten seerumin 
HMGB1-lähtötason olevan lupaava biomarkkeri onkolyyttiselle immunoterapialle. 
Väitöskirjatutkimuksemme tulokset edistävät onkolyyttisen immunoterapian tehon ja 
turvallisuuden parantamista erityisesti syövän yhdistelmähoidoissa, tarjoten perusteet kliinisiin 
jatkotutkimuksiin, ja esittelevät uusia biomarkkereita jotka voivat auttaa paremmin kohdentamaan 
immunoterapeuttiset hoitomuodot niistä hyötyville syöpäpotilaille. 
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PART B 
 
 
1. REVIEW OF THE LITERATURE 
 
1.1 Introduction 
 
Cancer remains the major cause of death worldwide and the incidence is rising. According to the 
World Health Organization (WHO) cancer statistics 2012 in Europe, the estimated risk of getting 
cancer before age 75 are 21.6% for women and 29.7% for men, while rates for cancer mortality 
before age 75, are 9.2% and 15.6% for women and men, respectively (Ferlay et al. 2014). 
Corresponding incidence numbers in Finland are 23.1% for women and 29.1% for men, while 
mortality rates are considerably lower at 7.6% and 10.7% for women and men, respectively. 
Figures are estimated in the absence of other causes of death. The mortality difference is partially 
explained by the fact that more curable cancer types, prostate and breast cancer, are more 
common in Finland (Figure 1), but it also reflects the socioeconomical advantages in Finland: 
functional health care system, resources for early diagnosis, effective cancer treatments that are 
based on the latest medical research, and continuously growing repertoire of treatment options.  
Worldwide, there were 14.1 million new cancer cases in 2012, and the incidence is expected to rise 
with over 20 million annual new cases expected by 2025 (Ferlay et al. 2014), all this despite the 
improvements in cancer prevention. For the first time in history, cancer now causes more deaths, 
altogether 8.2 million in 2012, than any other particular disease, bypassing even ischaemic heart 
disease, stroke, and infectious diseases (WHO Global Health Observatory Data Repository, 2012). 
Meanwhile, treatment of cancer has taken some major advances in the developed countries. 
Unfortunately this progress is yet largely unreachable by the low- and middle-income countries. As 
seen in Figure 1, three of the top cancer types in Finland, prostate, breast and colon cancer, are 
already mostly curable in majority of the cases. If comparing historically, this is very much owing to 
the progress in modern cancer research, since the 5-year survival rates of prostate and breast 
cancer in Finland in the 1960s were around 30% and 55%, respectively, after which both have 
increased to around 90% (Pukkala et al. 2011).  
 
Many medical advances account for this progress. Besides earlier cancer diagnosis allowing radical 
treatments at a less aggressive local stage, also conventional curative therapies have improved 
owing to novel surgical techniques, effective combinations of chemotherapeutic drugs, and 
targeted optimally fractionated radiotherapy. Nevertheless, yet disappointing outcomes are seen 
e.g. with regards to lung, pancreatic and ovarian cancer (Figure 1), and similarly, with advanced 
metastatic disease of any type. This represents the dilemma in oncology that deals with hundreds, 
if not thousands, of different genetic disorders of various origins, commonly referred to as 
“cancer”. Therefore, it is not expected that there is a magic bullet, a miracle cure for all cancer 
types, but instead novel modalities together with advances in conventional therapies are gradually 
increasing our tool box. Combinations of different tools can be then utilized to achieve more cures. 
Select tumor types, subtypes, or patients first seem to respond to certain (combinatorial) 
therapies, which are then taken forward into clinical trial testing in order to determine whether 
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the treatment increases survival rates as compared to standard therapy. Eventually, a new form of 
standard therapy may be assigned, which is then further developed, optimized and revised to 
improve cure rates and reduce possible adverse reactions. Gradually, along with the progress done 
in both basic and clinical cancer research, the emotionally and socially challenging historical 
concept of cancer as a lethal, life-stopping disease could change. To achieve this, however, much 
work remains to be done and novel treatment options are needed. 
 
 
 
 
 
Figure 1. Cancer incidence and mortality in Finland. A) Estimated age-standardized rates (ASR[W]) 
of cancer incidence (blue) and mortality (red) in Finland in 2012, including both genders. Rates 
represent the number of new cases or deaths per 100,000 persons per year, which are weighted 
for a standard age structure. Modified from: (Ferlay et al. 2014). B) Development of actual cancer 
incidence and mortality rates in Finland during 1953–2009. Modified from: (Pukkala et al. 2011). 
 
 
Biologically, cancer refers to a large group of genetic diseases, which may originate from virtually 
any cell type and organ in the body. All cancers arise as a result of numerous alterations occurring 
in the DNA sequence of cells. Consequently, some of the proteins encoded by these cells are 
differentially expressed or mutated, giving growth advantage and the ability to proliferate in 
defiance of physiological control. A localized, non-invasive tumor is called benign, whereas 
malignant tumor refers to a cancer which has acquired the capability to invade or disseminate 
from the site of primary tumor to other tissues. Metastases spawned by malignant tumors are the 
main cause of cancer-related deaths in humans (Mehlen and Puisieux 2006). 
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Oncolytic viruses are one promising treatment modality for cancer, which has recently gained 
attention as the first positive clinical phase III results in the Western countries were announced in 
2013 (Andtbacka et al. 2013). In addition, two oncolytic adenovirus products have already been 
approved and are in clinical use in China since 2003 and 2005 (Guo and Xin 2006). Oncolytic 
adenoviruses are genetically modified to target and replicate only in cancer cells, and thus 
represent a form of targeted cancer gene therapy. As adenoviruses are originally human 
pathogens, multiple host immune mechanisms, and also counteractive circuits in the virus, have 
emerged during evolution. Therefore, it is not surprising that besides replicating in and lysing the 
infected cancer cells, oncolytic adenoviruses also induce prominent immune reactions at the 
tumor site. Furthermore, oncolytic viruses can be genetically modified to express immune-
stimulating transgenes, which further boost immune responses, directed not only against the virus 
but also to the host tumor cells (Lichty et al. 2014). Hence, oncolytic virus field has naturally moved 
towards immunotherapy, aimed at stimulating patient’s own immune system against the mutated 
altered self, cancer, in order to achieve long-lasting antitumor responses. 
 
Nevertheless, as experimental virotherapy has been around since the mid-19th century, and only 
now the first approved cancer therapy applications are emerging, it is obvious that obstacles have 
been encountered. Oncolytic virotherapy is appearing safe approach with over 1,000 cancer gene 
therapy trials carried out and more than 5,000 cancer patients treated without treatment-related 
deaths or major limiting toxicity (Ginn et al. 2013). Challenges have lied in the lack of efficacy in 
clinical trials. This partially reflects the lack of optimal preclinical models to test efficacy, because 
human adenoviruses do not properly replicate in tissues of other species, forcing researchers to 
use xenogeneic animal models, i.e. human tumor xenografts in immunodeficient mice, which 
feature fundamental differences in tumor architecture and impaired immunity. Syrian hamsters 
have been proposed as a model to circumvent this limitation, but have been found only semi-
permissive for replication of human adenovirus (Thomas et al. 2006, Bramante et al. 2014) and 
represent largely uncharacterized immune system. Therefore, besides developing preclinical 
testing and more suitable models, reporting and learning from available clinical data is of 
particular importance.  
 
Both preclinical and clinical evidence suggests that efficacy can be improved, even synergistically, 
by combining oncolytic immunotherapy with conventional treatment modalities such as 
chemotherapy and radiotherapy. In preclinical part of this thesis we study combinatorial effects of 
oncolytic adenoviruses together with radiotherapy and certain chemotherapeutic drugs, and 
provide mechanistic rationale and show that improved antitumor efficacy can be achieved. In 
addition, we study the acquired resistance mechanisms against oncolytic adenovirus in ovarian 
tumors, and reveal relevant pathways, potential tumor marker and targets, which could be utilized 
in developing countermeasures. In the clinical part, we study altogether 238 patient treatments 
with oncolytic adenoviruses given in the context of an Advanced Therapy Access Program (ATAP) 
for patients with metastatic solid tumors progressing after conventional treatments. We 
demonstrate safety of the approach, and report objective signs of treatment efficacy and 
antitumor immune responses. In particular, we focus on patients treated, as first-in-humans, with 
an attractive combination of oncolytic immunotherapy and low-dose chemotherapy that was 
found synergistic and immunogenic preclinically. Finally, we report finding of a novel serum 
biomarker that is prognostic and tentatively predicts responsiveness to oncolytic immunotherapy 
with adenoviruses. Our findings set the stage for testing the combinations and biomarkers in 
clinical trials, which may ultimately have an impact on cancer therapy in practice. 
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1.2 Conventional cancer therapies 
 
Conventional treatments of malignant diseases traditionally consists of surgery, chemotherapy and 
radiotherapy, which are all based on established scientific evidence and have been proven 
effective in numerous clinical situations. Surgery became the cornerstone of treatment for solid 
tumors with the discovery of ether anesthesia, which was first used by William T. G. Morton in 
1846. Forty-six years later another William, bone surgeon William B. Coley, introduced a mixed 
bacterial vaccine called Coley’s toxin for treatment of cancer that became the first immunotherapy 
preparation (Nauts et al. 1946). However, with the discovery of x-rays and radiation therapy in 
1896, followed by addition of chemotherapy to the armament after the First World War, 
immunotherapy was long forgotten. Radiotherapy was found effective and resulted in immediate 
tumor reduction and pain relief, but the therapy responses remained often temporary and 
localized (Holsti 1995). The first cytotoxic chemotherapy agent was nitrogen mustard, adopted 
from its original use in chemical warfare (mustard gas), and applied for the treatment of e.g. 
lymphomas and leukemias in the 1940s (Goodman et al. 1984). Hormonal therapy was introduced 
for the treatment of prostatic cancer in 1941 (Crawford 2004). During the last twenty years, more 
targeted and less toxic treatments have been developed, including more tolerable 
chemotherapeutics, small-molecule inhibitors and monoclonal antibodies (e.g. angiogenesis and 
growth factor inhibitors) (Demarest et al. 2011, Hojjat-Farsangi 2014).  
 
1.2.1 Radiotherapy 
 
Modern radiation oncology has changed a lot from its original use of rough x-ray apparatuses in 
the beginning of the 20
th
 century. Radiotherapy today can be generally divided into two main 
categories: teletherapy, which involves an external source delivering radiation to patient, and a 
newer form of brachytherapy, in which radiation is delivered in direct contact or within the patient 
by using an implant or mold with radioactive sources. In addition, boron neutron capture therapy 
(BNCT) and proton therapy are used in modern radiation oncology. Advances in targeting 
techniques and fractionation have improved the use of traditional teletherapy (McGovern and 
Mahajan 2012). Various types of solid tumors in multitude of locations can now be treated with 
minimal radiation exposure of normal surrounding tissues by utilizing e.g. intensity modulated 
techniques, arc therapies with image-guidance, and stereotactic hypofractionation.  
 
Therapeutic effects of radiation are based on its ability to damage cellular components such as 
DNA or cell membranes, leading to cell death in high enough doses. An important aspect of 
radiotherapy is the radiosensitivity of tissues, which varies widely even within the tumor. 
Consequently, some tumor lesions are essentially radioresistant, while others may be curative by 
radiation. The molecular mechanisms underlying the differences in sensitivity and responsiveness 
to radiation are traditionally based on five main principles, termed as the 5Rs of radiobiology: 
repair, redistribution, repopulation, re-oxygenation, and radiosensitivity, which were in harmony 
with the original hallmarks of cancer (Harrington et al. 2007). First, sub-lethal damages in genomic 
DNA can be repaired more successfully in normal cells than in tumor cells between the treatment 
fractions. Second, cells are redistributed with regards to cell cycle, so that with fast-dividing cancer 
cells are more likely to be in the radiosensitive M-phase, late G1-phase or late G2-phase than 
normal cells. Third, repopulation of the irradiated necrotic tumor area seems to be slower than in 
healthy tissues, in part because cancer cells are susceptible to late radiation-induced death by 
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entering mitosis with unrepaired DNA damage (mitotic catastrophe). Fourth, tumors featuring 
neo-angiogenesis are effectively re-oxygenated, which potentiates the radiotherapy response via 
formation of oxygen radicals damaging DNA. The fifth R, the intrinsic radiosensitivity of cells, was 
later added because the previous 4Rs were insufficient in explaining some of the differences in 
responsiveness between certain tumors at mechanistic level.  
 
With regards to radiotherapeutic effects, direct damage on biological material accounts for ca. 
30% of the net effect, while the rest is mediated indirectly via formation of reactive oxygen species 
(ROS), such as free hydroxyl radicals, that cause lesions in cellular membranes, and 
macromolecules including DNA (Russi et al. 2014). Both of these are detrimental to cells: Ionizing 
radiation (and the generated ROS) causes hydrolysis of membrane phospholipids and fatty acids, 
which then act as second messengers to initiate apoptotic cascades, even in the absence of DNA-
damage signaling (Haimovitz-Friedman et al. 1994). The most prominent cell death signaling, 
however, occurs through DNA damage. Radiotherapy leads to single- and double-strand DNA 
breaks, of which single-strand breaks are rarely lethal (if two breaks occur at close proximity), 
whereas double-strand breaks (DSB) are harmful due to potential genomic rearrangements and 
require immediate repair. There are several mechanisms to detect and signal, and two 
mechanisms to repair DSBs: non-homologous end joining and homologous recombination 
(Kavanagh et al. 2013). In normal cells, initiated repair cascades strive for immediate cell cycle 
arrest in order to prevent the transfer of damaged genomic DNA to progeny cells. The MRN 
complex (Mre11, Rad50, and NBS1) is a key regulator in DSB sensing, signaling and repair (Carney 
et al. 1998, Williams et al. 2007, Gatei et al. 2014). Followed within minutes after induction of 
DSBs, nuclear MRN binds to the broken ends of DNA and recruits ataxia-telangiectasia mutated 
(ATM) and ATM-Rad3-related (ATR) proteins to initiate repair and signal transduction pathways 
(Figure 2). These signaling cascades that include multiple DNA repair and checkpoint proteins, such 
as Chk1, Chk2, and H2AX, eventually lead to G2/M or S-phase checkpoint induction and cell cycle 
arrest, during which DSB repair takes place (Carson et al. 2003). However, with vast enough 
radiation damage, DSBs cannot be repaired, cellular homeostasis is disrupted, and the cell is killed, 
indicating on a molecular level that cytotoxicity caused by ionizing radiation is dose-dependent 
after reaching a certain threshold level (Kavanagh et al. 2013). Radiotherapy induces several types 
of cell death mechanisms including apoptosis, autophagic cell death, mitotic catastrophe, and 
necrosis. In normal cells that are exposed to genomic DNA damage, p53 protein functions as the 
major gatekeeper in determining between growth arrest/DSB repair and cell death through 
classical apoptosis, whereas in cancer cells with mutated p53 (ca. 50% of all cancers), cell death 
usually occurs via other mechanisms (Golden et al. 2012). In fact, other forms of cell death may be 
more beneficial for overall therapeutic responses. 
 
Recently, along with revision of the hallmarks of cancer (Hanahan and Weinberg 2011), also 5Rs of 
radiobiology have been revisited with a particular focus on the immune system (Good and 
Harrington 2013). Originally radiotherapy was regarded as a local treatment, where only tumor 
cells within the radiation fields are killed without much effect on the surroundings, underlined by 
the fact that intensive high-dose radiotherapy can be quite immunosuppressive due to 
radiosensitivity of lymphocytes. However, it has been long since characterized, and is now well-
established, that with correct dosing and fractionating strategies, preferential elimination of 
suppressor T-cells over effector T-cells is attainable (North 1986). Therefore, potential for 
radiotherapy to induce adaptive antitumor immune responses exist. 
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Mechanisms of radiation-induced systemic effects are complex: As demonstrated by the adverse 
reactions seen after radiotherapy in e.g. head and neck tumors, tissue-specific inflammatory 
reactions such as dermatitis and mucositis are intertwined with systemic effects, both pathogenic 
and therapeutic (Russi et al. 2014). Oxidative stress first triggers a release of critical molecules 
from dying tumor/normal cells and surrounding stromal cells to induce innate immune responses. 
The production of cytokines at auto-, para-, and endocrine levels then culminates in widespread 
effects on immune cells and subsequently tissues throughout the body. The characteristics and 
magnitude of this phenomenon depends largely on the mechanism of cell death, particularly 
whether immunogenic or tolerogenic in nature. Autophagic and necrotic forms of cell death are, 
under certain circumstances, very immunogenic featuring release of danger associated molecular 
patterns (DAMPs) that activate dendritic cells and increase antigen-presentation to CD8+ T-cells 
(see below for details) (Golden et al. 2012). Finally, growing body of evidence suggests that 
curative effects of radiotherapy and the potential of eradicating even distant metastases depends 
on the activation of antitumor CD8+ T-cells (Lee et al. 2009, Takeshima et al. 2010).  
 
 
 
Figure 2. Repair of the double-strand DNA breaks and adenovirus-mediated inhibition of the 
repair. Ionizing radiation causes double-strand DNA breaks (DSBs) in the cell genome (top of the 
picture). Normally, the key regulator of DSB sensing and signaling, the MRN complex (Mre11, 
Rad50, and NBS1) binds to free DSB ends and serves as a platform for repair (left side). 
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Concurrently, the MRN complex upregulates ataxia-telangiectasia mutated (ATM) and ATM-Rad3-
related (ATR) kinases that transduce signals to checkpoint proteins such as Chk1 and Chk2. Finally, 
cell faith depends on various signals transduced to major effector proteins p53 and p21 that 
control cell cycle progression, DNA repair, and apoptosis. The presented MRN-mediated repair and 
signaling pathway is the main mechanism, but also other important MRN-dependent and -
independent pathways exist and thus the figure is simplified. With regards to cell faith, alternative 
cell death pathways, such as autophagic and necrotic death, are prominent especially in p53-
mutated tumor cells, which lack the function of the main effector protein p53. Importantly, robust 
accumulation of extensive DNA damage (right side) can also lead to alternative types of cell death; 
this radiosensitivity can be enhanced by serotype 5 adenovirus infection that leads to degradation 
or de-targeting of the MRN complex by adenoviral proteins E4orf3, E4orf6, and to a lesser extent 
E1B55K, as indicated in study I. Alternatively, virus infection can lead to cell death through 
oncolysis (middle): adenoviral double-stranded DNA genomes entering the cell nucleus inactivate 
the MRN-complex to avoid being sensed as DSBs by the host cells, subsequently avoiding cell cycle 
arrest. Interference with the DSB sensing machinery therefore leads to promotion of S-phase, 
continuous virus replication, and ultimately cell lysis and release of virus progeny. The 
interconnected molecular mechanisms of radiotherapy and oncolytic adenoviruses provide 
rationale for combination approaches to improve efficacy and minimize curative radiation doses. 
Of note, histone protein γH2AX is phosphorylated following induction of DSBs, which serves as a 
mediator of repair and indicates presence of DSBs, as tested by immunohistochemistry and 
Western blot in study I. E4orf6 protein has been shown to inhibit dephosphorylation of γH2AX, 
leading to prolonged DSB signaling and atypical apoptosis. Modified from: (Mirzayans et al. 2013).  
 
1.2.2 Chemotherapy 
 
Traditionally, chemotherapeutic drugs were designed to mediate direct cytotoxic activity. By 
impairing cellular functions, e.g. via interfering with cell division mechanisms or damaging cellular 
DNA, chemotherapeutics lead to killing of essentially all cell types if given in high enough dose. 
However, with controlled dosage and administration (therapeutic window), the effect can be 
harnessed against fast-dividing cells, which is a general characteristic for malignant cells. 
Nevertheless, repeated monitoring of bone-marrow function is often needed during 
chemotherapy, since hematopoietic precursor cells that give rise to erythrocytes, platelets, and 
leukocytes, are also relatively fast-dividing and thus sensitive to chemotherapy. This can lead to 
major myelo- and immunosuppression in patients being treated with high-dose chemotherapy, 
which is only desirable for allogeneic bone-marrow transplantation but unfavorable in all other 
instances.  
 
Given the dose-dependent cytotoxic response on different cell types, it is not surprising that 
certain chemotherapeutics have been found to mediate immunomodulating functions when 
administered in low-dosage (Ghiringhelli et al. 2004, Shevchenko et al. 2013). Furthermore, unlike 
the traditional direct cytotoxicity paradigm would suggest, immunogenic type of cell death and 
immune activation has been found essential for long-lasting antitumor effects mediated by several 
conventional chemotherapeutic drugs (Apetoh et al. 2008, Tesniere et al. 2010, Michaud et al. 
2011). Hence, there is rationale for combining certain chemotherapeutics with oncolytic 
immunotherapy. In this thesis, we investigate the use of alkylating chemotherapeutics 
cyclophosphamide (CP) and, for the first time, temozolomide (TMZ), which were both used in low-
dose as virus sensitizers preclinically and in combination treatments of advanced cancer patients.  
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Alkylating agents are the oldest group of chemotherapeutics derived from the aforementioned 
mustard gas, which act by alkylating (transferring an alkyl/methyl group to) molecules, causing 
cross-linking and damage of DNA that eventually leads to apoptosis (Lind 2008). 
Cyclophosphamide is used typically together with other chemotherapeutics to treat wide range of 
malignancies including lymphomas, leukemias, retinoblastoma, neuroblastoma, ovarian cancer, 
and breast cancer (Early Breast Cancer Trialists' Collaborative et al. 2012, Skoetz et al. 2013). CP is 
also widely used as a low-dose metronomic chemotherapy. A recent systematic literature analysis 
found that nearly half (46 studies) of the low-dose chemotherapy studies conducted, used CP 
either as combination or monotherapy, with promising results that are now being evaluated in 
phase III trials (Lien et al. 2013). The hypothesis behind most of these trials has been anti-
angiogenic effects of low-dose chemotherapy, since preclinically it mainly inhibits growth of 
endothelial cells without much effect on fast-dividing tumor cells per se. Despite the apparent anti-
angiogenic properties of low-dose chemotherapy, another recent literature analysis failed to 
identify consistent correlations between outcome and angiogenesis-related biomarkers in clinical 
trials, suggesting that other factors may also play a role (Cramarossa et al. 2014). Indeed, variety of 
other mechanisms, including alteration of the tumor microenvironment, eradication and 
disruption of cancer stem cells, and inhibition of immunosuppressive regulatory T-cells are likely to 
contribute to the antitumor activity of low-dose chemotherapy (Loven et al. 2013). In summary, 
given the excellent safety profile and desirable anticancer effects, a decade of research on low-
dose chemotherapy, with CP in the forefront, is leading towards clinical applications, mostly likely 
in an adjuvant setting combined with other anticancer agents.  
 
TMZ is also an oral alkylating agent, which is used as a standard therapy for certain gliomas, in the 
first line combined with radiotherapy (Stupp et al. 2005). TMZ has a favorable toxicity profile, 
causing relatively mild, non-cumulative myelosuppression in high dosage, which renders it 
attractive drug for combinations and for treatment of even metastatic disease. In fact, it has been 
proposed for treatment of brain metastases together with radiotherapy, regardless of the primary 
tumor origin (Zhu et al. 2014). In addition, TMZ has been used as an off-label treatment after 
standard therapies in metastatic melanoma, pituitary cancer, and lymphomas with some evidence 
of efficacy (Raverot et al. 2012, Velho 2012, Tatar et al. 2013). Standard dose of TMZ in adjuvant 
setting together with radiotherapy varies from 150 to 200 mg/m
2
/day (ca. 300 – 400 mg/day) in 
the treatment of glioma. TMZ has also been assessed in a phase II trial of recurrent glioma, as a 
low-dose metronomic chemotherapy using 50 mg/m
2
/day (ca. 100 mg/day) for up to 1 year or 
until progression (Perry et al. 2010). Interestingly, patients who had progressed during/after the 
conventional high-dose TMZ therapy seemed to benefit from the continuous low-dose TMZ 
administration, when compared to other corresponding phase II recurrent glioma trials. Resistance 
to high-dose alkylating TMZ has been linked to expression of the O6-methylguanine DNA 
methyltransferase (MGMT) protein in tumor cells, which is a repair enzyme that removes methyl 
and alkyl groups from guanine residues restoring the normal function of DNA (Pegg 1990). Thus, it 
was even more surprising, when Perry et al. found in their phase II study that progression-free 
survival was comparable in patients with and without MGMT promoter methylation (inactivation) 
in tumors. As speculated by the authors, efficacy of low-dose TMZ therapy may be mediated by 
anti-angiogenic effects, and/or inhibition of immunosuppressive regulatory T-cells, both of which 
have been observed to occur after low-dose TMZ treatment preclinically (Kurzen et al. 2003, 
Banissi et al. 2009). Thus, low-dose TMZ seems to possess some very similar immune-modulating 
and anti-angiogenic characteristics as low-dose CP, potentially common for many forms of low-
dose chemotherapy. 
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Finally, an important emerging paradigm that might account for the antitumor effects mediated by 
chemotherapeutics involves autophagy: TMZ treatment induced autophagy can trigger autophagic 
cell death, especially when used in combination treatments (Kanzawa et al. 2004, Palumbo et al. 
2012). This type II programmed cell death is characterized by increased turnover of cellular 
organelles leading to cell death, which can be useful in the treatment of apoptosis-resistant cancer 
cells (Lefranc et al. 2007). In addition, autophagy has recently been implicated as a prerequisite for 
immunogenic cancer cell death (ICD) (Michaud et al. 2011, Martins et al. 2012), which can lead to 
efficient antigen-presentation by dendritic cells and induction of antitumor immunity (Hannani et 
al. 2011). Thus, even though baseline autophagy can be viewed as a survival process (Kanzawa et 
al. 2004), mortal autophagic flux leading to ICD appears to be useful for anticancer therapy. With 
regards to TMZ, benefits of autophagic cell death have been attributed to combinatory 
approaches, particularly with radiotherapy and another autophagy-modulating, antiangiogenic 
chemotherapeutic thalidomide (Gao et al. 2009), which have been studied in phase II trials with 
some signs of efficacy (Hwu et al. 2003, Chang et al. 2004b, Groves et al. 2007).  
Taken together, effects of radiotherapy and low-dose chemotherapy on tumor microenvironment, 
immune cells and alternative cell death pathways are essential considerations when designing 
novel combinatorial approaches. The discussed underlying biology and accumulating evidence 
creates strong basis for combining oncolytic adenoviruses with certain conventional treatments, 
such as radiotherapy, and low-dose CP and TMZ, which are discussed in more detail later. These 
rational multimodal treatments may lead to improved antitumor efficacy while maintaining low 
toxicity, and might be useful even for advanced metastatic diseases.   
 
 
1.3 Novel emerging cancer therapies 
 
1.3.1 Gene therapy 
 
Definition of gene therapy in a broad sense is the use of nucleic acids to treat diseases. Typically 
this involves introduction of genetic material into body, which is then transcripted into therapeutic 
proteins. The concept of gene therapy in which specific known genes are introduced, dates back to 
early 1960s, and was originally aimed at correcting monogenic disorders, such as hemophilia or 
combined immunodeficiency syndromes. During the following decades, gene therapy was 
experimented for treatment of multitudes of diseases in laboratory. The first gene therapy, and 
meanwhile the first cancer gene therapy trial was conducted in 1989 by Steven Rosenberg et al. 
who used genetically modified (retroviral gene transduction) tumor-infiltrating lymphocytes to 
treat metastatic melanoma (Rosenberg et al. 1990). Since then, more than 1800 gene therapy 
clinical trials have been conducted in over 31 countries, using more than a hundred different genes 
or vectors (Ginn et al. 2013).  
 
Theoretically, all cells in human body can be targeted and modified by means of gene therapy. 
However, ethical and legal aspects that have been developing in conjunction with the field, set 
important restrictions and quality standards for human gene therapy trials and treatment 
programs. For example, gene therapy boards monitor the quality of production, while 
international legislation prohibits e.g. the genetic modification of germ line (reproductive) cells, 
with the notable exception of the emerging mitochondrial gene transfer aiming at preventing 
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lethal inherited mitochondrial diseases (Vogel 2014). To date, gene therapy has been used for 
experimental treatment of wide range of diseases, for instance: In cardiovascular diseases, aimed 
at increasing angiogenesis to facilitate blood flow to ischaemic regions; In neurological diseases, to 
improve cholinergic transmission for Alzheimer’s disease, and to protect against 
neurodegeneration using neurotrophic factors in Parkinson’s disease; In hematological diseases, to 
correct many monogenic disorders including sickle-cell anemia, hemophilia and β-thalassemia; And 
in ocular diseases, to reverse the age-related macular degeneration, just to name a few. However, 
cancer is by far the biggest and increasingly popular condition for which human gene therapy has 
been applied, constituting around 65% of all gene therapy trials (Ginn et al. 2013).  
 
Gene transfer to a cell can be achieved by either of the two general methods, via viral 
transduction, or non-viral transfection (e.g. plasmid or liposomes). Although the use of virus 
vectors comes with certain well-documented but rare pitfalls including potential for inflammatory 
storms and insertional mutagenesis (Ginn et al. 2013), the benefit of viral transduction lies in its 
superior gene transfer efficacy, and this method has been used in ca. 75% of the clinical gene 
therapy trials thus far. Notably, increasing amount of approaches, especially in cancer therapy, 
uses viral vectors ex vivo to transduce new genes into cells followed by adopting them the cells 
humans. This type of gene therapy is often referred to as cell therapy.  
 
The first breakthrough for the field of gene therapy was achieved in 2000 with the successful 
treatment of a lethal monogenic disease, X-linked severe combined immunodeficiency (SCID-X1) 
(Cavazzana-Calvo et al. 2000). The disorder is commonly known as a form of bubble boy’s disease, 
where infants suffer from recurrent life-threatening infections and die of an early age, as a result 
of impaired humoral immunity due to a single gene defect in X-chromosome. In one of the original 
trials, nine patients with SCID-X1 were treated with a retrovirus coding for the missing gene, and as 
reported in 2010, eight patients were alive after a median follow-up of 9 years, and seven had 
sustained immune reconstitution and lived normal lives (Hacein-Bey-Abina et al. 2010); An 
impressive outcome, given that allogeneic bone marrow transplantation, which is used to treat the 
disease if a donor exists, associates with only ca. 72% long-term survival rates (Hacein-Bey-Abina 
et al. 2010). The retroviral treatment was, however, later associated with leukemia in four cases, 
of which three patients survived. Since this was a side-effect of the therapeutic mechanism of 
action, insertional mutagenesis of the therapeutic gene, it has led to tightened safety precautions 
and development of novel retroviral vectors with safer integration profiles. Notably, retroviruses 
(featuring a reverse-transcriptase enzyme) and adeno-associated viruses (low degree of 
spontaneous integration) are the only vectors currently in clinical testing that entail potential for 
this side-effect. Of the retrovirus family, lentiviruses are the most used vector systems when 
integration into the genome of a non-dividing host cell is desired. Recent years have provided 
further major advances in gene therapy: In 2012, an important milestone was reached when 
alipogene tiparvovec (Glybera[®]) was approved in Europe, becoming the first gene therapy 
product in the Western countries. Alipogene tiparvovec is an adeno-associated virus encoding a 
variant of the human lipoprotein lipase gene for the treatment of familial lipoprotein lipase 
deficiency (Gaudet et al. 2013). In 2013, two clinical trials using new generation lentiviral vectors, 
which belong to the family of retroviruses, reported promising results in a lethal 
neurodegenerative lysosomal storage disease (arrested progression) and in a fatal primary 
immunodeficiency syndrome (immunological and hematological improvement), both mediated by 
successful restoration of the missing gene expression (Aiuti et al. 2013, Biffi et al. 2013). 
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The most used gene therapy vector is adenovirus, constituting up to 23.3% of all gene therapy 
trials (Ginn et al. 2013). The main advantages are good safety and large amount of clinical data 
supporting that, capacity to carry relatively large DNA loads as transgenes, ability to infect also 
non-dividing cells, and high transduction efficiency coupled with high levels of gene expression. 
Another pro, or con depending on the application and perspective, is that adenoviruses are 
common human pathogens (discussed later). Adenoviral vectors mediate only transient gene 
expression, which is why they are not optimal for correcting long-term genetic defects such as the 
aforementioned SCID-X1 disease. Thus, it is logical that for a fatal disease with no other treatment 
options that requires very long-term gene expression, an integrative retroviral vector with known 
potential risks is being tested. Analogously, the choice of vector for non-lethal, e.g. cardiovascular 
or ocular diseases would be a safer adenovirus or adeno-associated virus, even though therapeutic 
efficacy might remain lower. Thus, the field of gene therapy takes on a panel of diseases to 
combat, and features multiple therapeutic strategies to achieve this, with basically only the use of 
genetic material as the common nominator. Use of adenoviruses and some other oncolytic virus 
vectors in the treatment of cancer is discussed in the following sections. 
 
1.3.2 Cancer gene therapy 
 
In gene therapy in general, the severity of the disease has impacted the choice of vector, so that 
lethal (monogenic) diseases are often treated with riskier vectors. However, with regards to cancer 
which is the deadliest disease of all (WHO Global Health Observatory Data Repository 2012), this 
does not hold true due to biological reasons: Tumor cells are inherently characterized by 
continuous proliferation, DNA replication and cell division, which is why gene therapy vectors 
targeting cancer cells should entail preference for metabolically active and fast-dividing cells. In 
addition, high amplitude of gene expression, instead of long-term stable expression, would be 
desired in order to produce a maximal therapeutic bystander effect to surrounding tumor cells. In 
fact, common human pathogenic viruses, including adeno-, herpes simplex, and reovirus, have 
evolved in humans to mediate this type of rapid replication on epithelial tissues to propagate 
enough virus to effectively spread from host to host. This renders adenovirus, together with 
certain other human pathogens, an attractive vector. Moreover, owing to the common evolution 
and inherent innate immunity in humans, adenovirus is a safe vector, when potential for liver 
toxicity is taken into account (discussed later). This is underlined by the fact that over 5,000 
patients have been treated and over 1,000 cancer gene therapy trials have been conducted 
without treatment-related fatalities (Ginn et al. 2013). To put these numbers into perspective, 
standard adjuvant chemotherapy in colorectal cancer using fluorouracil and oxaliplatin is 
associated with 1 – 3% treatment-related mortality (Sanoff et al. 2012). Further, in breast cancer, 
yet considered well-tolerated, the mortality rate using adjuvant anthracyclines and taxanes is still 
0.2 – 0.5% (e.g. acute chemotherapy-induced leukemia, cardiotoxicity) (Early Breast Cancer 
Trialists' Collaborative et al. 2012).  
 
Inherent ability of viruses to kill cancer cells has been regarded for over a century, along with 
observations that cancer patients who suffered from influenza infections seemed to slow down 
progression of their disease (Kelly and Russell 2007). However, the use of virotherapy for 
treatment of cancer sparked along with developments in basic virology in the 1950s. A few 
different viruses were tested in the first clinical trials at the time, including hepatitis B, West Nile 
virus, and adenovirus. Although clinical responses were observed in several different tumor types, 
also side-effects were notable, which is not surprising given the limited knowledge in virology and 
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inability to render viruses tumor-homing by means of gene therapy (Kelly and Russell 2007). These 
obstacles together with contemporaneous development of novel more efficient chemotherapeutic 
drugs, led to a few decades of decreased interest in virotherapy. In the 1990s, however, time was 
ready for genetic engineering of viruses, and thus virotherapy was bolstered by methods of gene 
therapy. Subsequently, a non-pathogenic Moloney murine leukemia virus was engineered to 
express thymidine kinase gene (tk) derived from a herpes simplex virus-1 (HSV), which became the 
first genetically-engineered virus (Ezzeddine et al. 1991). This strategy known as ‘suicide gene 
therapy’ utilizes a pro-drug conversion enzyme, here thymidine kinase, which converts a pro-drug, 
ganciclovir, into a toxic metabolite thus killing only the infected cells (expressing the tk protein). 
During the following years, similar approaches were intensively tested, mainly for treatment of 
malignant glioma that lacks curative treatment modalities, finally resulting in a phase III 
randomized trial in the late 20
th
 century (Rainov 2000): Researchers used carrier cells that were 
infected ex vivo with a retroviral vector containing the tk gene, and tested local injections of these 
cells given during surgery, coupled with ganciclovir treatment, as compared to the standard 
treatment in previously untreated glioblastoma. Although not reaching their primary endpoints 
probably due to poor delivery of the HSV-tk enzyme, the study proofed the biosafety and 
feasibility of the approach, which encouraged other researchers from Finland to proceed to 
another phase III trial that started in 2005 and the final results were recently announced 
(Westphal et al. 2013): This large multicenter trial used the same pro-drug converting enzyme but 
this time mediated by a replication-deficient adenovirus vector, which rendered more promising 
results; Median time to death or re-intervention (interim analysis) proved longer than with current 
standard therapy, but the overall survival was not significantly improved. 
 
The field of cancer gene therapy has grown from its infancy during the past decade, and the first 
marketing approvals have been achieved. As of 2003, China became the first country to approve a 
modified replication‐deficient serotype 5 adenovirus coding for p53 protein, Ad‐p53, which is used 
together with radiotherapy for the treatment of head and neck cancer (Pearson et al. 2004). Only 
two years later, China was again the first country in the world to approve an oncolytic, i.e. 
replication-competent adenovirus, H101 (Garber 2006). This serotype 5 adenovirus is rendered 
tumor selective by deletion of the E1B gene, which is necessary for virus replication in normal cells 
with intact p53 protein. H101 is also intended for the treatment of head and neck cancer. An 
important milestone for cancer gene therapy in the Western countries was achieved in 2013, when 
the first positive phase III trial results using an oncolytic herpes virus, talimogene laherparepvec (T-
VEC), in metastatic melanoma were announced last year (Andtbacka et al. 2013). T-VEC codes for 
granulocyte-macrophage colony-stimulating factor (GMCSF) protein to improve antitumor immune 
responses, and is expected to receive the first marketing license for oncolytic immunotherapy 
agent in the Western world in the near future.  
 
Above mentioned approaches that have reached far in clinical testing can be divided into six main 
categories or strategies how to combat cancer: (1.) HSV-tk strategy is an example of the described 
‘suicide gene therapy’; (2.) Ad‐p53 therapy aims at replacing missing or altered genes in tumor 
cells to induce cell death (replacing p53 protein); (3.) H101 and T-VEC are oncolytic viruses 
directed to specifically replicate in, and kill cancer cells via oncolysis. In addition, T-VEC can be 
regarded as a form of gene therapy aimed at (4.) improving host’s antitumor immune responses, 
which is achieved in this case by GMCSF expression as well as virus replication per se. Besides 
these approaches, researchers have investigated ways to transfer genes, usually by means of 
replication-deficient vectors, that would render target tumor cells (5.) more susceptible to 
radiotherapy, chemotherapy, or other treatments; or (6.) genes that inhibit tumor angiogenesis or 
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interfere with tumor metabolism, thus depriving cancer of nutrients. Nevertheless, the focus of 
this thesis is on oncolytic viruses, which appear to be one of the most promising cancer gene 
therapy approaches, as indicated by the recent success in clinical trials. 
 
1.3.3 Tumor immunology and immunotherapy 
 
Development of the Coley’s toxin in 1892, containing killed Streptococcus pyogenes and Serratia 
marcescens bacteria, was the second anticancer modality after surgery to reach “clinical” testing. 
It was sparked from an observation by Willliam Coley that tumors of a sarcoma patient 
disappeared following a high fever from erysipelas infection (Nauts et al. 1946). Thereafter Coley 
and others, and later a pharmaceutical company reported numerous similar cases by using the 
toxin preparations on cancer patients, occasionally coupled with some serious adverse reactions. 
With the inconsistency of treatment results and contemporary emergence of radiotherapy and the 
first chemotherapeutic drugs, Coley’s toxin, and with it the concept of activating body’s own 
immune system against cancer, nowadays known as cancer immunotherapy, was largely forgotten 
for nearly half a century. 
 
Immunosurveillance and immunoediting 
 
Dr. William Coley and colleagues were ahead of their time, because in order to develop tumor 
immunotherapy, it is necessary to understand tumor immunology. This has proven evidently true 
when looking back to the progress and convergence of these fields. Immunotherapy began lifting 
its profile again in the 1970s. This happened alongside with decades long debate in the scientific 
community whether a concept of cancer immunosurveillance existed, which was depicted by its 
developer and strongest supporter, Nobel Laureate Sir Frank Macfarlane Burnet in 1970 as follows: 
“In large long-lived animals, like most of the warm-blooded vertebrates, inheritable genetic 
changes must be common in somatic cells and a proportion of these changes will represent a step 
toward malignancy. It is an evolutionary necessity that there should be some mechanism for 
eliminating or inactivating such potentially dangerous mutant cells and it is postulated that this 
mechanism is of immunological character” (Burnet 1970). The concept got support with the first 
experimental findings by Burnet and colleagues in their series of crucial immunological 
experiments (Burnet 1970, Corthay 2014). Nevertheless, debate continued as later evidence 
proposed a dual role for immunity in the context of cancer: it was observed that parts of the 
immune system also promote tumor growth, in particular by selective advantage for cancerous 
lesions of low immunogenicity, i.e. lesions that are not empathically recognized by the immune 
system. As recently as in 2002, this lead to emergence of another, supplementing concept of 
“immunoediting” (Dunn et al. 2002). The process constitutes of three phases based on scientific 
evidence, denoted as the three E’s of cancer immunoediting (Dunn et al. 2004): Tumor cells are 
eliminated by the surveying immune system, but occasionally some cancer cells with low 
immunogenic phenotypes are spared due to fine balance between foreign and self, which are then 
selected by the Darwinian law and promoted for. This can lead to an equilibrium phase, lasting 
potentially for decades, where the tumor and the immune system are constantly selecting for 
clones and eradicating them, respectively, but maintaining a dynamic balance. Many lesions are 
spontaneously eradicated by the immune system during this phase, or prompted by natural 
infections and other external factors to be destructed. Some external factors can, however, offer 
additional selection advantage to the tumor lesions, such as viral oncoproteins or growth-
promoting mutations via carcinogens. Depending on the tipping of this scale, mutational 
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advantage may ultimately lead to the final phase of tumor escape, where the immune system can 
no longer restrain the growing tumor that effectively resists immune destruction, either via 
reduced immunogenicity (e.g. mutations leading to reduced antigen-presentation), or because of 
immunosuppression mediated by the selected tumor variants, or more usually, due to both. 
 
With regards to cancer immunotherapy, immunoediting mechanisms that are distinctive for the 
last escape phase are in the spotlight, in particular loss of tumor detection, and 
immunosuppression. This is logical since diagnosed cancer patients normally bear tumors that 
have already progressed into the immune-escaped phase. Therefore, the big question in cancer 
immunotherapy is: how can we reset or provoke patient’s immunosurveillance system to notice 
cancer? Improved understanding of the tumor immunity has implicated three main niche for 
therapeutic intervention: i) promoting the induction of antitumor effector cell (usually T-cells) 
responses, ii) promoting tumor-antigen presentation functions of dendritic cells, and iii) 
overcoming immunosuppression mediated by the tumor (Mellman et al. 2011). Indeed, for cancer 
immunotherapist, the escape phase of immunoediting is definitively not considered as the final 
phase. 
 
The first modern immunotherapies 
 
In the beginning of the modern cancer immunotherapy era, several immunotherapeutic 
treatments were tested in clinical studies. Notably, one of the first attempts clearly followed in the 
foot-steps of Dr. Coley, and became a still widely used treatment: bacillus Calmette‐Guerin as an 
immunomodulator in the treatment of bladder cancer (Morales et al. 1976). Although the specific 
mechanisms of this intravesical treatment are still unknown, it is believed to affect at least two of 
the main immunotherapeutic niche (i, ii): increased antigen presentation of both the foreign 
microbe and the tumor, and increased antitumor T-cell activation. Another well-established 
treatment dating back to the 1970s is allogeneic bone marrow transplantation (Weiden et al. 
1979). Interestingly, this therapy form was not originally intended as an immune-based treatment 
but rather as re-establishment of the vital bone marrow after high-dose chemo- or radiotherapy. 
Nevertheless, along with the notion of the graft-versus-leukemia effect, this approach has been 
since successfully used to treat thousands of patients with hematological diseases as well as some 
solid tumors (Dougan and Dranoff 2009). The main immunotherapeutic mechanism of action here 
is to induce antitumor T-cells (i), which achieved with the graft, bypassing the need for activating 
endogenous antitumor immunity. Unfortunately, the method is also associated with the unwanted 
graft-versus-host effect, and high mortality rates due to heavy myeloablation and high risk of 
sepsis. Of note, various supportive treatments used for the myeloablated, neutropenic patients, 
such as infusion of leukocyte growth factors, granulocyte (G) or granulocyte-macrophage (GM) 
colony stimulating factors (CSF), were noted to increase early survival after myeloablative 
treatments, and were later studied in the context of immunotherapy. 
 
Cytokine therapy 
 
Other early immunotherapeutic studies assessed the feasibility of infusing recombinant cytokine-
like molecules, e.g. interferon alpha (IFN-α), and tumor necrosis factor alpha (TNF‐α), GMCSF, and 
interleukin-2 (IL-2), some of which were shown to mediate promising efficacy in clinical trials. 
These therapies were the first rationally designed biological approaches, emerged with the 
deepening understanding of cancer immunosurveillance mechanisms, together with isolation and 
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recombinant production techniques. Besides several other direct or indirect cytotoxic effects, they 
also possess clear immunotherapeutic features (i, ii):  
 IFN-α increases major histocompatibility complex class I (MHC-I) antigen expression, 
crucial for initiation of antigen-presentation (Anderson et al. 1994), and was first 
approved for the treatment of hairy cell leukemia (Quesada et al. 1986), followed by 
several other indications such as hepatocellular carcinoma, bladder cancer and 
lymphoma.  
 With regards to TNF-α, systemic administration proved too toxic, but isolated limb-
perfusion using recombinant TNF-α together with chemotherapy showed impressive local 
efficacy with manageable safety profile in soft tissue sarcomas, and resulted in approval 
in Europe (Mocellin et al. 2005). Immunotherapeutic mechanisms of TNF-α are diverse, 
but they mainly involve production of inflammatory cytokines and maturation of dendritic 
cells for antigen-presentation (Mocellin et al. 2005).  
 Granulocyte‐macrophage colony‐stimulating factor (GMCSF) was characterized as a 
cytokine with great potential as an inducer of hematopoiesis and cellular immunity 
(Arellano and Lonial 2008), and was soon applied as supportive treatment for neutropenic 
patients (see above). Meanwhile, the effects of GMCSF on dendritic cells suggested 
potential use as primary immunotherapy: GMCSF promotes differentiation of progenitor 
cells into dendritic cells and enhances their antigen-presentation. In addition, it recruits 
monocytes, and actives lymphocytes including natural killer (NK) cells at the site of 
inflammation. As a result, systemic recombinant GMCSF was tested, together with other 
cytokines IFN-α and IL-2, and interestingly, also with temozolomide, for treatment of 
advanced melanoma (Arellano and Lonial 2008). However, dose-limiting toxicities were 
encountered using systemic GMCSF administration, although signs of promising efficacy 
were also noted. Due to this, and along with the notion that high systemic levels can 
induce immunosuppressive myeloid‐derived suppressor cells (MDSCs) (Serafini et al. 
2004), GMCSF was incorporated as an adjuvant in cancer vaccines and gene therapy 
approaches, including oncolytic viruses, with evident success since both have resulted in 
positive phase III results (discussed below). 
 IL-2 is a T-cell growth factor with evident immunotherapeutic effects, and high-dose IL-2 
regimen was designed in the 1980s followed by series of promising animal experiments. 
Since then hundreds of cancer patients have been treated alone or in combination with 
other treatments with recombinant IL-2, with most notable success in metastatic 
melanoma,  (Atkins et al. 1999). Many durable complete responses were observed that 
essentially established the curative potential of immunotherapy. Ultimately, recombinant 
IL-2, termed aldesleukin, was approved for treatment of metastatic renal cell carcinoma 
in 1993 and for metastatic melanoma in 1998. Downsides of high-dose IL-2 therapy are, 
however, that the curative response rates are low (ca. 6%) and hard to predict, and that 
the treatment contains a risk for immediate sepsis-like condition, fatal to ca. 2% of 
patients (Atkins et al. 1999). Of note, lower dose IL-2 regimens have also been tested, e.g. 
in metastatic renal cancer, which decreases the amount of serious adverse events, but 
this also accounts for less durable responses (Yang and Rosenberg 1997).  
It soon became apparent that although potentially effective, and even curative in some patients, 
recombinant cytokine-like molecules administered systemically mediated serious inflammatory 
side-effects, and thus their production at the tumor site by means of gene therapy gained 
attention (Liu et al. 2010). Alternatively, researchers started investigating the use of recombinant 
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cytokines as adjuvant therapies, and consequently, e.g. pre-conditioning with systemic IL-2 
therapy is a typical part of adoptive T-cell therapies as of now (Pellegrini et al. 2010).  
 
Antibody therapy 
 
More recently, the use of monoclonal antibodies as biological therapeutics has become 
increasingly popular. They possess a major benefit over many of the older immunotherapeutics, 
they are targeted against a specific antigen. Thus, theoretically all tumor-specific antigens could be 
targeted, however, this is not practical since tumor-antigens often resemble normal self-antigens. 
Currently, there are nine formally approved monoclonal antibodies for treatment of cancer, which 
target six tumor‐associated proteins (Mellman et al. 2011): Her2/neu, VEGF, EGFR, CD20, CD33 
and CD52. Although the main mechanism of action for these antibodies is considered to be 
inhibition of tumor-growth signaling pathways, they also mediate immune cell activations, 
specifically NK cell induction via binding to the tail-fragment of the IgG antibody when attached to 
the antigen on target cell. Nevertheless, the most important immunotherapeutic application in 
general, and for antibody therapy in particular, was the identification of an immune checkpoint 
protein CTLA-4 and subsequent development of an antagonistic antibody ipilimumab by Dr. James 
Allison and colleagues in the 1990s (Chambers et al. 2001). CTLA-4 molecule is a negative regulator 
of antigen-specific immune responses acting on many cell types. In brief, CTLA-4 impairs antigen-
presentation in the immunological synapse between T-cells and dendritic cells, while promoting 
regulatory T-cells (T-reg), an immunosuppressive subtype of T-cells (Chambers et al. 2001). In 
addition, tumor cells can express CTLA-4 which blocks the immune responses. Thus, ipilimumab 
represented the first-in-class strategy to combat the (tumor) immunosuppression (iii). However, 
critic was soon raised against ipilimumab (Bakacs et al. 2012), questioning the use of drug which 
releases breaks of the T-cells allowing widespread immunological adverse reactions that were 
totally new in oncology, and unfortunately included fatalities (2.1% in a phase III trial; (Hodi et al. 
2010)). In the next phase III trial involving 502 patients with metastatic melanoma, researchers 
were more prepared with earlier dose-reductions and effective use of steroids suggesting that 
most of these immune-related adverse events (ir-AEs) were actually manageable (Curran et al. 
2012): As a result, no treatment-related deaths occurred, although grade 3 or 4 adverse events 
occurred in 56.3% of patients as opposed to only 27.5% in the standard therapy group (Robert et 
al. 2011). Nevertheless, efficacy was unsurpassed with significant increase in median overall 
survival in both studies, and for the first time in history, around 22% of patients were showing 
durable responses at 3-year follow-up and ongoing (Couzin-Frankel 2013). Ipilimumab was 
approved by the United States and European authorities for treatment of metastatic melanoma in 
2011 and 2012, respectively, and is currently tested in several phase II-III studies alone or in 
combination with other modalities, for several tumor types including bladder cancer, lung cancer, 
and metastatic hormone-refractory prostate cancer. 
 
In the wave of this encouraging immune checkpoint research, another notable antibody target 
strategy has emerged that potentially entails more favorable safety-profile and even better 
efficacy: Blocking of programmed death-1 protein, or its ligand (PD-1 or PD-L1) mediates similar 
release of breaks on T-cell immunity as ipilimumab, but not in the immunological synapse but 
instead mainly at the tumor site between the cancer cell and T-cells. Thus, PD-1L signaling that 
many tumors exploit to inhibit T-cell functions, is more tumor-specific. Indeed, an early clinical trial 
of 296 patients was associated with less serious adverse events than ipilimumab (14% grade 3–4 
adverse events, 1% of fatal) and an impressive 20-25% durable response rate in patients with non-
small-cell lung cancer, metastatic melanoma, or renal-cell cancer (Topalian et al. 2012). 
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Importantly, responses correlated with PD-L1 expression status at the tumors, suggesting specific 
mechanism of action combating tumor-mediated immunosuppression. 
 
Therapeutic cancer vaccines 
 
Decades long research on therapeutic cancer vaccines has also gained attention in the recent 
years, as the first cancer vaccine sipuleucel‐T, a mixture of patient’s peripheral blood mononuclear 
cells supplemented with a GMCSF cytokine and a prostate tumor‐associated antigen (prostatic acid 
phosphatase), was approved in the United States for treatment of advanced prostate cancer in 
2010 (Kantoff et al. 2010). This cell-based cancer vaccine is administered intravenously and was 
found to improve median survival by 4.1 months. The immunotherapeutic niche of the cancer 
vaccine field is to promote the tumor-antigen presentation by dendritic cells (ii). Several strategies 
have been experimented, including cell-based (tumor and dendritic cell), purified component-
based, DNA-based, and tumor-peptide preparations that are administered either subcutaneously, 
intravenously or injected into tumor-draining lymph nodes or tumors (Aranda et al. 2013). 
Mechanistically, therapeutic cancer vaccines often present antitumor activity and research has 
provided valuable new knowledge on antitumor immunity. With the notable exception of 
sipuleucel‐T, however, success in clinical trials has been modest. Many reasons may account for 
this, such as need for personalized vaccination given the unique features of each tumor, 
intrinsically low antigenicity of cancer cells, and tumor-mediated immunosuppression. Moreover, 
the emerging concept immunogenic cell death indicates that certain cytotoxic anticancer agents 
can provoke antitumor immune responses merely via release of danger signals from dying cells 
(Apetoh et al. 2008). Thus, it is likely that immune activation without proper danger signaling at 
the tumor site, coupled with distortion of the immunosuppressive circuits, is not sufficient to 
mediate tumor rejection. Of note, an increasingly important means of utilizing the immunological 
memory, and a testament to the power of immunosurveillance, is the use of prophylactic cancer 
vaccination; Millions of children have been vaccinated against oncogenic microbes, including 
hepatitis B and human papilloma virus (Dougan and Dranoff 2009), thus preventing cancer even 
before occurrence.  
 
Immune-related tumor responses 
 
As mentioned, immune-related adverse events (ir-AEs) encountered with ipilimumab therapy were 
a new chapter in clinical cancer research. Another peculiar characteristic of immunotherapies, 
especially with immune checkpoint blocking antibodies and therapeutic cancer vaccines, is the 
inaccuracy of radiological response evaluations in predicting survival (Wolchok et al. 2009, Kantoff 
et al. 2010). Survival and quality of life are naturally the most relevant endpoints for cancer 
patients. However, for development of treatments in clinical trials, as well as for improving cost-
effectiveness and clinical decision making in oncology practice, surrogate endpoints such as 
radiological response evaluation are widely used. In fact, several modern trials use progression-
free survival as their interim primary endpoint. Currently, contrast enhanced computed 
tomography (CT), is the leading method for radiological response evaluation and anatomical 
criteria such as Response Evaluation Criteria in Solid Tumors (RECIST) are frequently used for the 
characterization of responses in trials (Eisenhauer et al. 2009). These evaluation standards are 
suitable for many traditional treatments, such as chemotherapy and radiotherapy, where tumor 
shrinkage is measured as a sign of treatment benefit (Wolchok et al. 2009). However, with regards 
to immunotherapy, including also oncolytic viruses, responses are elicited in a more complex way: 
Besides tumor cell killing, there is a major inflammatory response due to danger-signals and 
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foreign antigens from both the virus/vaccine and the tumor, which provokes migration of immune 
cells coupled with extravasation. Thus, the activation of the immune system can lead to tumor 
swelling and initial increase in tumor diameters which might actually indicate therapeutic efficacy 
– an early sign of mounting an inflammatory response due to the treatment instead of progression 
(Wolchok et al. 2009).  
 
In an attempt to circumvent this problem, metabolic response evaluations as assessed by e.g. 
positron emission tomography (PET) that measures e.g. [18F]-fluorodeoxyglucose (FDG) activity, 
have been developed (Wahl et al. 2009). This method registers the glucose uptake as a sign of 
tissue metabolism, and because increased consumption is a characteristic of most cancers, the 
uptake of FDG indicates tumor cell viability. In contrast, decreased signal represents reduced 
viability (Young et al. 1999), and could also reveal “pseudo-progression” mediated by therapeutic 
inflammation, because swelling is later associated with increased water content. Indeed, FDG-PET 
has been regarded with better biological predictive value than anatomic imaging (CT or magnetic 
resonance imaging [MRI]) in certain cancer types, including mesotheliomas, lymphomas, lung 
cancer, and esophageal cancer, especially early during therapy (Wahl et al. 2009). The metabolic 
response evaluation with FDG-PET might therefore be more feasible than anatomical imaging in 
detecting patients who are likely to benefit from immunotherapy. Another attempt to this end 
involves more appropriate evaluation criteria. Immunotherapy consortia and health authorities 
have worked together to develop immune-related response criteria (ir-RC) that take inflammatory 
reactions better into account. They not only allow certain initial increases in tumor diameters, but 
also regard development of certain new lesions in stable disease, because these may indicate 
immunological activity in tumor-draining lymph nodes (Wolchok et al. 2009). Besides important for 
response evaluations in clinical trials, these aspects have direct impact in patient care as well: If 
the therapeutic inflammation (“pseudo-progression”) leads to premature attenuation of the 
therapy, it could be detrimental to the patient. Another unique characteristic in response patterns 
seen after immunotherapy is the durability of responses due to immunological memory. This has 
led to re-evaluation of statistics, particularly, of the Kaplan–Meier survival curves, to emphasize 
the delayed separation of the curves in order to assess impact of the treatment on long-term 
survival (Hoos et al. 2010). 
 
Adoptive T-cell therapy 
 
T-cells that have been cross-primed (activated) by dendritic cells are capable of directly recognizing 
their specific antigen, kill the target cell, and mediate clonal expansion, ultimately eradicating the 
tumor. Activated T-cells move through tissues, including tumor beds, scanning for MHC-I peptide 
complexes loaded with cellular antigens on the cell surfaces. Accumulating evidence suggests that 
the migration of antitumor T-cells is arrested in advanced tumors even if they encounter their 
antigens (Restifo et al. 2012), which is likely due to lack of danger-signals and/or multiple layers of 
immunosuppression mediated by the tumor. This is a possible explanation for typical presence of 
tumor-infiltrating lymphocytes in certain advanced stage tumors, such as melanoma, that can no 
longer control tumor growth although activation signal has been provided. 
 
One highly anticipated form of immunotherapy is adoptive cell therapy, which generally involves 
the use of autologous tumor-infiltrating or circulating T-cells, which are “adopted” from the 
patient, genetically-modified and expanded, or only expanded ex vivo, and then infused back to 
patients. As mentioned, Dr. Rosenberg and colleagues were the first to conduct a cancer gene 
therapy trial in 1989 using genetically modified tumor-infiltrating lymphocytes (TILs) for treatment 
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of metastatic melanoma (Rosenberg et al. 1990). Since then, these techniques have been 
developed rigorously by a few researchers. The immunotherapeutic niche exploited here involves 
direct induction of antitumor T-cells (i). Thus, it circumvents the problem of antigen-presentation, 
or presumes that it has already occurred when using tumor-infiltrating lymphocytes (TILs). 
Presence of TILs at the tumor site, together with possibility to excise and grow them out, is 
therefore a prerequisite for TIL therapy. Alternatively, circulating lymphocytes can be utilized by 
genetically modifying them, by means of retroviral transduction, to express an artificial T-cell 
receptor against a tumor-antigen. Two main strategies to achieve this are T-cell receptor (TCR) 
modified, and chimeric antigen receptor (CAR) T-cells (Hinrichs and Rosenberg 2014). The major 
difference between these technologies is that CAR T-cells do not require MHC-I presentation of 
antigens, but can be targeted against cell surface proteins, such as CD19 in leukemia. Important 
factors contributing efficacy after adoptive cell transfer are also preparative lymphodepletion by 
chemo- or radiotherapy, and pre-conditioning of the patient with systemic IL-2 infusion. These 
regimens are associated with significant toxicity, while e.g. tumor-lysing and cytokine release 
syndromes after application of the T-cell graft pose further problems. TCR therapies can also cause 
autoimmune reactions due to off-target toxicity (homology between self- and tumor-antigen) 
(Hinrichs and Rosenberg 2014). Nevertheless, even metastatic patients who have exhausted all 
other available treatments have shown remarkable complete responses; In one center giving TIL 
therapy for example, a clinical trial series of 93 metastatic melanoma patients showed 56% 
objective response and 22% durable complete response rates (Hinrichs and Rosenberg 2014).  
 
With the use of TCR and CAR T-cell technology, collection of TILs can be avoided, which has 
allowed clinical testing in several other malignancies, including B-cell malignancies and synovial 
sarcoma. The strongest testament for the curative potential of T-cell therapy was, however, seen 
last year when researchers announced results of an early trial using CD19-targeted CAR T-cells in 
pediatric patients with chemotherapy-refractory, stem cell transplantation refractory, acute 
lymphoid leukemia (Grupp et al. 2013): Both patients went into continuing remission, with 
establishment of an evident T-cell memory against leukemic cells. Very recently, another CD19 
CAR T-cell trial reported corresponding results, showing complete remission in 27 out of 30 
pediatric and adult patients with refractory acute lymphoblastic leukemia and a 78% overall 
survival rate at six months (Maude et al. 2014). Severe cytokine-release syndrome was reported in 
27% of patients, but no treatment-related deaths occurred. Since adoptive T-cell therapy is more 
of a technology than a drug at this stage, future applications are still open but are likely to have 
strong impact on treatment of refractory cancer. Of note, pharmacological companies have 
already noted the promise of the approach and medical development is well underway (Maude et 
al. 2014).  
 
The immunotherapeutic strategies colliding with contemporary knowledge on tumor immunology 
show that there are multiple strategies to combat even metastatic tumors, but they must be 
tailored and optimized for each patient. As the different immune-mechanistic niches (i,ii,iii), and 
different approaches inside each niche suggest, combinatorial immunotherapies are most likely to 
increase the rates of durable responses to higher percentages. However, many more challenges lie 
ahead because not all tumors, such as pancreatic and colon carcinoma, are yet susceptible to 
present clinical or experimental immunotherapy.  
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Unmet challenges in tumor immunology 
 
Dendritic cells are bone-marrow derived professional antigen-presenting cells that are crucial in 
initiating CD8+ cytotoxic and CD4+ helper T-cell responses (Gajewski et al. 2013). Foreign antigens 
can be loaded onto MHC class I for cross-presentation to CD8+ T-cells, which is believed to occur 
after the phagocytosis of immunogenic cells, sampling of live cells, or shuttling of immunogenic 
peptides to dendritic cells by heat shock proteins (van der Most et al. 2006). Unfortunately, the 
frequency of activated CD8+ T cells or their function often remains too low to mount an effective 
antitumor response after immunotherapy. Reasons for this are many, and mostly due to highly 
evolved immunosuppressive circuits in the tumor microenvironment.  
 
Given the enormous mutation rate of malignant tumors, all types of cancer contain significant 
amounts of tumor-associated or tumor-specific antigens that are subject to immunoediting by T-
cells. Analogously, cancer types that best respond to current immunotherapies, such as malignant 
melanoma and bladder cancer, seem to fall into the highest end of mutation rate frequencies as 
revealed by recent cancer genome sequencing efforts (Alexandrov et al. 2013). However, some 
other high-mutational tumor types such as lung or colorectal cancer remain hard to control by 
immunotherapeutics despite the plentiful targets for T-cell responses, suggesting major 
immunosuppressive mechanisms. To evade immunosurveillance and eradication by the immune 
system, tumors have developed multiple mechanisms to hide from the immune system, many of 
which remain still unknown. One such mechanism is by recruiting immunosuppressive cells (Figure 
4), such as regulatory T-cells, immature myeloid cells, and tumor-associated macrophages to the 
tumor site and local lymph nodes. This can lead to excessive production of chronic inflammatory 
mediators such as IL-6, TNF-α, and HMGB1 that leads to polarization of the cross-primed CD4+ T-
cells into T-helper type 2 (Th2) cells, which are responsible for mediating mostly humoral immunity 
(Coussens et al. 2013, Li et al. 2013a). Th2 type immunity is ineffective in tumor eradication, and 
further promotes accumulation of immunosuppressive cells to the tumor microenvironment. 
 
Regulatory T-cells are an immunosuppressive subset of CD4+ T-cells that are mainly responsible for 
regulating peripheral tolerance by suppressing dendritic cells and effector T-cells reactive to self-
antigens (Daniel et al. 2009). Since tumor-antigens are presented similar to self-antigens on MHC 
class I molecules, regulatory T-cells are also effective in reducing antitumor immune responses. 
Advanced tumors exploit this function by secreting immunosuppressive cytokines such as 
transforming growth factor beta (TGF-β) (Lindau et al. 2013). In addition to recruiting regulatory T-
cells, TGF-β directly inhibits cytotoxic and helper T-cells, e.g. by downregulating their cytotoxic 
capacity and IFN-γ production, respectively (Tian et al. 2011). Effector T-cells can be also 
suppressed by several other tumor-derived soluble and cell surface proteins such enzyme 
indolamine-2,3-dioxygenase (IDO) that deprives tryptophan causing local T-cell anergy (Muller and 
Prendergast 2007), CTLA-4 that inhibits the immunological synapse between dendritic cell and T-
cell (Seliger et al. 2008), and PD-ligand 1 which is a co-inhibitory signal to T-cells (McDermott and 
Atkins 2013). Some tumors have been also shown to downregulate their MHC class I processing, 
presentation and tumor-antigen exposure, thus leading to decreased T-cell recognition (Leone et 
al. 2013). Furthermore, effector T-cells can be committed to apoptosis by tumor-derived Fas-ligand 
(Houston et al. 2003).  
 
Several immature myeloid cell types mediate immunosuppressive functions, such as immature 
dendritic cells that can abrogate antigen cross-presentation to effector T-cells (Kusmartsev and 
Gabrilovich 2006). Myeloid-derived suppressor cells (MDSCs) are considered an important 
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suppressor mediating e.g. PD-L1, TGF-β, nitric oxide production, and recruitment of regulatory T-
cells (Lindau et al. 2013). Tumor-associated macrophages with M2 phenotype provide anti-
inflammatory molecules, such as IL-10 and TGF-β to promote immune evasion (Hao et al. 2012). 
Certain pancreatic cancer-associated fibroblasts have been suggested to de-target T-cells by 
secreting chemokine CXCL12 (Feig et al. 2013). Finally, there is strong clinical correlative data on 
the impact of different immune cell subtypes on prognosis: the presence of immunosuppressive 
cells accounts for poor prognosis (Chikamatsu et al. 2007, Perrot et al. 2007, Tadmor et al. 2013, 
Tanchot et al. 2013), whereas the effector T-cells have been linked with improved outcome (Hodi 
and Dranoff 2010, Nosho et al. 2010). 
 
These aspects highlight the importance of immunosuppression for progressive human tumors. 
Many of the aforementioned mechanisms are overlapping and hierarchy of immunosuppression 
has recently been identified in e.g. pancreatic cancer in vivo (Feig et al. 2013), although the picture 
is likely to be even more complex in human tumors that develop over years if not decades. 
Identifying the immunosuppressive circuits that distinct tumor types typically exploit can help in 
developing countermeasures. Indeed, several approaches are currently being investigated to 
overcome each of the aforementioned challenges (Mellman et al. 2011, Loven et al. 2013, Kyi and 
Postow 2014, Lichty et al. 2014). Emerging clinical data suggests that rational combinations of 
different immunotherapeutics and immune-modulating chemotherapeutics that combat several 
levels of suppression can improve the efficacy even in synergistic manner (Cerullo et al. 2011, 
Emens 2012, Puzanov et al. 2014). 
 
 
1.4 Adenovirus 
 
Developments in cell culture and virus propagation methods in the 1950s led to rapid progress in 
basic virology and discovery of several new viruses, including adenovirus (Rowe et al. 1953). The 
name originates from the site of its discovery, the adenoid structures, which are lymphatic tissues 
located in the nasopharynx. The family of adenoviruses, Adenoviridae, is divided into five genera, 
of which human adenoviruses constitute the Mastadenovirus genus. They are further divided into 
seven species, A – G, based on their ability to agglutinate human erythrocytes. Using genomics as a 
method for typing adenoviruses, already 59 different serotypes have been discovered (Liu et al. 
2012), with most of these belonging to species D. However, in this thesis and in the following 
chapters, we focus on serotype 5 and 3 adenoviruses, which belong to the species C and B, 
respectively. Both of these serotypes are endemic in most parts of the world as seroprevalence for 
adenovirus species C (incl. serotype 5) varies from 35% up to 97%, and for serotype 3 ranging 
between 40–80% (Nayak and Herzog 2010, Arnberg 2012). 
 
Human adenoviruses are considered as low-pathogenic viruses, since they mostly cause self-
limiting infections (Kunz and Ottolini 2010). However, also severe infections and complications 
have been reported, especially in immune-deficient individuals and infants. As epithelial cells are 
the primary targets for adenovirus pathology, respiratory infections, gastroenteritis, and epidemic 
conjunctivitis are the most common manifestations. In rare occasions, adenoviruses can also cause 
liver and urinary bladder infections, and even more sporadically, myocarditis and meningitis. With 
regards to respiratory tract infections, which are the most common, potential complications 
include secondary bacterial pneumonia and bacterial empyema, pleural effusion, and acute 
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respiratory distress syndrome (Kunz and Ottolini 2010). Different serotypes are associated with 
distinct pathogenicity and manifestations. Epidemic outbreaks or severe complications have been 
linked to serotypes 4, 7, 11, 14, 21 and 35. Notably, serotype 5 adenovirus, the most used cancer 
gene therapy vector, has only been associated with upper respiratory tract infections. Serotype 3 
adenovirus has been identified to cause also lower respiratory tract infections, pharyngo-
conjunctival fever, and conjunctivitis, which are mainly self-limiting (Kunz and Ottolini 2010).  
 
Febrile acute respiratory diseases caused by adenoviruses are mainly encountered in infants and 
school‐aged children, but also in military recruits. The various diseases caused by adenoviruses 
manifest usually relatively mildly, as acute self‐limiting infections. However, for 
immunosuppressed patients and infants they can be severe and even life‐threatening, manifesting 
as fulminant hepatitis, pneumonia and even meningoencephalitis. For unknown reasons different 
serotypes are characteristically responsible for different disease manifestations. For example Ad40 
and Ad41 infections cause gastroenteritis, Ad8, Ad19 and Ad37 are typically related to epidemic 
keratoconjunctivitis and Ad11 and Ad21 are principal serotypes encountered in hemorrhagic 
cystitis infections (Kunz and Ottolini 2010). Sporadic pathological infections of pancreatic tissue, 
myocardium and central nervous system have also been reported. 
 
1.4.1 Adenovirus structure 
 
Adenoviruses are double-stranded DNA viruses surrounded by an icosahedral protein capsid, and 
no envelope. Virus particle measures ca. 90 nm in diameter, weights ca. 150 MDa, and shows a 
fiber projecting from each vertex of the capsid (Figures 2 and 3), which consists of seven proteins 
(87% of mass is protein): II (hexon, 240 units), III (penton base, 12 units), and IV (knobbed fiber, 12 
units), which are the major proteins of the capsid, and IIIa, VI, VIII, and IX, the minor proteins 
(Smith et al. 2010) (Table 1). Inside the capsid lie the linear double-stranded DNA genome (13% of 
mass) and the associated core proteins. Genome is 36 kilo-base pairs long and, in the case of 
serotype 5, was fully sequenced over 20 years ago (Chroboczek et al. 1992). Core proteins provide 
structure, link the genome to the capsid, and are needed for packaging of the virions. In addition, 
the terminal core protein that attaches to the 5’ ends of the genome, which have inverted terminal 
repeats (ITRs), is necessary for initiation of viral DNA replication (Rekosh et al. 1977). Figure 3 
illustrates, and Table 1 describes the main functions of the adenovirus particle proteins. 
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Figure 3. Adenovirus particle structure and schematic representation of the adenoviral genome. 
Left part: Adenovirus structure. Virus particle is composed of the outer capsid and the core. 
Penton base, hexon, and fiber protein with a knob, constitute the icosahedral capsid illustrated 
here in two dimensions. Other main proteins are depicted in roman numerals and their functions 
are described in Table 1. Right part: Schematics of the adenovirus genome. E = early genes, L = late 
genes, MLP = major late promoter, Ψ = packaging signal, which acts as a starting point for virus 
replication, LITR/RITR = left/right inverted terminal repeats, which are crucial for complementary 
DNA pairing during virus replication. Certain proteins coded by early regions, that are central for 
this thesis, are shown in parenthesis are (E1B55K, E4orf3, and E4orf6). Modified from: (Russell 
2000). 
 
 
Table 1. Adenovirus particle proteins and their main functions. Capsid proteins are bolded. 
References: (Saban et al. 2006, Russell 2009).  
 
Protein  Function 
Protease Involved in the production of infectious virions from the procapsid by cleaving 
the precursors into structural proteins IIIa, VI, VII, VIII, X, and terminal protein. 
Terminal 
protein  
Required for viral DNA replication, facilitates circularization of the genome.  
II = Hexon Four types of hexons (H1–4) constitute the total of 240 hexon proteins of the 
capsid, providing solid icosahedral structure. 
III = Penton  Provides capsid structure. Arg-Gly-Asp (RGD) motif on the penton base is 
central for virus internalization by interacting with α,β integrins on the cell 
surface. 
IIIa Stabilizes the capsid by associating with the hexon and penton proteins. 
IV = Fiber Fiber knob is the first component interacting with target receptors. Varies 
between different serotypes, thus altering the primary adenovirus receptor. 
 36 
 
IVa2 Binds to DNA and is critical for the packaging process of the virus genome.  
V Provides a bridge between the core and capsid proteins. 
VI Stabilizes the virus capsid by linking the hexon and penton proteins to the core. 
Required for the rupture of early endosomes, releasing the viral DNA to 
cytoplasm.  
VII Binds to DNA and spreads along the length of the virus DNA, providing 
protection. 
VIII Stabilizes the inner capsid by associating with hexon and penton proteins. Links 
the hexons to other capsid proteins at their base.  
IX Stabilizes the outer capsid by associating with hexon and penton proteins. 
X Protein X, also known as µ, has protamine-like properties. 
 
 
1.4.2 Adenovirus life cycle 
 
The adenovirus life-cycle is typically divided into early and late phases: In the early phase, 
infectious virus particle enters the host cell in a process called transduction, followed by 
unpackaging, transfer of the virus into nucleus, and transcription and translation of the early 
genes. In the second phase, late adenoviral genes are expressed and then processed in the 
nucleus, followed by packaging and maturation of infectious virus particles, the virions. Newly 
formed virions then lyse the host cell and spread. Serotype 5 adenovirus expresses first its five 
early transcriptional units (E1A, E1B, E2, E3, and E4), after which viral DNA replication takes place, 
followed by expression of the second phase genes that include three intermediate/delayed units 
(IX, IVa2, and E2 late) and one major late unit, which is processed into five late subunits (L1-L5) 
(Russell 2000). Depending on the permissivity of the cell, the early phase takes ca. 6 – 8 hours, and 
the second phase 4 – 6 hours (Russell 2000). Adding the phases of DNA replication and cell lysing, 
the total time from cell entry until release of new virions takes usually 24 – 36 hours. Figure 3 
represents the schematics of the adenovirus genome.  
 
1.4.3. Transduction and biodistribution 
 
Adenoviruses use primarily their knob region of the capsid fiber to bind to cell surface receptors. 
As adenoviral transmission usually occurs via aerosol route on oropharyngeal, respiratory, 
conjunctival or gastrointestinal lining, adenoviruses have evolved multiple cell entry mechanisms 
to epithelial cells. For species C (serotype 5) adenoviruses, the primary high-affinity receptor was 
identified as the same as for coxsackie B virus, which is why the protein was termed Coxsackie-
adenovirus receptor, i.e. CAR-receptor (Bergelson et al. 1997). Subsequently, CAR-receptor was 
found to be the prime receptor for also all other species, excluding species B (serotype 3) 
adenoviruses (Roelvink et al. 1998). Biologically, CAR-receptor protein belongs to the 
immunoglobulin superfamily and is involved in the formation of tight junctions between epithelial 
cells (Cohen et al. 2001). Therefore, it is basolaterally localized and it still remains unclear how 
adenovirus initially reaches the CAR-receptor, although other receptors and adapter molecules 
may play a major part here (see below). In contrast, later replication cycles have been shown to 
facilitate CAR-receptor reaching by producing excess amounts of fiber proteins that bind to CAR-
receptors and disrupt the tight junctions (Walters et al. 2002).  
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With regards to species B adenoviruses, the main cell entry receptor was identified as CD46 
(Gaggar et al. 2003), but some serotypes like serotype 3 seemed to require an unknown high-
affinity receptor, which was only very recently identified as desmoglein 2, i.e. DSG2-receptor 
(Wang et al. 2011). Interestingly, binding of serotype 3 adenovirus to the DSG2-receptor was 
demonstrated to transiently open intercellular junctions, allowing the virus to reach other 
receptors. Thus, DSG2-receptor interaction of serotype 3 knob can be exploited in cancer gene 
therapy, by incorporating serotype 3 knob to other species adenoviruses like serotype 5 (i.e. 5/3-
chimera), potentially improving binding to other non-apical receptors as well (Kanerva et al. 
2002a).  
 
Other characterized receptors for species C (serotype 5) adenoviruses besides the CAR-receptor, 
include MHC-I molecule alpha2 domain (Hong et al. 1997), heparan sulfate glycosaminoglycans 
(Smith et al. 2003), vascular cell adhesion molecule-1 (Chu et al. 2001), and scavenger receptor A, 
which is responsible for virus uptake and subsequent degradation in macrophages (Haisma et al. 
2009). For serotype 3 adenovirus, in turn, other identified receptors besides DSG2 and CD46, are 
CD80 and CD86 (Short et al. 2004). In addition, several adapter molecules have been identified, 
which can serve as carrier molecules that the virus exploits to avoid neutralization outside the cell, 
or linkers between the virus and the cell surface receptors. These include coagulation factors IX 
and X, lactoferrin, and dipalmitoyl phosphatidylcholine for species C, and coagulation factor X for 
species B adenoviruses (Arnberg 2012). Importantly with regards to virology and cancer gene 
therapy, simple modifications of these adapter molecules in vivo, such as impairing coagulation 
factor synthesis by warfarin treatment, can reduce adenovirus transduction to unwanted organs 
like liver, spleen and lung, while retaining high transduction of tumors (Koski et al. 2009), thus 
potentially enhancing its biodistribution profile. 
 
After binding to primary receptor, such as CAR-receptor for serotype 5, the capsid fiber bends and 
allows secondary binding of a penton base motif, namely Arg-Gly-Asp (RGD) motif, to αβ integrins 
on the cell surface (Mathias et al. 1998). Subsequently, virus is internalized from the clathrin-
coated pits into endosomes (Wang et al. 1998). In addition to penton protein, also fiber shaft 
interactions with cell surface heparan sulfate glycosaminoglycans seem to be important for proper 
attachment and internalization (Dechecchi et al. 2001). Interestingly, modifications/deletions in 
the fiber region responsible for this binding have been shown to reduce liver transduction of 
serotype 5 and 5/3-chimeric adenoviruses (Bayo-Puxan et al. 2009, Koski et al. 2013b), suggesting 
further means by which tumor-to-liver targeting ratio could be enhanced. Of note, besides 
receptor and adapter molecule interactions, also several other factors impact the biodistribution 
of human adenoviruses in circulation. These physiological mechanisms have evolved to minimize 
potential for fulminant infections, by homing maximal doses of virus to liver where it can be 
neutralized, but this may also markedly decrease tumor transduction efficacy of adenoviral gene 
therapy when administered or spread intravenously. Interactions with blood cells, coagulation 
factors and complement, as well as natural adenoviral tropism to liver can decrease tumor 
transduction, while rapid clearance from bloodstream by liver sinusoidal endothelial cells and 
tissue macrophages, such as Kupffer cells, can in turn increase liver transduction (Khare et al. 
2011). Importantly, however, when using normal treatment doses, uptake of the virus by the liver 
sinusoidal and Kupffer cells does not appear to mediate virus production or gene expression at the 
liver (Hegenbarth et al. 2000, Wheeler et al. 2001). Even if reaching tumor site, physical barriers 
such as intratumoral stroma and high interstitial fluid pressure can limit virus propagation. To 
these ends, means for intensive replication and virus arming with extracellular matrix-degrading 
enzymes have been tested (Smith et al. 2011). Finally, antiviral innate and adaptive immune 
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responses, although also contributing to immunotherapeutic efficacy, as well as newly 
characterized acquired tumor resistance against adenovirus pose problems, which are discussed 
later in more detail. 
 
1.4.4. Early phase and DNA-repair inhibition 
 
Infectious adenovirus particle is internalized via clathrin‐mediated endocytosis (Wang et al. 1998). 
Inside the endosome, virus capsid is disrupted by acidification of the vesicle followed by 
conformational changes that require e.g.  adenoviral protein VI leading to release of the virus from 
the endosome (Wiethoff et al. 2005, Campos and Barry 2007). Subsequently, virus particle 
surrounded by only hexon proteins attaches to the nuclear pore complex and a nuclear factor 
CRM1 (Strunze et al. 2005), which mediate dissociation of most of the remaining capsid proteins 
and transfer the viral DNA with the associated core proteins into the nucleus (Greber et al. 1997). 
Viral DNA highjacks the host cell’s transcription machinery, for which core proteins are essential, 
and transcription of the early genes is initiated (Russell 2009). Viral DNA transcription takes place 
in the nucleus, while the viral proteins are translated in the endoplasmic reticulum, and then 
transported back to nucleus. Viral DNA replication and assembly of the new virions are also 
performed in the nucleus in so called viral factories (Chaly and Chen 1993). Adenoviral genes and 
their main functions are well-characterized, allowing rational genetic engineering and appliance 
for therapeutic purposes such as cancer gene therapy. 
 
Early genes of the E1-E4 regions are expressed before viral DNA replication. Their main functions 
involve interference with the host cell cycle signaling, innate defense, and apoptotic pathways 
(Berk 2005). E1A and E1B coded proteins are rapidly expressed after entering the nucleus, and 
they activate transcription of other early genes, modulate cellular metabolism to render the host 
cell susceptible to virus replication, e.g. by interfering with NF-κB and p53 proteins, and promote 
entry of the cell cycle into S phase (Berk 2005). Notably, these functions promote apoptosis, which 
is counteracted by other early genes of the E1B region (see below). In addition, E1A proteins 
inhibit IFN-α and IL-6 responsive elements and thus play a role in counteracting innate immune 
responses (Anderson and Fennie 1987, Takeda et al. 1994). 
One of the best-characterized and exploited functions of E1A genes is the binding of 105K protein 
to Retinoblastoma (Rb) family proteins (Whyte et al. 1988, Sherr 1996): this interaction releases 
E2F transcription factor, which in turn activates genes required for promotion of the S phase. The 
importance of this discovery culminates in present adenoviral cancer gene therapy, where a 24-bp 
deletion (Δ24) in the Rb-binding site of the E1A is often utilized, because this attenuates virus 
replication and most of the later gene expression in normal cells that have wild-type 
retinoblastoma protein, but maintains replication cancer cells with defective Rb/p16 pathway that 
includes almost all human tumor types (Whyte et al. 1989, Fueyo et al. 2000, Kanerva et al. 2003). 
Finally, direct antitumor activities and chemotherapy-sensitizing effects of adenoviral E1A region 
have been demonstrated in several preclinical and clinical studies (Chang et al. 2014).  
 
E1B region is crucial for adenovirus replication in normal cells because E1B55K protein mediates 
inhibition of p53 protein by several means, leading to cell cycling and inhibition of apoptosis 
(Sarnow et al. 1982, Berk 2005). However, in p53-mutated cancer cells, these functions are 
dispensable (Marcellus et al. 1996), and have been utilized in the early-generation conditionally-
replicating adenoviruses such as ONYX-015 (see below). Adenovirus infection, especially the 
double-stranded DNA genomes in the nucleus, are sensed by the same cellular mechanisms as 
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ionizing radiation induced DSBs (Lilley et al. 2007). Therefore, adenovirus proteins have evolved to 
inhibit DNA damage response signaling that would lead to cell cycle checkpoint and apoptosis. In 
addition to blocking p53 protein, E1B55K has been shown to associate with two other adenoviral 
proteins, E4orf3 and E4orf6, which disable the DSB-sensing MRN complex (Leppard and Everett 
1999, Lilley et al. 2007, Schwartz et al. 2008). Consequently, E1B55K has been proposed to 
augment in DSB repair inhibition, although its impact has remained controversial in this regard 
(Hart et al. 2005). Other E1B gene products are important in eliminating other cell death 
mechanisms, transporting viral RNAs for translation, and initiating DNA replication (Russell 2000). 
The other main gene product, E1B19K, functions to attenuate p53-independent apoptotic 
pathway, particularly by mimicking an anti-apoptotic BCL-2 family member protein MCL-1 
(Cuconati et al. 2003). Interestingly, also this mimicry is involved in DNA-damage response, 
because MCL-1 degradation is yet another early response to DNA damage signaling (Nijhawan et 
al. 2003). Nevertheless, this pathway directly induces apoptosis instead of cell cycle stop, thus 
rendering E1B19K less interesting with regards to radiosensitizing potential.  
 
E2 region encodes proteins crucial for viral DNA replication (Russell 2000), whereas E3 genes are 
dispensable for replication in vitro, which has been utilized to clear room for therapeutic 
transgenes (E3-deleted adenoviruses). Nevertheless, these genes are needed for downregulation 
of host antiviral immune responses, both innate and adaptive, and also for efficient lysis of the 
host cell mediated by the adenovirus death protein (ADP) (Tollefson et al. 1996a). Deletion of the 
E3 gene product gp19K has been widely used in gene therapy since this removal does not hamper 
virus replication in vitro, because gp19K functions to inhibit expression and transportation of MHC-
I molecules from the endoplasmic reticulum to the cell surface (Bennett et al. 1999). However, 
reduced display of viral antigens loaded onto MHC-I complex would suggest in vivo implications. 
Indeed, recent evidence in semi-permissive immunocompetent Syrian hamster model indicates 
that the deletion of gp19K, and another E3 gene 6.7K, can lead to faster clearance of virus by 
antiviral immune responses (Bortolanza et al. 2009a). 
 
The E4 region proteins are all transcribed initially as the same mRNA, but alternatively spliced into 
six different open reading frames (orf). Most of these E4orf-proteins promote viral late gene 
expression over host gene expression, and facilitate viral mRNA metabolism, e.g. by providing 
nuclear export signals (Halbert et al. 1985, Weigel and Dobbelstein 2000). The third and the sixth 
protein, namely E4orf3 and E4orf6, have been identified to mediate important cell cycle interfering 
functions, often together with E1B55K, as mentioned earlier. Inhibition of the DSB-sensing protein 
complex MRN by these proteins has been well-characterized (Figure 2): E4orf3 mislocalizes the 
MRN complex to cytoplasmic aggresomes, while E4orf6 targets it to proteasome-mediated 
degradation (Stracker et al. 2002, Araujo et al. 2005). E4orf6 has also been shown to radiosensitize 
cells by an alternative, E1B55K-independent mechanism, not affecting the MRN levels (Hart et al. 
2005). Experiments on mutant viruses have revealed that infection with E4orf3/6-deficient 
adenoviruses activate robust DSB repair signaling via ATM and ATR cascades that lead to 
recruitment of repair proteins to viral factories, hampering the virus DNA replication and virion 
production (Stracker et al. 2002, Carson et al. 2003). Notably, E4orf6 protein has also been shown 
to inhibit dephosphorylation of γH2AX, a histone protein involved in DSB-sensing and repair 
(Figure 2), thus paradoxically prolonging DNA damage signaling via other mechanisms and 
promoting atypical, caspase-independent cell death (Hart et al. 2007). 
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1.4.5. Late phase and mechanism of cell death 
 
After transcription of the early genes, viral DNA replication takes place in the nuclear viral 
factories. This process requires the terminal proteins attached to the inverted terminal repeats 
(ITRs) of both ends of the genome, from which DNA replication begins (Rekosh et al. 1977). 
Intermediate genes IVa2 and IX are expressed next, and function to activate the major late 
promoter, promoting transition into late phase (Lutz and Kedinger 1996, Lutz et al. 1997). The late 
genes (L1-L5) located under the major late promoter code for proteins involved in maturation and 
encapsulation of the virions (Russell 2009), as well as the structural proteins (Table 1). In the last 
step of its life-cycle adenovirus triggers cell lysis, and new infectious virions are released into 
extracellular space.  
 
The mechanism of cell death is important in determining the nature of subsequent immune 
activations, and there are indications that adenovirus mediated cell lysis is highly immunogenic. 
Adenovirus death protein (ADP) differs from all other E3 proteins in that although being an early 
gene, it is expressed in very low quantities until the activation of the major late promoter 
(Tollefson et al. 1992). Soon after its characterization, ADP was found to mediate atypical form of 
cell death, morphologically resembling to what it is now regarded as autophagic cell death 
(Tollefson et al. 1996b). Of note, characteristics of several death mechanisms have been later 
identified, including apoptotic, autophagic and necrotic cell death, but especially with regards to 
cancer virotherapy, autophagy appears to gain support (Rajecki et al. 2009, Tazawa et al. 2013). 
Under physiological conditions, autophagy is a catabolic process that is activated during starvation 
and provides energy by degrading cytoplasmic organelles in autophagosomes (Mizushima and 
Komatsu 2011). However, several chemotherapeutics, such as TMZ, and oncolytic viruses have 
been shown to induce autophagic cell death (type II programmed cell death), which is 
characterized by increased turnover of cellular organelles beyond reversibility (Chen and Karantza 
2011). Importantly, autophagic cell death has been regarded highly immunogenic (Guo et al. 
2014). While a “silent” form of cell death, such as apoptosis, can lead to immunological tolerance 
(Green et al. 2009), immunogenic cell death activates dendritic cells leading to increased cross-
presentation of antigens to effector T-cells (Hannani et al. 2011). Immunogenic cell death is 
characterized by exposure of calreticulin on the plasma membrane, followed by release of other 
danger-associated molecular patterns (DAMPs), adenosine-triphosphate (ATP) and nuclear protein 
high-mobility group box-1 (HMGB1), which has been also regarded for oncolytic adenovirus in this 
thesis and elsewhere (Diaconu et al. 2012). Each of these DAMPs are needed to activate the 
nearby dendritic cells and they also function to attract other immune cells (Hannani et al. 2011, 
Guo et al. 2014). In addition to releasing potent DAMP signals, activation of autophagy also leads 
to upregulation of MHC-I and II complexes that mediate antigen-presentation (Dengjel et al. 2005). 
Indeed, functional autophagy has been regarded as a prerequisite for activation of antitumor 
immune responses (Michaud et al. 2011, Guo et al. 2014).  
 
Prompt danger-signaling, MHC complex upregulation, and the fact that no specific autophagy-
inducing genes have been identified from adenovirus, may suggest that autophagy is actually a 
host defense and alert mechanism against this intracellular intruder. This may hold true in normal 
cells, but with regards to cancer cells that are devoid in apoptotic mechanisms, several oncolytic 
viruses seem to benefit from autophagy (Guo et al. 2014). Specifically with regards to adenovirus, 
autophagy may be exploited to generate nutrients needed for building viral progeny particles, and 
it has positive effect on virus replication (Jiang et al. 2011, Rodriguez-Rocha et al. 2011). Growing 
body of evidence indicates that autophagy accounts for improved antitumor efficacy in the context 
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of oncolytic virotherapy (Tazawa et al. 2013): 12 out of 14 recent preclinical publications reported 
that autophagy coincided with, or contributed to improved anticancer efficacy. Oncolytic 
immunotherapy in an immunocompetent host would be expected to benefit even further from 
this immunogenic type of cancer cell death. 
 
1.4.6 Host antiviral defense mechanisms 
 
Humans have evolved in close contact with plethora of infectious agents and parasites, which is 
why sophisticated immune defense mechanisms and extensive inter-individual variation are 
necessary for us to survive. As previously discussed, there is a delicate balance between non-self 
and self when immune system determines between activation and tolerance. Thus, the existence 
of autoimmune diseases, where overactive immunity destroys healthy tissues, and immune-
escaped tumors, where body’s own transformed cells have tamed the immune system, is not 
actually surprising. Human immune system consists of innate (i.e. natural) immunity and adaptive 
(i.e. acquired) immunity. The innate immunity forms the first-line defense against novel 
pathogens, and is mostly mediated by cells that are always present in the body. In fact, most of the 
human tissues, with the notable exception of central nervous system, possess some degree of 
innate immune responsiveness. For example epithelial cells produce type I interferons soon after 
virus infection, which mediate direct antiviral effects, but also recruit immune cells such as 
macrophages and natural killer cells. Innate immune components act very rapidly, usually within 
minutes after assault, but responses are unspecific and can eradicate only sporadic pathogens 
without the help from adaptive immunity. In contrast, adaptive immunity is based on targeted 
responses mediated mainly by T and B-lymphocytes, which are potent in eradicating infections and 
tumors, but require cross-presentation from innate immunity, maturation, and lack of suppressive 
signals. However, once established, immunological adaptive memory maintains the prompt 
responsiveness against possible recurrent encounters. With regards to oncolytic viruses, immune 
system plays a pivotal role: Antiviral immune responses may lead to rapid clearance of the virus 
and poor oncolytic efficacy. However, oncolytic virus replication may also provide danger-signals 
and tumor-antigen spreading necessary to induce antitumor immune responses, and thus helps in 
breaking the tumor-induced immune tolerance. The latter notion has led to the development of 
oncolytic immunotherapy concept (Lichty et al. 2014). Of note, different characteristics of 
genetically-modified adenoviruses, such as capsid-modifications and deletions of the E3 region 
genes, alter the host immune responses, and therefore identified mechanisms in basic virology 
and immunology are not always directly applicable for oncolytic immunotherapy (Zaiss et al. 2009, 
Thaci et al. 2011). Furthermore, tumor immunology, as previously discussed, will undoubtedly 
further confound the picture (Gajewski et al. 2013), which is why experimental approaches 
studying both the innate and adaptive arms of the immune system are crucial for development of 
oncolytic immunotherapy. 
 
Innate antiviral immunity 
 
Innate immunity composes mainly of autocrine and paracrine signaling of the infected cell, 
epithelial barriers, mast cells, phagocytic neutrophils and macrophages, natural killer (NK) cells, 
and the complement system. Dendritic cells are often regarded as innate immune cells as well, 
although they function in borderlands between innate and adaptive immunity together with other 
antigen-presenting cells.  
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Adenovirus is often encountered by the epithelial cells of the respiratory or gastrointestinal tract, 
and in the case of oncolytic virotherapy, by the tumor or tumor endothelial cells. Outside the cell, 
adenovirus is susceptible to neutralizing effects of the complement system, as well as neutralizing 
antibodies, if pre-existing from a previous encounter with the same serotype virus (Zaiss et al. 
2009). As discussed, intravenous administration leads to major elimination of the virus by liver 
sinusoidal endothelial and Kupffer cells, in which the virus does not replicate, demonstrated by ca. 
90% decrease in the originally administered virus DNA during the first 24 hours by the liver innate 
immune system in mice (Worgall et al. 1997). 
 
Primary task of the innate immunity is to recognize the virus, because many physiological 
processes utilize the same endocytotic cell entry mechanisms. Indeed, already at the binding of 
adenovirus to its CAR-receptor on cell surface, viral capsid proteins are sensed as foreign, which 
triggers initial innate immune responses (Tamanini et al. 2006). Other early receptors include toll-
like receptor 2 (TLR-2) on the cell surface, the α,β integrins that function as secondary adenovirus 
entry receptors, and toll-like receptor 9 (TLR-9) that is located in the endosome. Once the viral 
DNA is released from the endosome into cytosol, it can be further sensed by DNA-dependent 
activator of IFN-regulatory factors (DAI) and nucleotide oligomerization domain (NOD)-like 
receptors (Thaci et al. 2011). TLRs belong to the pattern-recognition receptor family of proteins 
that function to detect pathogen-associated molecular patterns (PAMPs). TLR-9 recognizes 
unmethylated CpG dinucleotide sites that appear to be more prominent in adenoviral genomes 
than in normal cellular DNA (Hemmi et al. 2000), although this varies by serotype, and species C 
serotype 2, and thus probably also serotype 5 adenovirus, seem to be less immunogenic in this 
regard (Krieg et al. 1998). Interestingly, TLR-2 appears to be activated also by the endogenous 
HMGB1 protein that is released from dying tumor cells in immunogenic cell death (Curtin et al. 
2009, Li et al. 2013a). HMGB1-TLR-2 interaction was shown to mediate antitumor immune 
responses in a glioma model, when treated with oncolytic adenovirus, TMZ, and radiotherapy. 
Notably, all treatments alone lead to HMGB1 release as well. In summary, it appears that DAMPs 
that are secondary danger signals, are crucial in potentiating the immune responses via similar 
mechanisms as PAMPs in order to produce effective antitumor response (Li et al. 2013a). 
 
After activating innate immune receptors, signals are transduced via several different adaptor 
proteins, such as MyD88 and TRIF, and mitogen-activated protein kinases (MAPKs), to effector 
proteins including transcription factors, NF-κB and IRF3/7, and signal transducer and activator of 
transcription 1/2 (STAT1/2) that induce cytokine and/or interferon (IFNs) production, and hinder 
cell cycling (Kawai and Akira 2006, Zhu et al. 2007). Thus, receptor signals lead to rapid alteration 
of host gene expression and metabolism, as well as paracrine signaling to the neighboring cells and 
associated immune cells. In principle, characteristics of the innate immune response depend on 
the cell type, and on the integrative actions of different PAMP signals. There are several 
independent receptors and associated downstream mediators in innate immunity, but the two 
main distinct signaling pathways are interleukin-1 receptor (IL-1R) and interferon α receptor (IFN-
αR) mediated pathways. Downstream effector proteins of these two pathways attempt to block 
virus replication in separate ways: the interleukin pathway triggers inflammatory response that 
calls innate immune cells for help to eliminate the virus, whereas the IFN pathway strives for 
shutdown of cellular mechanisms both on autocrine and paracrine levels (Thaci et al. 2011).  
 
IL-1R signaling leads to inflammatory response, release of chemokines and cytokines, aimed at 
controlling the infection locally by recruiting neutrophils, macrophages, and NK-cells, to 
phagocytose and lyse the infected cells and further amplify the response (Thaci et al. 2011). The 
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pattern of different inflammatory cytokines, in conjunction with e.g. IFN response, danger signals 
and immune cells, dictates whether the response is pro- or anti-inflammatory (Hendrickx et al. 
2014). In general, IL-10 has been regarded as anti-inflammatory, whereas IL-8 and TNF-α are 
examples of mainly pro-inflammatory cytokines, but again depending on the context and kinetics 
(Muruve 2004). Many cytokines of acute innate response, especially interleukins, act in the 
borderlands between innate and adaptive immunity, and can either stimulate or inhibit e.g. 
dendritic cells and effector lymphocytes. For example, IL-12 and 18 stimulate NK T-cells to produce 
IFN-γ (see below) that is needed for effective helper T-cell type 1 (Th1) adaptive immune 
responses (Taniguchi et al. 2003). 
 
IFNs are classified according to the receptor through which they signal: Type I IFNs (mainly IFN-
α/β) are the main antiviral innate immune signals that activate the IFN-αR, while type II IFNs (-γ) 
are part of the adaptive immune system secreted by lymphocytes during infection and signal 
through IFN-γR. In addition, more recently discovered type III IFNs (-λ) comprise another part of 
innate immunity with many similarities to the type I IFN response, but are activated in response to 
different viruses, such as rhino- and influenza A virus (Hermant and Michiels 2014). To date, no 
evidence of IFN-λ response in adenovirus infection exists. Hence, type I IFNs play the key role in 
innate defense against adenovirus: They can be divided into IFN-α (includes 13 subtypes), IFN-β, 
IFN-κ, IFN-ε, IFN-ο, IFN-τ and IFN-δ. Type I IFN response is initiated by interaction of adenoviral 
DNA with some of the aforementioned intracellular receptors, followed by an attempt to block 
adenoviral replication in an autocrine manner (Thaci et al. 2011). In addition, type I IFN production 
by the infected cell leads to a more rapid IFN-αR-mediated signaling in the neighboring cells, which 
activates JAK-STAT pathway and leads to formation of IFN-stimulated gene factor 3 (ISGF3) 
transcriptional complex that results in expression of more than 300 IFN-stimulated genes (ISGs) 
(Thaci et al. 2011). Thus, the surrounding uninfected cells can produce extensive defense 
mechanisms that prevent possible replication attempts. Notably, if adenovirus already manages to 
express its E1A genes, the ISG production is nearly abolished via inhibition of ISGF3 (Anderson and 
Fennie 1987, Kalvakolanu et al. 1991). However, some ISGs, such as protein kinase R (PKR) and 
Myxovirus resistance protein A (MxA), that can be induced even during infection, are able to limit 
adenovirus replication to certain degree (Shi et al. 2007). In particular, MxA protein is located at a 
critical intersection between several interferon-mediated antiviral signaling pathways (Randall and 
Goodbourn 2008). It has been shown to block viral replication at early stages by trapping viral 
proteins and preventing viral protein synthesis, although its impact on adenovirus infection 
remains unknown (Staeheli and Pavlovic 1991, Kochs and Haller 1999, Haller et al. 2007). Critical 
role of the type I IFN response in adenovirus infection is underlined by the finding that breast 
cancer initiating/ stem cells that have dysfunctional toll-like receptor signaling, show increased 
susceptibility to oncolytic adenoviruses (Ahtiainen et al. 2010). Ultimately, a complex interplay 
between IFN and inflammatory cytokine responses is needed to clear adenoviral infections. 
 
Cytokine and IFN responses can control adenovirus infection locally, by recruiting NK-cells, 
granulocytes, macrophages, and dendritic cells to phagocytose the infected cells (Hendrickx et al. 
2014). These innate immune cells also amplify and modulate the response by secreting more 
cytokines. As their name indicates, NK-cells are natural born killers capable of rapidly eliminating 
infected cells based on their innate immune stress-response (Ferlazzo and Munz 2004), and 
activate other immune cells by e.g. secreting IFN-γ, GMCSF, and TNF-α (Ferlazzo and Morandi 
2014). Dendritic cells and macrophages are the main professional antigen-presenting cells (APCs) 
that have a similar capacity to phagocytose without pre-stimulation or MHC class I presentation, 
and they also internalize cellular fragments and proteins via endocytosis (Nayak and Herzog 2010). 
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Dendritic cells recognize the internalized adenovirus or viral DNA fragments as pathogenic by their 
endosomal TLR‐9 receptor (Hendrickx et al. 2014), after which they process the engulfed viral 
antigens and present them via MHC-II to CD4+ and CD8+ T-cells (Muruve 2004), acting as the first 
step of adaptive immune involvement. This antigen-presentation occurs in local lymph nodes, but 
requires several stimulatory signals, such as IFN-γ, TNF-α, DAMPs, PAMPs, and/or antigen-antibody 
immune complexes, for proper activation of APCs (Li et al. 2013a, Platzer et al. 2014). In contrast 
to stimulating immune cells, certain cytokine profiles and their interplay with local immune cells 
can alternatively lead to immune tolerization of dendritic cells, which is exploited by advanced 
tumors (Green et al. 2009). APCs can be also inhibited, edited, or stimulated by other immune cells 
at later stages, such as regulatory T-cells, MDSCs, and NK-cells that provide additional control over 
engagement of the potent adaptive immunity (Lindau et al. 2013, Ferlazzo and Morandi 2014). 
Thus, the innate immune mechanisms are intertwined with adaptive immunity which is described 
later. Tipping of the scales between the two opposing outcomes, i.e. immune activation and 
tolerance, as well as the nature of the response (i.e. Th1 versus Th2-type response, see below), 
depends on the previously discussed mechanism of cell death, the immunogenicity of the 
pathogen, and on the predominant immune status at the infection site. With regards to the latter, 
extracellular HMGB1 protein has gained attention as a central cytokine for all immune cells, 
bridging the gap between innate and adaptive immunity.  
 
HMGB1 as a multi-faceted modulator of immunity 
 
HMGB1 was first identified as a nuclear chromatin protein, but after its identification as a late 
mediator of sepsis in 1999 (Wang et al. 1999), the multifunctional extracellular role of HMGB1 has 
gained much attention. HMGB1 is a central player in local inflammation, where it can be passively 
released by virtually any cell type undergoing immunogenic cell death (discussed above), while 
being actively secreted by innate immune cells such as macrophages, monocytes and dendritic 
cells (Sims et al. 2010). In principle, the former release as a DAMP accounts for immune activation, 
whereas the latter chronic production promotes immunosuppression, for example by recruiting 
suppressive cell types and by inhibiting dendritic cell functions and maturation (Figure 4). To this 
end, high levels of HMGB1 can also prevent macrophages from effectively phagocytosing dying 
cells, which further hinders antigen-presentation (Liu et al. 2008, Friggeri et al. 2010). Of note, also 
NK cells can produce HMGB1 as a means of impacting the inflammatory milieu in dendritic cell 
editing (Semino et al. 2005). HMGB1-mediated modulation of immunity is not, however, limited to 
innate immune cells (see below for adaptive immunity): Immunogenically released HMGB1 acts as 
a chemotactic substance attracting T and B-cells to the site of tissue damage, and also induces 
CD4+ and CD8+ T-cell proliferation (Li et al. 2013a). Under chronic HMGB1 stimulation, however, 
IFN-γ production of T-cells is suppressed, while immunosuppressive regulatory T-cells are 
promoted via RAGE-receptor (receptor for advanced glycation end-products). 
 
The fate between the two opposing outcomes is dictated by different post-translational 
modifications of the HMGB1 molecule, its redox status, spatiotemporal changes in concentration, 
and other concurrent cytokine and molecular patterns, all of which affect the receptor interactions 
on immune cells (Kang et al. 2014). Moreover, one peculiar characteristic of HMGB1 is that it 
interacts with several different receptors that may have completely opposing effects, not only on 
different cells, but also on the same cell type. Thus far, various TLRs and RAGE have been identified 
as the main receptors (Figure 4), while many others like TIM-3 (T-cell immunoglobulin domain and 
mucin domain 3) and CXCR4 (chemokine receptor type 4) have been also proposed (Li et al. 
2013a). In a recent comprehensive review, Kang et al. covered the diverse biological roles of 
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HMGB1, and its involvement in the pathogenesis of over 50 diseases (Kang et al. 2014). The 
authors paid heed to the potential of HMGB1 as a clinical biomarker and a therapeutic target in a 
wide range of conditions, and listed over 200 therapeutic strategies employed to target HMGB1 
either specifically or indirectly; Remarkably, around three-thirds of these experimental approaches 
have been published quite recently since 2010, indicating that the research field is currently 
blooming and many applications are awaited. In the context of clinical cancer research, vast 
majority of studies have implicated HMGB1 as a marker of poor prognosis in many tumor types (Li 
et al. 2012, Fahmueller et al. 2013, Stoetzer et al. 2013, Wittwer et al. 2013). However, certain 
adjuvant chemotherapies in gastric and breast cancer were associated with improved outcome 
and smaller tumor burden, respectively, when the tumors showed high HMGB1 expression (Bao et 
al. 2010, Yamazaki et al. 2014), probably reflecting the capacity to release HMGB1 in response to 
immunogenic treatments. To summarize, depending on the local microenvironment, source and 
dynamic changes, as well as coordination with other stimuli, HMGB1 can either promote or 
suppress immune reactions, which appears crucial for most if not all immune cells. 
 
 
 
Figure 4. Dual roles of extracellular high-mobility group box 1 (HMGB1) protein in regulating 
immune functions. HMGB1 is passively released in immunogenic cell death, which can be triggered 
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by certain chemotherapeutics, radiotherapy, and oncolytic adenoviruses (left part). In cooperation 
with other danger-associated molecular patterns (DAMPs), dynamically released HMGB1 
stimulates dendritic cells (DCs) by binding to toll-like receptors (TLRs), specifically TLR-2 and TLR-4, 
or as an immune complex with DNA fragments to the endosomal TLR-9. Subsequently, TLR-
signaling leads to modulation of gene transcription via NF-κB, resulting in enhanced antigen-
presentation and T-helper type 1 polarization of adaptive immunity. In a striking contrast, 
constitutive secretion of HMGB1 by tumor-associated macrophages and monocytes can results in 
immunosuppression (right part): High levels of oxidized HMGB1 leads to direct inhibition of DC 
maturation, probably via binding to Receptor for Advanced Glycation End-products (RAGE), 
followed by production of chronic inflammatory mediators such as IL-6, IL-10, and TNF-α that 
further suppress cell-mediated immunity and have tumor-promoting functions. HMGB1 possesses 
also chemokine and cytokine activities that attract immune cells and regulate their activity: 
Immunogenic HMGB1 release enhances migration and activation of effector T-cells, whereas 
chronic HMGB1 exposure leads to accumulation of immunosuppressive myeloid-derived 
suppressor cells (MDSCs) and regulatory T-cells (T-regs). Monocytes are also attracted but fall in 
between these two main phenotypes, because once in the periphery they can mature either into 
suppressive or antigen-presenting macrophages/DCs, depending on the local microenvironment. 
Modified from: (Hagemann et al. 2007). 
 
Adaptive antiviral immunity 
 
Infected cells express the viral antigens together with their endogenous antigens on the cell 
surface MHC class I molecules, which are recognized by mobile T-cells that constantly screen for 
antigens loaded onto MHC I (Muruve 2004). Once encountering its specific antigen, cytotoxic T-cell 
(CD8+) eliminates the cell and signals for other cytotoxic T-cells, T-helper (CD4+) cells, and 
antibody secreting B-cells to expand and activate against the recognized pathogen (Zaiss et al. 
2009). However, the adaptive immune cells require priming by innate immunity in order to 
recognize antigens in the first place, and even if encountered before, the resting effector cells 
need co-stimulatory signals for reactivation. APCs mediate this cross-presentation by forming an 
immunological synapse with a T-cell in lymph nodes, where the APCs not only present their 
antigens on MHC I and II molecules to the CD8+ and CD4+ T-cells, respectively, but also needs to 
provide co-stimulatory signals, such as B7 and CD40 molecules, in order to activate the T-cell 
(Seliger et al. 2008, Smith 2014). Once correctly primed, the immune response leads to organized 
interplay between T-helper, cytotoxic T-cells and B-cells, inducing activation of cellular (T-cells) and 
humoral (B-cells) immunity (Zaiss et al. 2009, Nayak and Herzog 2010). Ultimately, these cells 
mediate system-wide, specific immune responses capable of eradicating the infected cells via 
cytotoxic T-cell responses, and eliminating free adenoviruses and boosting further antigen-specific 
immunity by secreted antibodies.  
 
Both arms of the adaptive immunity, cellular and humoral response, are necessary for clearing 
infections, but with regards to anticancer immunotherapy, engagement of the cellular immunity is 
more desirable. Following dendritic cell mediated cross-presentation at the lymph nodes, 
polarization of the cross-primed CD4+ T-cells either into T-helper (Th) type 1 or type 2 phenotype 
leads to preferential induction of cytotoxic CD8+ T-cells or antibody-producing B-cells, 
respectively. These adaptive immune cell phenotypes (polarized CD4+ T-cells and their associated 
effector cells) can be distinguished by their secreted cytokine profiles: type 1 responses are 
dominated by production of IFN-γ and IL-2, while type 2 responses are characterized by production 
of IL-4, IL-5, and IL-10 (Morel and Oriss 1998). Even though the Th1 and Th2 cytokine profiles and 
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their immunological consequences always show considerable overlapping, the dominance of 
either response can downregulate the other, resulting in systemic polarization of the adaptive 
immunity. Immune-escaped, advanced tumors are able to repress both arms, but also 
preferentially misdirect the mounted immune responses towards Th2 pathway, for example by 
secreting IL-10, TGF-β and prostaglandins, because humoral immunity is ineffective in eradicating 
cancer cells (Ichim 2005). This is demonstrated by the systemic Th2-skewed balance observed in 
many cancer patients (Sato et al. 1998, Lauerova et al. 2002, Zanussi et al. 2003). In contrast, most 
viral infections and adenovirus vectors have been found to result mainly in Th1-type immunity 
(Miller et al. 2002, Lee et al. 2008, Cox et al. 2013), which is logical since cellular immunity is more 
potent in eliminating infected cells. Of note, adenovirus as well as other virus infections increase 
also anti-inflammatory IL-10 levels, reflecting the natural (or tumor-induced) peripheral tolerance, 
which is crucial in limiting the inflammation (Reid et al. 2002b, Cox et al. 2013). Finally, the feature 
of adenovirus vectors to induce Th1-type immunity has been adapted and further enhanced in the 
context of oncolytic immunotherapy by arming the virus with immunostimulatory transgenes such 
as GMCSF and CD40-ligand, which have shown promise in redirecting the ineffective Th2 cytokine 
profile towards Th1-type responses, as will be discussed later (Malmstrom et al. 2010, Cerullo et 
al. 2011, Pesonen et al. 2012). 
 
The recruitment of adaptive immunity takes usually around 4–7 days, while the innate immune 
responses are instant, underlining the need for both arms to control the infection (Muruve 2004). 
The mounting of an effective adaptive response can be observed as a second peak in inflammatory 
cytokines in blood, resulting from cytotoxic T-cells killing the infected cells. B-cell activation and 
antibody production is even slower in primary infections, partly because they need two signals for 
activation, one from the antigen and another from the Th2-type CD4+ cell. Thereafter, B-cell 
activation leads to antibody production against adenoviral proteins that peaks in 2–4 weeks in 
humans (Pesonen et al. 2010). Majority of the antibody responses to adenovirus vectors is 
directed towards the hexon protein (Sumida et al. 2005). With regards to adenoviral cancer gene 
therapy, conflicting reports have been published about the role of neutralizing antibodies: A phase 
I clinical trial using repeated intrapleural injections of a replication-deficient adenovirus vector 
coding for IFN‐β reported high levels of IFN‐β in pleural effusion after the first dose, but 
significantly lower levels after subsequent treatment doses (Sterman et al. 2010); Here, the lack of 
IFN‐β expression was correlated with induction of virus-neutralizing antibodies that most likely 
hampered therapeutic transgene production. In contrast, efficient transgene expression was 
reported after intratumoral administration of a replication-deficient adenovirus coding for IL‐24, 
despite the presence of neutralizing antibodies (Tong et al. 2005). Nonetheless, the impact of pre-
existing immunity is likely to be the opposite when considering oncolytic immunotherapy where 
the oncolytic virus is actually desired to induce potent immune responses against the host tumor 
cell. Indeed, in this setting the existence of neutralizing antibodies has not been correlated with 
reduced antitumor efficacy (DeWeese et al. 2001, Reid et al. 2002a), but rather in a striking 
contrast, even more pronounced antitumor immune responses have been noted in pre-immunized 
animals and patients (Tuve et al. 2009, Kanerva et al. 2013), which has been further associated 
with improved therapeutic outcome (Alemany and Cascallo 2009, Tuve et al. 2009). Finally, 
neutralizing antibodies appear to be important from a safety perspective in oncolytic adenovirus 
treatments (Pesonen et al. 2010). 
 
Adaptive immunity is capable of creating an immunological memory after primary virus infection, 
which is long-lasting and allows for faster and more specific responses against potential re-
infections (Nayak and Herzog 2010). As discussed here and previously, these principles can be 
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adapted to antitumor immunity as well. In summary, the nature of adaptive immune response 
relies on several factors, such as cytokine responses, immunogenicity and dose of the antigen, 
presence of immunosuppressive cell types, and genotypic characteristics such as immune-receptor 
polymorphisms (van Sorge et al. 2003, Nayak and Herzog 2010, Lindau et al. 2013). Immune 
system can also become tolerant to antigens, which is crucial for limiting autoimmune reactions, 
but can be devastating with regards to cancer (Smith 2014). Adaptive antiviral immunity is 
essential for effective eradication of infected cells and circulating viruses, but it has a dual role 
with regards oncolytic immunotherapy: On one hand antiviral responses can limit the replication in 
tumors and restrict the vector distribution to distant metastases, but on the other hand robust 
antiviral immunity towards infected cancer cells, coinciding with immunogenic oncolysis, danger-
signaling, release of tumor-specific antigens, and skewing of the immunity towards Th1 type 
responses, can lead to enhanced antitumor immunity (Melcher et al. 2011, Kanerva et al. 2013). As 
recent advances in clinical oncolytic immunotherapy suggest, the latter scenario clearly seems to 
have an upper hand when properly designed and applied (Andtbacka et al. 2013, Lichty et al. 
2014). 
 
1.5 Cancer-therapeutic adenovirus vectors 
 
Growing numbers of different oncolytic viruses have been tested in clinical I-III phase trials during 
the past two decades (Pol et al. 2014). As of June 2014, there were 1331 registered cancer gene 
therapy trials, of which replication‐deficient or oncolytic adenovirus accounts for 26% either alone 
or in combination with other modalities (Journal of Gene Medicine, 
http://www.abedia.com/wiley/index.html). Thus, adenovirus is an important vector in clinical 
development for several tumor types. Moreover, this translates into large body of safety data, 
indicating overall good tolerability with the approach. Other promising vectors include herpes 
simplex virus, reovirus, vaccinia virus, and Newcastle disease virus (Pol et al. 2014). The earliest 
clinical trials date back to the 1950s, when certain non-attenuated virus strains, such wild-type 
adenovirus, hepatitis B virus, and West Nile virus were tested in advanced cancer patients (Kelly 
and Russell 2007). The modern era of cancer gene therapy began, however, in the early 1990s 
after the genetic modification techniques became available to design safer tumor-targeted virus 
vectors. 
 
Two major classes of adenoviruses used in experimental and clinical settings are replication‐
deficient and replication-competent, i.e. oncolytic adenoviruses. Replication‐deficient viruses have 
been rendered incapable of replicating by producing large genomic deletions, and are used to 
carry therapeutic genes to the target tissues, i.e. tumors. In contrast, oncolytic viruses entail only 
minor genetic deletions or modifications that modify them selective for cancer cells, where they 
can replicate, causing oncolysis, and spread to other cancer cells (Russell et al. 2012). Importantly, 
oncolytic viruses have either natural selectivity to cancer cells, such as oncolytic reovirus, or have 
been genetically modified to prevent replication in normal cells, as in the case of oncolytic 
adenovirus (Fukazawa et al. 2010, Kyula et al. 2012). In this thesis we have used adenoviruses as 
tumor-selective oncolytic agents, and therefore the preclinical and clinical focus is on 
adenoviruses, although landmark studies with other oncolytic viruses are discussed as well.  
 
The main advantages of using adenoviruses as gene therapy vectors are that adenoviruses can 
infect both dividing and non-dividing cells, adenoviral DNA does not naturally integrate into the 
host genome, relatively high levels of transgene expression can be achieved, and adenovirus has  
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reasonably high transgene capacity (depending on the vector generation; see section 1.6) (Russell 
2000, Alba et al. 2005). Practical benefits include the facts that adenovirus biology is well-
characterized, adenoviral genome is relatively easy to modify, adenovirus particle and its DNA are 
stable to storage even for prolonged periods, production of new virions is straightforward, and as 
a result, high viral titers can be produced (Smith et al. 2010).  
 
Adenovirus has also several constrains that limits its use. The main limitation for many gene 
therapy approaches is the transient nature of gene expression, rendering the use of adenoviruses 
insufficient in certain diseases that require long-lasting expression of the genetic material (Russell 
2000). Natural tropism to liver can also increase liver toxicity while decreasing target tissue 
transduction (Arnberg 2012). Since adenoviruses are common human pathogens, the immune 
system can eradicate the virus rather efficiently and many individuals also possess pre-existing 
immunity, which are problematic to therapeutic transgene expression (Hendrickx et al. 2014). 
However, this immunogenicity can also account for treatment efficacy when considering cancer 
gene therapy with oncolytic viruses, as will be discussed later (Lichty et al. 2014). Further 
specifically with regards to cancer gene therapy, low expression of CAR receptors on many tumor 
types can reduce cancer cell transduction (Arnberg 2012). In order to circumvent these problems, 
adenoviruses have been genetically modified to increase gene expression, to improve tumor 
targeting over liver tropism, and finally, to evade or further induce immune responses depending 
on the utility. Strategies to achieve these goals are next discussed in more detail. 
 
1.5.1 Transductional targeting 
 
Viral selectivity to cancer cells can be enhanced by various genetic alterations that reduce 
biodistribution to normal tissues such as liver, improve homing to tumors, and reduce replication 
in normal cells, while increasing oncolysis of cancer cells. These modifications can ultimately 
enhance both treatment efficacy and safety of adenoviral cancer gene therapy. Two main ways to 
achieve improved targeting are transductional and transcriptional targeting. The previous 
technique involves modification of the viral capsid or coating of the virus, in order to enhance and 
target viral entry to cancer cells. The latter one, in turn, comprises of engineering the viral genome 
to allow and enhance replication and gene expression to occur only in cancer cells. 
 
Adenovirus serotype 5 is the most used cancer gene therapy vector (Khare et al. 2011). Given the 
preclinical importance of CAR-receptor for its cell entry (Bergelson et al. 1997), much effort has 
been focused on re- or co-targeting the virus to other receptors in order to increase its 
transduction to cancer cells with low CAR-receptor expression (Rauen et al. 2002). In fact, low CAR-
receptor expression has been shown to correlate with more aggressive disease, possible due to 
metastatic characteristics of the cancer, which may be a central reason for its downregulation in 
tumor cells (Matsumoto et al. 2005). Nevertheless, the importance of CAR-receptor for serotype 5 
binding in human gene therapy is less clear (Hall et al. 2010). The most utilized means of increasing 
adenovirus transduction is fiber pseudotyping, where the entire knob is replaced with its structural 
counterpart from another serotype. This results in so called chimeric adenovirus, of which the first 
example is adenovirus serotype 5 replaced with a serotype 3 knob (Krasnykh et al. 1996). As a 
consequence, this 5/3 chimeric adenovirus is able to transduce cells via serotype 3 receptors, 
which were much later identified, and the main receptor appearing desmoglein-2 (Short et al. 
2004, Fleischli et al. 2007, Wang et al. 2011). The chimeric serotype 5/3 adenovirus has since 
shown favorable efficacy in several preclinical and clinical therapy settings (Kanerva et al. 2003, 
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Koski et al. 2010, Hemminki and Hemminki 2014). One distinct example of transductional targeting 
is to extend the use of adenoviruses to other serotypes. As mentioned, serotype 3 adenovirus 
utilizes different receptors for transduction, and due to different capsid conformation, is not 
abolished by neutralizing antibodies directed against serotype 5 (Smith et al. 2010). An oncolytic 
adenovirus based on serotype 3 has been engineered, and was shown to mediate efficient 
antitumor inhibition in vivo without being neutralized by anti-serotype 5 antibodies (Hemminki et 
al. 2011). Moreover, the serotype 3 oncolytic virus was well-tolerated with potential signs of 
efficacy seen in refractory cancer patients (Hemminki et al. 2012). Interestingly, pre-existing 
serotype 5 immunity did not seem to abrogate the functions of the serotype 3 virus in patients, 
suggesting that serotype switching might be a feasible approach for prolonged treatment periods. 
 
Ligand incorporation is another means by which cancer cell transduction can be increased, at least 
preclinically. Besides downregulating multiple cell surface proteins, progressing tumors also 
upregulate some adhesion molecules that allow rational targeting by incorporating their ligands to 
the virus capsid (Nicklin et al. 2005, Hall et al. 2010). Thus, various fiber knob modifications have 
been tested: For example, adding an RGD-motif to the HI loop of the knob can redirect and 
increase the virus attachment to cell surface integrins that are plentiful in majority of the tumors, 
as demonstrated in pancreatic cancer and malignant glioma (Bilbao et al. 2002, Tyler et al. 2006). A 
similar infectivity-enhanced conditionally-replicating adenovirus Ad5-Δ24-RGD was tested in a 
phase I clinical trial in 21 progressing ovarian cancer patients (Kimball et al. 2010): Treatments 
were well-tolerated, seven patients had prolonged virus genomes in circulation, and 71% of the 
patients showed disease control after one month of follow-up. Incorporation of polylysine motif 
(pk7) that binds to heparan sulfate proteoglycans on is another experimental example, although 
more controversial due to natural presence of the receptor on also normal cells (Zheng et al. 
2007). Furthermore, novel ligands can be incorporated also to adenoviruses lacking the natural 
fiber knob. The replacement of the knob by human CD40-ligand, for example, showed increased 
virus transduction to cancer cells expressing CD40 (Belousova et al. 2003, Izumi et al. 2005). 
 
In addition to genetic transductional modifications, also adapter molecules have been tested 
preclinically that cross-link the adenovirus capsid proteins with specific cell surface molecules. As 
an early example, the folate receptor, which is ubiquitously expressed in cancer cells, was targeted 
by using a folate ligand conjugated to an anti-fiber antibody (Douglas et al. 1996). In another 
attempt, an EpCAM tumor-antigen was targeted in a similar approach because of its high 
expression in several tumor types including breast, ovarian, colon and lung cancer (Haisma et al. 
1999). However, these attempts have not been yet tested clinically, mostly due to safety concerns 
regarding the use of a separate chemical linker molecule besides the well-studied adenovirus 
(Verheije and Rottier 2012).  
 
1.5.2 Transcriptional targeting 
 
Tumor-targeted viral gene expression and replication are the most important means by which 
gene therapy vectors are rendered cancer selective. There are two main approaches for 
transcriptional targeting: genetic deletions and incorporation of tumor-specific promoters. Genetic 
deletions are much utilized for targeting adenoviruses, owing to their ability to express viral 
proteins in cancer cells that complement the missing gene functions (Berk 2005). E1A and E1B 
regions are essential for adenovirus replication and for transcription of the later genes, as 
previously discussed (Stillman 1986, Whyte et al. 1988). Thus, deletion of these regions renders 
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the virus replication-deficient in normal cells, but tumor-specific pathways that complement these 
defects allow conditional replication in cancer cells. The most known example, the matriarch of 
conditionally-replicating adenoviruses, is ONYX-015 that has deletions in the gene coding for 
E1B55K, which is responsible for inhibition of p53 protein. This attenuates replication in normal 
cells with intact p53, but allows ONYX-015 to replicate in p53-deficient cancer cells (Bischoff et al. 
1996). ONYX-015 has been tested perhaps the most extensively both preclinically and in clinical 
trials (discussed in section 1.7). Early on it was shown to specifically replicate in p53-mutated cells 
(Heise et al. 2000), but the E1B55K deletion also reduced the cell killing potential, given the several 
important actions of E1B55K (Dix et al. 2001). Instead of deleting the whole adenoviral early gene, 
a partial genomic deletion has been introduced with promising results: Protein products of the E1A 
gene normally bind to the retinoblastoma protein (Rb) that releases the E2F transcription factor, 
which is required for activating genes that promote the S phase and consequently virus replication 
(Whyte et al. 1988). However, in cancer cells that feature dysregulated Rb/p16 pathway, free E2F 
is constantly available, rendering this function of E1A dispensable (Sherr 1996). Thus, a targeted 
deletion to the Rb binding site of E1A region, such as 24 base-pair deletion (∆24), makes the virus 
transcriptionally cancer-selective by attenuating replication in normal cells (Fueyo et al. 2000). 
These ∆24 oncolytic adenoviruses have been widely used due to their improved oncolytic capacity 
over the early-gene deleted adenoviruses (Kanerva et al. 2003, Hakkarainen et al. 2009), and their 
clinical use is discussed later. 
 
Incorporation of tumor-specific promoters to viral genome controlling its gene expression is 
another way to target replication to cancer cells. Prostate-specific antigen (PSA) targeted 
adenovirus was one of the first attempts where prostate-specific enhancer was inserted to control 
the E1A region, and resulted in selective replication in PSA-expressing prostate tumors and 
showed promising efficacy in vivo (Rodriguez et al. 1997). Carcinoembryonic antigen (CEA) specific 
suicide gene (thymidine kinase mediated pro-drug conversion) expression approach was tested in 
colorectal cancer mouse model with fair efficacy and reduced liver toxicity as compared to 
irrelevant cytomegalovirus promoter (Brand et al. 1998). Given the natural tropism of human 
adenovirus to liver, as earlier discussed, treatment of liver carcinoma seems appealing. To this end, 
a tumor-specific α-fetoprotein driven E1B55K-deficient adenovirus was shown to mediate 
regression of hepatocellular carcinoma after intravenous injections in mice, although virus 
replication was slow probably due to E1B55K-deletion (Ohashi et al. 2001). Furthermore, a 
carcinoid tumor specific Chromogranin A was utilized to control E1A region of a conditionally-
replicating adenoviruses that did not show viral gene expression in normal hepatocytes, but 
mediated selective carcinoid tumor inhibition in vivo (Leja et al. 2007).  
 
Aforementioned examples of promoters are very tumor-type specific, which may increase their 
specificity but often limits applicability since they have been designed for a very narrow indication. 
Moreover, as the common tumor resistance against small-molecular inhibitors suggests, some 
cancer clones of a progressing tumor are likely to be resistant or become resistant to a selective 
pathway inhibition or targeting (Hojjat-Farsangi 2014). Therefore more recent attempts have 
focused on designing pan-tumoral selective promoters. A logical extension to the Rb de-targeting 
of the ∆24-deleted adenovirus is an E2F-specific promoter. This approach utilizes the same Rb/p16 
pathway dysregulation entailed by virtually all tumors (Sherr 1996), in that it requires free E2F that 
binds to the promoter controlling the E1A region. Since normal cells halt their cell cycle when 
infected by an adenovirus, they lack free E2F transcription factor thus attenuating virus replication 
(Rojas et al. 2009, Hemminki and Hemminki 2014). Interestingly, these double transcriptionally 
targeted adenoviruses harboring both E2F-promoter and ∆24-deletion seem to benefit from the 
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double-control of E1A due to positive feedback loop of free E2F binding in cancer cells. Another 
example is the cyclooxygenase 2 (Cox-2) promoter, which exploits the ubiquitous expression of 
Cox-2 in various cancer types (Wang and Dubois 2006). Accordingly, Cox-2 promoter is also used to 
control E1A expression together with ∆24-deletion and has been tested preclinically and in 
refractory cancer patients with good safety and potential signs of efficacy (Bauerschmitz et al. 
2006, Pesonen et al. 2010). In addition, vascular endothelial growth factor (VEGF) promoter has 
been evaluated preclinically, and together with Cox-2 promoter, the nature of these promoters 
allowed external control by using common anti-inflammatory drugs such as dexamethasone and 
salicylic acid (Kanerva et al. 2008). Finally, one emerging notable promoter is the human 
telomerase reverse transcriptase (hTERT) promoter controlling E1A, which is based on a 
fundamental hallmark of cancer that high telomerase levels can maintain telomere lengths and 
promote tumor growth (Hanahan and Weinberg 2011). Indeed, this promoter has been tested in a 
variety of preclinical and clinical settings with favorable results (Ito et al. 2006, Hemminki et al. 
2011, Diaconu et al. 2012, Hemminki et al. 2012, Pesonen et al. 2012).  
 
1.6 Replication-deficient adenoviruses and their clinical use 
 
Replication-deficient adenovirus vectors have been improved over the years owing to the 
achievements in virus- and immunobiology. These vectors are widely used for both cancer therapy 
and to correct various monogenic diseases and inherited enzyme deficiencies (Ginn et al. 2013). 
Adenoviruses have a limited capacity to carry additional DNA, very alike other vectors, which is 
why construct of novel vectors has been based on deleting viral genes; Adenovirus can become 
unstable if the genomic load is more than 105% of the wild-type cargo (Bett et al., 1993). Thus, the 
first generation adenovirus vectors were deleted of the E1 gene region and often also E3 region, 
while a therapeutic transgene was typically inserted in the place of E1 region (Hall et al. 2010). 
These viruses can accommodate fairly large transgenes of up to 8.2 kilo-base pairs (Alba et al. 
2005). A major set-back for the first generation adenoviruses is that the transgene expression, 
although typically potent at start after a successful transduction, remains transient due to inability 
of the vector to replicate, and immune responses efficiently eradicating the vector (Muruve 2004). 
Nevertheless, these viruses have been utilized to deliver various anticancer transgenes such as 
anti-angiogenic proteins (Im et al. 2001), monoclonal antibodies (Jiang et al. 2006), cytokines (Sung 
et al. 2002), tumor‐suppressor proteins (Nielsen et al. 1998), and prodrug converting enzymes 
(Tyynela et al. 2002). One notable clinical success story among the first-generation vectors is the 
Ad‐p53 (Gendicine), which was approved for the treatment head and neck cancer in China in 2003, 
becoming the first gene therapy modality in clinical use (Peng 2005). Ad-p53 is an E1-deleted 
serotype 5 adenovirus coding for p53 tumor-suppressor protein under a rous sarcoma virus (RSV) 
promoter. Combination of Ad-p53 together with radiation showed even synergistic efficacy in 
head and neck cancer (Peng 2005), and was later studied with radiotherapy also in liver cancer 
with promising results (Yang et al. 2010). In addition, Ad-p53 was reported to mediate antitumor 
efficacy when combined with other conventional treatments, such as cisplatin and 5-fluorouracil in 
advanced lung cancer, and chemoembolization in liver cancer (Peng 2005). The reasons why this 
first-generation adenovirus vector has been clinically so successful particularly in China are likely 
many, ranging from patient availability to different regulatory authorities (Pearson et al. 2004). 
Nevertheless, as 10% of the over two million head and neck cancer patients in China are estimated 
to receive the treatment annually, large bulk of safety and efficacy data should be generated in the 
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years to come. Ultimately, large cohorts of patients are needed to reliably evaluate treatment 
efficacy and to further develop clinical practice (administration route, dosing, fractionation, etc.). 
 
Second generation adenovirus vectors were designed to overcome the limited transgene 
expression capacity by targeting deletions also to viral genes in the E2 and E4 regions that are 
highly immunogenic, thus decreasing antiviral immune responses (Hall et al. 2010). These 
adenoviruses have been utilized in similar approaches as the first generation vectors (Alba et al. 
2005, Murugesan et al. 2009), but still suffer from the same problem of rapid immune eradication 
(O'Neal et al. 1998). As a result the third generation vectors were designed: They are called gutless 
vectors, devoid of all natural viral genes except the packaging signal and inverted terminal repeats 
(see Figure 3), which also cleared more room for therapeutic transgenes, and can carry up to 36 
kilo-base pairs of foreign genetic material (Alba et al. 2005). Gutless adenoviruses are helper-
dependent, because they require co‐infection with a helper adenovirus that provides it with 
essential genes to produce new virions. These last generation of replication-deficient adenovirus 
vectors have the advantage of evoking a minimal immune response, thus resulting in longer gene 
expression. Indeed, these vectors have been actively tested for various gene replacement 
therapies (Ginn et al. 2013).  
 
1.7 Oncolytic adenoviruses and their clinical use 
 
Oncolytic viruses are defined as viruses that selectively replicate in tumor cells rather than normal 
cells. The modern use of oncolytic viruses stems from the fact that replication-deficient virus 
vectors proved safe but therapeutically insufficient in cancer gene therapy trials (Rein et al. 2006). 
Conditionally replicating adenoviruses were the first selectively replicating, i.e. oncolytic, 
adenoviruses developed: By applying tumor-specific transductional and transcriptional targeting, 
they mediate both transgene expression and virus replication in the infected cancer cell, followed 
by lysis of the host cell and release of new virus progeny that are able to further spread and infect 
other cancer cells (Figure 5). Thus, virus replication also leads to improved transgene expression in 
tumors, further potentiating treatment efficacy. The discussed strategies to control the expression 
of E1A region, along with subsequent gene regions and viral DNA replication, have been found 
effective in confining oncolytic adenovirus replication to cancer cells (Fueyo et al. 2000, Reid et al. 
2002a, Bauerschmitz et al. 2006). Oncolytic adenovirus dl1520, better known as ONYX-015, was 
the first to employ this approach: Deletion of the early E1B55K gene rendered the virus selective 
for cancer cells with dysfunctional p53 gene (Bischoff et al. 1996). Given the many functions of 
E1B55K, however, it was later discovered that defects in viral mRNA export also accounted for the 
attenuation of virus replication in normal cells (O'Shea et al. 2004). ONYX-015 was the first 
oncolytic virus tested in clinical trials for treatment of advanced head and neck cancer in 1996 
(Ganly et al. 2000), and since then ONYX-015 has been studied in phase I-II clinical trials for 
treatment of various tumor types such as head and neck cancer, advanced sarcoma and ovarian 
cancer (Nemunaitis et al. 2000, Vasey et al. 2002, Galanis et al. 2005). Safety of the virus was good 
throughout, but efficacy was modest in most of the trials: As a single agent, ONYX-015 showed ca. 
15-21 % response rate in head and neck cancer (Ganly et al. 2000, Nemunaitis et al. 2000), while 
lack of notable efficacy was reported in pancreatic, ovarian, and colorectal cancer (Vasey et al. 
2002, Hamid et al. 2003, Hecht et al. 2003). Importantly, ONYX-015 was very early on noticed to 
synergize with conventional treatment modalities preclinically. Therefore it was tested together 
with cisplatin and 5-fluorouracil for treatment of head and neck cancer: while ONYX-015 as a single 
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treatment reach only 21% tumor response rate (partial response of >50%) in advanced head and 
neck cancer patients (Nemunaitis et al. 2000), combining it with chemotherapy increased the 6-
month durable response rate up to 63%, and 8 out of 30 patients showed complete response 
(Khuri et al. 2000). However, another early combination therapy trial, assessing ONYX-015 
together with mitomycin, doxorubicin and cisplatin for the treatment of advanced sarcomas 
showed again less than 20% response rate, indicating that only certain combinations and/or tumor 
types can lead to clinical benefit. These data underline the importance for rational combinations 
and indications: Some of the potential mechanisms underlying combinatorial benefit with 
conventional therapies have been previously discussed, and are studied in this thesis.  
 
Another oncolytic adenovirus studied extensively in China, H101 (Oncorine), is very similar to 
ONYX-015 but it also lacks the complete E3 region (Garber 2006, Yu and Fang 2007). This deletion 
may result in more rapid clearance of the virus by the immune system, given the importance of E3 
region proteins in counteracting host immune responses (Bortolanza et al. 2009a). It has also been 
linked to improved oncolytic potency in vitro (Suzuki et al. 2002). Nevertheless, H101 has shown 
good safety and efficacy in clinical trials (Yu and Fang 2007), and it became the first oncolytic 
adenovirus approved for treatment of cancer in 2005, indicated for head and neck cancer therapy 
in China (Garber 2006). In fact, E3-deletion may serve a paradoxical benefit of increased immune 
activation against the virus in patients, which can lead to enhanced immunotherapeutic antitumor 
activity. Unfortunately, the initiated phase III clinical trial in head and neck cancer using ONYX-015 
that has the intact E3-region was never accomplished due to funding issues, and therefore cross-
comparison between H101 and ONYX-015 is difficult. The fact that clinically evaluated E1B55K-
deleted adenoviruses, H101 and E1-deleted Ad-p53, appear to synergize with radiotherapy 
suggests that E1B55K protein would not be crucial for its radiosensitizing effects. However, its 
impact on tumor radiosensitation has not been previously assessed in comparison to other 
proposed radiosensitizing adenoviral proteins (Figure 2). Approval of H101 was based on a 
randomized phase III trial where intratumoral injection of H101 together with cisplatin/adriamycin 
and 5-fluorouracil was compared to chemotherapy alone (Xia et al. 2004): H101 showed 
significantly higher overall response rate of 78.8 % as compared to 39.6 %, in cisplatin 
chemotherapy, whereas adriamycin-based regimen failed to show difference (50.0 % in both 
groups). Survival data was, however, not reported due to difference in regulations between the 
health authorities: China relied at the time on objective responses, while the Western countries 
have always based their approval on survival benefit. Other examples of clinically tested oncolytic 
adenoviral constructs with promising data include an oncolytic adenovirus based on the E1B55K-
deleted backbone of ONYX‐015, which is armed with a cytosine deaminase/HSV‐tk fusion suicide 
gene, for treatment of prostate cancer (Freytag et al. 2007), a PSA tumor-antigen targeted 
oncolytic adenovirus CG7870 for the treatment of metastatic prostate cancer (Small et al. 2006), 
and a hTERT promoter‐driven oncolytic adenovirus, Telomelysin, in advanced solid tumors 
(Nemunaitis et al. 2010).  
 
Reovirus is an interesting exception to other oncolytic viruses in that the type 3 (Dearing) naturally 
prefers to replicate in tumor cells that have an activated Ras signalling pathway (Kyula et al. 2012). 
It has been studied extensively for treatment of e.g. metastatic head and neck cancer with 
promising efficacy, and has reached phase III evaluation in combination with 
carboplatin/paclitaxel. Furthermore, a very recent phase II randomized trial studying reovirus for 
treatment of advanced pancreatic cancer failed to meet its primary endpoint of progression-free 
survival in the total patient population in this very dismal cancer type, but showed a trend for 
improved survival (39% increase in median progression-free survival) in a sub-analysis where only 
 55 
 
KRAS-mutated patients were included (ClinicalTrials.gov Identifier: NCT01280058). Thus, a rational 
approach of exploiting the altered Ras-pathway as a “natural” targeting strategy seemed to work 
in this disease. 
 
1.7.1. Oncolytic immunotherapy 
 
Tumor-selective adenoviruses initiate immune reactions when entering and replicating in cancer 
cells. While the classical view of gene therapy is to minimize the antiviral immunity, oncolytic 
immunotherapy exploits it, and aims at further boosting and redirecting immune reactions against 
the tumor (Figure 5). Adenovirus is a highly immunogenic human pathogen, owing to the lack of 
efficient immune-escape mechanisms by the virus, and lack of immunological tolerance by the 
host (Tuve et al. 2009). This leads to multilevel cross-talk between the host and the virus, and 
acute immune response described earlier. Oncolysis caused by the virus releases danger-signals 
and tumor‐associated antigens that augment in breaking the immunotolerance of the advanced 
tumors, which can lead to mounting of antitumor immune responses (Melcher et al. 2011). Thus, 
immune activation at the tumor site was soon discovered to associate with treatment benefits 
(Lichty et al. 2014). The main components of this effect include virus-triggered immunogenic cell 
death that leads to release of danger-signals (DAMPs), spreading of tumor-specific antigens that 
are taken up by antigen-presenting cells, processing and cross-presentation of these tumor-
antigens to effector T-cells at local lymph nodes, and sufficient stimulus (lack of 
immunosuppression) to activate antitumor T-cell responses (Figure 5). In addition, infection and 
oncolysis can alter the cytokine milieu and skew the immunosuppressive environment at the 
tumor, thus further attracting and activating immune cells (Lichty et al. 2014). Viruses have also 
direct effects on the infiltrating immune cells. This has been demonstrated preclinically in various 
tumor models and for many different oncolytic viruses (Choi et al. 2006, Diaz et al. 2007, Fukuhara 
and Todo 2007, Prestwich et al. 2009, Diaconu et al. 2012, Parviainen et al. 2014). Specifically with 
regards to adenovirus, intratumoral treatment given to syngeneic mice that were immunologically 
tolerant to neu‐positive mammary tumors were shown to induce potent immune responses both 
at the tumor site and at the tumor‐draining lymph nodes (Tuve et al. 2009). Treatment with 
replication-deficient adenovirus led to generation of both adenovirus- and neu‐specific effector T-
cells in the lymph nodes, while at the tumor site, there was an expansion of adenovirus‐specific T-
cells, despite the presence of immunosuppressive regulatory T-cells. Indeed, these antiviral T-cells 
could efficiently kill virus-infected cancer cells and restrict tumor-growth. Moreover, the authors 
showed that pre-existing immunity against adenovirus actually increased antitumor efficacy that 
was mediated by CD4+ helper and CD8+ cytotoxic T-cells, despite the induction of neutralizing 
antibodies. These data suggest that both antiviral and antitumor immune responses can be 
generated by tumor-selective adenoviruses, and that antiviral immunity may overcome the tumor-
mediated immunosuppression, potentially unmasking also tumor-specific T-cell responses. 
Accumulating preclinical and clinical evidence supports these findings (Choi et al. 2006, VanOosten 
and Griffith 2007, Kanerva et al. 2013, Hemminki and Hemminki 2014). 
 
It should be noted, however, that direct cytotoxicity via oncolysis can result in significant 
therapeutic efficacy as well, and appears an important component of efficacy. Historical data on 
the first oncolytic virus trials suggested feasibility of direct tumor cell killing, i.e. tumor debulking 
(Kelly and Russell 2007): Several non-attenuated virus strains such as mumps virus were tested 
clinically, and some showed remarkable responses often in immunocompromised patients. These 
cases showed unrestrained infections, but were often associated with severe side-effects, and with 
the emergence of advanced chemotherapeutic regimens, the approach of using non-targeted 
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oncolytic viruses was largely abandoned. Nevertheless, these historical data demonstrate the 
capacity of direct oncolysis. In the light of newer evidence, the effective oncolysis and tumor 
debulking is not necessarily counterintuitive to immune activation. A recent preclinical study using 
intravenously delivered oncolytic vesicular stomatitis virus to treat murine multiple myeloma, 
reported a single-shot cure by debulking all tumor lesions in less than 72 hours (Naik et al. 2012). 
Importantly, this approach also generated antimyeloma T-cells that were reported to eradicate the 
minimal residual disease. Generation of immunological memory against the cancer is the most 
notable perk of immunotherapy that allows prolonged disease-free survival, which has been 
demonstrated even in patients with metastatic treatment-refractory cancer (Kyi and Postow 2014, 
Maude et al. 2014). Hence, the field of oncolytic virotherapy has shifted towards oncolytic 
immunotherapy and several strategies have been developed to further boost the antitumor 
immunity (Lichty et al. 2014). Supporting antitumor immunity over immunosuppression with the 
use of immunomodulatory low-dose chemotherapy has been employed by the cancer vaccine field 
as well as oncolytic immunotherapy (Curtin et al. 2009, Cerullo et al. 2011, Sistigu et al. 2011). This 
strategy has been discussed earlier, and is further studied in this thesis. 
 
Figure 5. Schematic mechanism of 
action of oncolytic immunotherapy. 
Intratumoral injection of oncolytic 
adenovirus leads to transduction 
and selective replication in cancer 
cells (bottom box), but not in 
normal cells because of targeted 
genetic modifications done in the 
virus genome (transcriptional 
targeting). Thereafter, oncolytic 
adenovirus triggers immunogenic 
cell death, releasing danger-signals 
and new virions that are ready to 
infect surrounding cancer cells and 
spread via circulation to distant 
metastases. Simultaneously, tumor‐
associated antigens are spread from 
the lysed cancer cell that are picked 
up and processed by dendritic cells, 
which are activated by danger-
signals. This augments in breaking 
the immune tolerance, leading to 
migration of dendritic cells to 
tumor-draining lymph nodes (top 
box) where they cross-present the 
virus- and tumor-antigens to 
effector T-cells. Primed and activated 
T-cells then travel via circulation to 
the site of infection, eradicating the 
virus-infected tumor cells and other 
unmasked tumor cells. Modified 
from: (Lichty et al. 2014). 
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1.7.2. Virus arming with immunostimulatory transgenes 
 
Infusion of recombinant cytokines, such as previously discussed IFN-α, TNF‐α, GMCSF, and IL-2, 
have been tested clinically, and are still used as an immunotherapeutic approach to treat certain 
malignancies (Lejeune et al. 1998). Nevertheless, most of these treatments were too toxic due to 
systemic effects of pro-inflammatory mediators. Arming of oncolytic viruses with 
immunostimulating molecules is appealing due to local production at the tumor site, thus 
providing spatiotemporal stimulatory signals, while minimizing the systemic side-effects. A 
plethora of different cytokine-like molecules have been investigated preclinically, while only a 
handful has entered clinical testing. In the context of adenovirus vectors, arming strategies have 
included the aforementioned TNF‐α, IFN‐α, and IL‐2, as well as IFN‐β, IFN‐γ, IL-4, IL-12, IL‐15, CD40-
ligand, and GM-CSF, and T-cell co-stimulatory molecule B7-1 (Li et al. 2005). As interferons 
mediate antiviral responses, the incorporation of IFN‐α and IFN‐β in virus vectors may seem 
controversial. However, several tumor types and cancer stem-like cells have been found deficient 
in interferon signaling (Critchley-Thorne et al. 2009, Ahtiainen et al. 2010), suggesting the 
downregulation as a means of immune evasion. An acute type I IFN production may therefore 
induce immune reactions at the tumor site. Indeed, a replication-deficient adenovirus coding for 
IFN‐β was shown to eradicate mesothelioma tumors by enhancing antitumor immunity in mice 
(Odaka et al. 2002). IFN‐β coding adenoviruses have been since studied in clinical trials, which have 
implied antitumor immune inductions also in patients (Chiocca et al. 2008, Sterman et al. 2010). 
TNF‐α armed adenovirus vectors have been extensively studied in laboratory (MacGill et al. 2007), 
where promising results have led to clinical testing of a replication‐deficient adenovirus expressing 
TNF‐α under the control of a radiation‐inducible promoter (Senzer et al. 2004). Intriguingly, a 
phase I clinical trial reported no dose-limiting toxicities in combination with radiotherapy, and 
objective tumor responses were seen in 70% of patients with various advanced solid tumors 
(Senzer et al. 2004). Another phase I trial assessing the combination for treatment of advanced 
soft tissue sarcomas reported equally well-tolerated profile and showed 85% response rate 
(Mundt et al. 2004). Supported by further encouraging results in phase I/II dose-escalation studies 
(Chang et al. 2012, Hecht et al. 2012), randomized controlled trials using the approach are 
underway (Hernandez et al. 2010). 
 
Several cytokines have shown promise as arming molecules in the context of oncolytic 
adenoviruses as well. IL‐12 activates NK cells and T-cells and is naturally produced by antigen‐
presenting cells. A replication-deficient adenovirus vector coding for IL-12 was tested in a phase I 
trial of 21 patients with advanced digestive tract tumors (Sangro et al. 2004): While the treatment 
was well-tolerated, and showed 29% disease control rate together with significant increases in 
effector immune cells in the post-treatment biopsies, the effects were transient probably due to 
low production of the cytokine. Therefore, IL-12 expressing oncolytic adenoviruses are being 
investigated in immunocompetent murine models for clinical testing (Bortolanza et al. 2009b). 
Anti-CTLA4 antibody ipilimumab, which has been approved for treatment of melanoma, is an 
appealing arming molecule given its function of releasing the immunosuppressive breaks of the T-
cells (Hodi et al. 2010). Results of a combination therapy trial with oncolytic herpes simplex virus  
T-VEC have been recently reported with impressive signs of preliminary efficacy and manageable 
safety profile in metastatic melanoma patients (Puzanov et al. 2014). Nevertheless, local 
production of the antibody might further improve the safety. Also given the virus-induced 
accumulation of tumor-infiltrating lymphocytes and their local suppression in the tumor 
 58 
 
microenvironment, local production ipilimumab from a vector combined with immune activation 
by the virus would seem feasible. This approach has been tested preclinically: Both a replication-
deficient and an oncolytic adenovirus coding for ipilimumab showed increased antitumor immune 
responses and high efficacy in vivo (Liu et al. 2011a, Dias et al. 2012).  
 
Oncolytic adenoviruses expressing CD40-ligand 
 
Another attractive candidate to stimulate T-cells is CD40-ligand (CD40L), a transmembrane protein 
expressed mostly on CD4+ helper T-cells, which binds to the CD40-receptor on antigen-presenting 
cells such as macrophages and dendritic cells (Grewal and Flavell 1998). Activation of CD40 by its 
ligand enhances antigen presentation and IL-12 production by these cells, resulting in more potent 
innate immune response and increased T-cell priming (van Kooten 2000). Thus, CD40 is a critical 
costimulatory signal that can trigger T-cell expansion and polarize effector functions towards Th1-
type response, both of which are required for effective antitumor cytotoxic T-cell responses 
(Loskog et al. 2005). In addition, CD40L can induce apoptosis of tumor cells, further directly 
activates cytotoxic T-cells, and reduces immunosuppression (Grewal and Flavell 1998, Loskog et al. 
2005). These characteristics render CD40L an appealing arming molecule. Similar to many 
cytokines, systemic side-effects limit the use of recombinant CD40L. In the context of adenoviral 
cancer gene therapy, however, CD40L has been tested preclinically and in cancer patients: Phase I-
II clinical trials studying a replication-deficient adenovirus for treatment of invasive bladder cancer 
(Malmstrom et al. 2010) and chronic lymphocytic leukemia (Wierda et al. 2010), resulted in good 
safety and evidence of biological activity but modest efficacy. Furthermore, an oncolytic 
adenovirus coding for CD40L has shown promising antitumor efficacy in syngeneic murine models, 
together with evidence of antigen-presenting cell induction, IL-12 production, Th1 polarization and 
effector T-cell infiltration to the tumor site (Diaconu et al. 2012). Accordingly, the CD40L-coding 
oncolytic adenovirus was assessed in patients with treatment-refractory solid tumors, and showed 
good safety, Th1 type immune responses in majority of the patients, antitumor T-cell inductions in 
peripheral blood, and promising signs of efficacy (Pesonen et al. 2012). 
 
Oncolytic adenoviruses expressing GM-CSF 
 
GMCSF is a potent cytokine and a leukocyte growth factor that enhances the function of antigen-
presenting cells. Local increase in GMCSF levels stimulates recruitment of monocytes and induces 
their maturation into dendritic cells and macrophages (Chang et al. 2004a). In addition, GMCSF 
activates several types of innate immune cells, including NK-cells, dendritic cells, and 
macrophages, thus leading to enhanced tumor cell killing, and subsequent tumor-antigen 
processing and presentation to effector T-cells (Arellano and Lonial 2008). However, similar to 
many other cytokines, systemic use of recombinant GMCSF is compromised by serious 
inflammatory side-effects, while the efficacy has remained modest due to low levels in tumors 
(Arellano and Lonial 2008). Moreover, high systemic GMCSF levels have been correlated with 
induction of immunosuppressive MDSCs (Serafini et al. 2004), whereas local production and low 
systemic levels have not been associated with the effect. In fact, GMCSF mobilizes myeloid cells 
which is a logical reason also for MDSCs accumulation after systemic exposure, while locally it acts 
as a chemoattractive molecule and a local activator of immune cells (Arellano and Lonial 2008). 
Therefore, GMCSF has been widely used as an adjuvant in various immunotherapeutic strategies 
(Mellman et al. 2011), along with evident success as in the case of approved cancer vaccine 
sipuleucel-T (Kantoff et al. 2010). In cancer gene therapy, GMCSF has been perhaps the most used 
arming cytokine. Replication-deficient adenovirus vector expressing GMCSF was shown to increase 
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efficacy of an oncolytic adenovirus in an adjuvant manner in vivo (Burroughs et al. 2004). 
Furthermore, oncolytic adenoviruses coding for GMCSF have been tested in several mouse and 
semi-permissive hamster models including head and neck, liver, bladder, and pancreatic cancer 
with impressive efficacy and evidence of antitumor immune activations (Koski et al. 2010). 
Moreover, the GMCSF-coding oncolytic adenovirus has been recently assessed in cancer patients: 
Intratumoral treatments were well-tolerated in advanced head and neck cancer patients in a 
phase I trial, together with signs of systemic biological activity and local objective responses mainly 
in the injected lesions (Chang et al. 2009). In another clinical report, patients with advanced solid 
tumors who received a GMCSF-expressing serotype 5 oncolytic adenovirus showed good overall 
safety, antiviral and antitumor immune activations, and possible signs of efficacy with disease 
stabilization in 50% of patients (Cerullo et al. 2010). Moreover, a chimeric serotype 5/3 adenovirus 
coding for GMCSF was assessed in a similar setting, and presented corresponding safety, signs of 
biological and immunological activity, and disease stabilization in 67% of patients (Koski et al. 
2010). The latter treatment agent is currently being investigated in phase I-II clinical trials.  
 
Other promising GMCSF-coding oncolytic viruses include a vaccinia and a herpes simplex virus. 
Vaccinia virus is a highly immunogenic virus of the pox‐family of viruses, rendering it attractive for 
cancer immunotherapy. Certain strains of vaccinia have been genetically modified selective for 
cancer, and have been studied preclinically and clinically. JX‐594 is an oncolytic vaccinia genetically 
engineered cancer-selective and inserted with GMCSF transgene, which has shown promising 
results in clinical trials: JX‐594 was well-tolerated after intratumoral injections in phase I trial 
together with signs of immunological and antitumor efficacy (Mastrangelo et al. 1999, Park et al. 
2008, Hwang et al. 2011). A recent randomized phase II dose-finding trial in liver cancer, showed 
good tolerability and intrahepatic disease control rate of 50%, which included both injected and 
non-injected lesions (Heo et al. 2013). In addition, virus replication and GMCSF expression were 
shown to precede the induction of antitumor immunity. The most notable clinical example of 
GMCSF-expressing viruses is, however, talimogene laherparepvec (T-VEC), a GMCSF-coding 
oncolytic herpes simplex virus, which has been extensively tested in clinical trials (Senzer et al. 
2009, Harrington et al. 2010). A major breakthrough for the field of oncolytic immunotherapy was 
achieved in 2013, when T-VEC was reported to improve 6-month progression-free survival over 
subcutaneous GMCSF for the treatment of 295 patients with advanced melanoma (Andtbacka et 
al. 2013): Objective response rate in the T-VEC arm was 26% and durable response rate 16%, both 
of which were significantly higher than the 6% and 2% in the GMCSF arm, respectively. Serious 
adverse reactions occurred in 26% of T-VEC and 13% of GMCSF-treated patients, but over grade 3 
reactions were less frequent than 3% in both arms. Thus, the treatment was well-tolerated and the 
study met its primary endpoint, and T-VEC is expected to receive approval by the health 
authorities in the near future. Conclusive long-term overall survival data has not yet been 
reported, as of November 2014. 
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2. AIMS OF THE STUDY 
 
 
The aim of this thesis is to improve efficacy while maintaining low toxicity by combining oncolytic 
immunotherapy with conventional treatment modalities, and to identify novel predictive and 
prognostic factors for better patient selection. Thesis studies are depicted with roman numericals 
(I-IV). Specific aims of the studies I to IV are detailed below. 
 
 
• Study I: To evaluate the potency and study the mechanisms behind radiosensitizing effects of 
adenoviral proteins E1B55K, E4orf3 and E4orf6 in prostate cancer preclinically 
 
• Study II: To identify signalling pathways and marker proteins relevant for acquired resistance 
against oncolytic adenoviral immunotherapy in ovarian carcinoma xenografts 
 
• Study III: To study the safety, efficacy and immunological effects of oncolytic immunotherapy 
combined with low-dose chemotherapeutics temozolomide and cyclophosphamide preclinically, 
and in patients with advanced metastatic cancer 
 
• Study IV: To study the potential and role of serum HMGB1 protein as a novel predictive and 
prognostic biomarker for oncolytic immunotherapy in cancer patients with advanced solid tumors 
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3. MATERIALS AND METHODS 
Materials and methods are described in more detail in the original publications.  
 
3.1 Cell lines 
 
In all preclinical studies, virus production was done in human lung adenocarcinoma cell line A549 
(American Type Culture Collection [ATCC], Manassas, VA) and tittering in human E1-transformed 
embryonal kidney cell line 293, obtained from Microbix (Toronto, Ontario, Canada). In studies I 
and III, metastatic human prostate cancer cell line PC3-MM2 (ATCC, Manassas, VA) was used in 
subcutaneous mouse models in vivo, and primarily used in vitro. In addition in study I, we used 
another prostate cancer cell line DU-145, a breast cancer cell line M4A4-LM3, cervical cancer 
Henrietta Lacks (HeLa) cells (all from ATCC, Manassas, VA), and head and neck cancer primary 
explant UT-SCC8 cells , and in study III, a breast cancer cell line MDA-MB-436 was used (ATCC, 
Manassas, VA). In study II, we used human ovarian adenocarcinoma SKOV3 derived cell lines: 
SKOV3.ip1, generated by passaging via mouse peritoneal cavity, was provided by Dr. Price (M. D. 
Anderson Cancer Center, Houston, TX), and transgenic firefly luciferase expressing SKOV3-Luc cells 
were provided by Dr. Negrin (Stanford Medical School, Stanford, CA). Summary of cell lines is 
presented in Table 2. 
 
Table 2. Cell lines used in thesis studies. 
 
Used in 
study 
Cell line (name) Description Source or 
reference 
I, III PC-3MM2 human prostate cancer cells ATCC 
I DU-145 human prostate cancer cells ATCC 
I UT-SCC8 head and neck squamous cell carcinoma cells provided by Dr. Erjala 
I HeLa human cervical cancer cells (Henrietta Lacks) ATCC 
I M4A4-LM3 breast cancer cells ATCC 
II SKOV3.ip1 human ovarian carcinoma cells provided by Dr. Price 
II SKOV3-Luc human ovarian carcinoma cells provided by Dr. Negrin 
II A549 human lung adenocarcinoma cells ATCC 
II HEK293 transformed human embryonic kidney cells  Microbix 
III MDA-MB-436 human breast cancer cell line ATCC 
 
 
3.2 Adenovirus constructs 
 
Virus cloning and production, if not stated otherwise, is described in the original publications 
and/or references. In order to characterize and titer the produced viruses, constructs were tested 
for the presence of transgenes and genetic modifications/deletions, and for the absence of wild-
type virus by polymerase chain reaction (PCR). Virus particle concentration (VP/ml) was 
determined spectrophotometrically (l = 260 nm), and the amount of infectious particles per ml 
(pfu/ml) was measured by a standard tissue culture infectious dose 50 (TCID50) assay on 293 cells 
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(see below). For patient treatments, virus production was done according to the current good 
manufacturing practice by Oncos Therapeutics, Inc. (Helsinki, Finland), which was regulated by the 
Gene Technology Board. Adenoviruses in used studies I-IV are summarized in Table 3. 
 
3.2.1 Replication-deficient adenoviruses 
 
Recombinant replication-deficient serotype 5 adenoviruses rAdE4orf6 (Querido et al. 1997), 
rAdE4orf3 (Araujo et al. 2005), and rAdE1B55K  used in study I were provided by Dr. Matthew D. 
Weitzman (Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA). These 
viruses are E1- and E3-deleted and the transgene (E4orf6, E4orf3 or E1B55K) is located in the 
deleted E1 region under the cytomegalovirus (CMV) promoter. In addition, rAdE4orf3 virus 
encodes green fluorescent protein (GFP) under the same promoter for visualization of transgene 
expression. Ad5(GL) control virus is a similar replication-deficient construct but expresses GFP and 
luciferase as transgenes (Wu et al. 2002). As a replication-competent control in study I, we used a 
wild-type serotype 5 adenovirus Ad300wt, obtained from ATCC (Manassas, VA). In neutralizing 
antibody assays of study III, we used a matching capsid harboring replication-deficient 
adenoviruses expressing luciferase: Ad5Luc1 (Krasnykh et al. 2001), Ad5/3Luc1 (Kanerva et al. 
2002a), Ad3Luc1 (Fleischli et al. 2007), and Ad5lucRGD (Kanerva et al. 2002b).  
 
3.2.2 Oncolytic adenoviruses 
 
Oncolytic adenovirus Ad5/3-Δ24 used in preclinical experiments in study II (Kanerva et al. 2003), 
and Ad5/3-Δ24-GMCSF (Koski et al. 2010) in study III, were both produced in A549 cells and 
purified on double cesium chloride gradients. Ratio of VP/infectious units was 6 for Ad5/3-Δ24, 
and 18 for Ad5/3-Δ24-GMCSF. All oncolytic adenoviruses used in patient treatments (III, IV) have 
been previously published and are described in Table 3.  
 
For increased transductional targeting, 5/3 chimeric viruses are serotype 5 adenoviruses modified 
with a serotype 3 knob (Kanerva et al. 2003), whereas RGD coding viruses are capsid-modified at 
the RGD-4C motif in the HI-loop of the fiber (Dmitriev et al. 1998). Serotype 3 knob replacement 
extends the cell entry repertoire to serotype 3 receptor, which has recently been proposed to be 
desmoglein 2 (Wang et al. 2011), while the RGD modification improves virus binding to integrins 
that are found on cancer cell surface (Hemminki et al. 2001) and tumor vasculature (Arap et al. 
1998). The fully serotype 3 oncolytic adenovirus Ad3-hTERT-E1A (Hemminki et al. 2011), in turn, 
may circumvent neutralizing antibody response mounted against serotype 5, while still boosting 
antitumor immune responses in patients (Hemminki et al. 2012).  
 
With regards to transcriptional targeting, the Δ24 viruses harbor a 24 base-pair deletion in the 
retinoblastoma (Rb) binding site of E1A region, which attenuates replication at an early phase in 
normal cells that have wild-type retinoblastoma protein (Fueyo et al. 2000). As a consequence, 
Δ24-viruses replicate only in cells with Rb/p16 pathway defects, including nearly all human tumor 
types (Sherr 1996). Alternatively or in addition, a tumor-specific promoter is utilized to target virus 
replication: human telomerase (hTERT) promoter controlling the E1A restricts virus replication to 
immortalized cells with high telomerase activity (Fujiwara et al. 2008). The E2F-promoter, featured 
in ICOVIR-7 and Ad5/3-E2F-Δ24-GMCSF viruses, works hand in hand with the Δ24 deletion by 
activating E1A transcription in cells where free E2F is available, owing to the dysregulation of the 
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Rb/p16 pathway (Rojas et al. 2009). Finally, the cyclooxygenase 2 (Cox-2) was utilized as a 
promoter controlling E1A (Pesonen et al. 2010), since high Cox-2 expression is a hallmark of 
various tumor types (Wang and Dubois 2006).  
 
The purpose of immunogenic transgenes is to stimulate antitumor immunity: Granulocyte-
macrophage colony-stimulating factor (GMCSF) and CD40-ligand (CD40L) were featured in most of 
the viruses. GMCSF mobilizes immune cells and enhances type 1 dendritic cells to initiate cytotoxic 
immune responses. It has been widely used in cancer immunotherapy as an immune stimulant 
(Arellano and Lonial 2008). CD40L, on the other hand, is a co-stimulatory signal that binds to its 
CD40 receptor on antigen-presenting cells, mainly macrophages and dendritic cells, and leads to 
efficient antigen presentation, cytokine production, and eventually T-cell priming (van Kooten and 
Banchereau 2000). Soluble CD40L (Vonderheide et al. 2001) or gene therapy with CD40L 
(Malmstrom et al. 2010, Pesonen et al. 2012) has been used in cancer immunotherapy to a lesser 
extent, but early phase trials have demonstrated safety and evidence of antitumor activity in 
humans. Besides these immunogenic transgenes, a sodium iodide symporter protein (hNIS) was 
used as a radiotherapy adjuvant and for virus tracking purposes (Hakkarainen et al. 2009).  
 
 
3.3 Preclinical in vitro experiments 
 
3.3.1 Efficacy and synergy experiments 
 
Combination efficacy experiments with external beam radiotherapy or chemotherapeutics in 
studies I and III, respectively, were performed on prostate cancer PC3-MM2 and DU-145, head-
and-neck cancer explant UT-SCC8, and breast cancer MDA-MB-436 and M4A4-LM3 cells. The latter 
were cultured in RPMI-1640 (Lonza, Basel, Switzerland), and the others in Dulbecco’s modified 
Eagle medium (DMEM; Lonza), both supplemented with 10% fetal bovine serum (2% during virus 
infections to avoid virus neutralization by serum), 1% L-glutamine, and 1% penicillin-streptomycin. 
The cells were maintained at humidified 37°C and 5% CO
2
 incubators, and on a slow rocker during 
virus infections. Studies were performed in triplicates and readings/results were compared to 
untreated (mock) cells. 
 
In study I, cells were seeded into 96-well plates, the next day infected with virus(es) for 2 h 
followed by 24 h incubation, and then irradiated with 0, 2 or 8 Gy depending on the relative 
sensitivity of each cell line (Rajecki et al. 2009, Dias et al. 2010). External beam irradiation was 
administered by a linear accelerator (Clinac 600C/D, Varian Medical Systems, Palo Alto, CA, USA) 
using a 6 MV photon beam and a dose rate of 400 MU/min (ca. 4 Gy/min) through a 1-cm thick 
plastic phantom bottom containing 1 cm of water. Cell viability was assessed by CellTiter 96 
Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI), measuring optical density 
with spectrophotometer at 490 nm. In clonogenic assays, the treatments were carried out similarly 
in 24-well plates using PC3-MM2 cells, but the treated cells were then transferred into 6-well 
plates at 1000 cells/well and incubated for 10 days. Colony formation was assessed by fixing the 
cells with 10% paraformaldehyde, and staining with 1% crystal violet in 70% ethanol, followed by 
counting colonies under a light microscope.  
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In study III, cancer cells (PC3-MM2 or MDA-MB-436) were seeded on 96-well plates and (co-
)treated with oncolytic adenovirus Ad5/3-D24-GMCSF, temozolomide (TMZ; MSD, Espoo, Finland), 
and/or 4-hydroperoxycyclophosphamide (4-HPCP), which is an active metabolite of 
cyclophosphamide (D-18864; NIOMECH, Bielefeld, Germany). Treatments were performed in a 
total volume of 100 μl of growth medium per well, adding 100 μl after 24 h for incubation. When 
cytopathic effect was observed (ca. day 4 post-treatment), all comparable plates were 
simultaneously measured for cell viability by using CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay (Promega) with spectrophotometer at 490 nm. 
 
3.3.2 Immunofluorescence and protein analyses 
 
Visualization of DNA double strand breaks in study I was performed by phospho-γH2AX 
immunofluorescence: PC-3MM2 cells were fixed on slides at 24 h post-treatment (infection and/or 
irradiation) with 4% paraformaldehyde for 20 min, permeabilized with ice-cold 70% ethanol, and 
blocked with 0.5% bovine serum albumin (BSA) supplemented with 0.05% sodium azide in 
phosphate-buffered saline (PBS) for 1 h. Slides were incubated with primary mouse monoclonal 
phospho-γH2AX antibody (Upstate, clone JBW301, Boston, MA; 1:1000) for 1 h, washed twice, and 
then incubated with secondary Alexa Fluor 594 antibody (Invitrogen, Carlsbad, CA; 1:500). For 
detection of adenovirus capsid in the same study, treated cells were permeabilized with 0.1% 
Triton (x100) supplemented with 0.5% BSA in PBS, and blocked for 1 h with an immunomix 
containing 5% normal donkey serum, 0.2% BSA, and 0.05% sodium azide in PBS. We used primary 
goat polyclonal anti-adenovirus (anti-hexon) antibody Virostat #1401 (Virostat, Portland, ME; 
1:200) and secondary antibody Alexa fluor 594 (Invitrogen; 1:500). Slides were mounted using 
Vectashield with DAPI counterstaining (H-1200, Vector Laboratories, Peterborough, UK) and 
analyzed by confocal microscopy (see below). In addition, GFP expression signal of the rAdE4orf3 
virus treated cells was also visualized by immunofluorescence.  
 
In study II, induction of Myxovirus resistance protein A (MxA) expression was studied by 
immunofluorescence: To simulate the effect of stromal cells, SKOV3.ip1 cells were pretreated with 
or without recombinant universal type I interferon-α (IFN-αA/D, Sigma-Aldrich, St Louis, MO; 100 
IU/ml) 16 h before and again during infection, and infected with 100 VP/cell of Ad5/3-∆24 
adenovirus for 30 min on ice (on coverslips). Following 0 min, 30 min, 1 h and 2 h incubation, cells 
were washed, and fixed with 4% paraformaldehyde for 10 min. We used primary rabbit polyclonal 
anti-MxA antibody (H-285, Santa Cruz Biotechnology, Dallas, TX; 1:100) and primary anti-
adenovirus antibody Virostat #1401 (Virostat; 1:50), and then Alexa fluor 405 and Alexa fluor 594 
secondary antibodies (Invitrogen), respectively. In all immunofluorescence studies, cells were 
visualized using a laser scanning confocal microscope Zeiss LSM 5 Duo (Jena, Germany). Captured 
images were processed with Adobe Photoshop and Illustrator softwares (Adobe Systems, San Jose, 
CA).  
 
In addition to immunofluorescence in study I, we also analyzed virus transgene production and 
quantity of DNA double strand breaks by Western blot. For virus transgene analysis, PC-3MM2 
cells were infected with recombinant viruses and 24 h later harvested, lysed with CelLytic M 
(Sigma-Aldrich), and protein normalized. For γH2AX immunoblotting, PC-3MM2 cells were 
harvested at 30 min or 24 h post-treatment (infection and/or irradiation), sonicated, and acid-
extracted overnight with 0.2M hydrochloric acid to detach H2AX histone protein from DNA. We 
used ultraviolet-B irradiated (ca. 150 J/m
2
) HeLa cells as a positive control for DNA double strand 
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breaks as published (Halicka et al. 2005). Primary antibodies were mouse polyclonal anti-E1B55K 
(2A6; 1:20), rat polyclonal anti-E4orf3 (6A11; 1:25), mouse polyclonal anti-E4orf6 (Rsa#3; 1:20), 
and rabbit monoclonal anti-phospho-H2A.X (#9718; Cell Signaling Technology, Danvers, MA; 
1:1000). The 2A6 (E1B55K) and the Rsa#3 (E4orf6) antibodies were provided by Dr. David A. 
Ornelles (Wake Forest University School of Medicine, Winston-Salem, NC), and the 6A11 (E4orf3) 
antibody was provided by Dr. Thomas Speiseder (Heinrich-Pette-Institute for Experimental 
Virology, University of Hamburg, Germany). In addition, mouse monoclonal anti-GAPDH antibody 
(#39-8600, Invitrogen; 1:2000) was used for visualization of normalized gene expression.  
 
3.3.3 Immunogenicity of cell death experiments 
 
Immunogenic cell death is an increasingly well-documented concept, where certain DAMPs, i.e. 
calreticulin, adenosine triphosphate (ATP) and high-mobility group box 1 (HMGB1), are 
released/exposed from dying cells, and subsequently activate the associated immune cells 
(Hannani et al. 2011). Immunogenicity of cell death in study III was assessed by measuring 
calreticulin exposure on the cell surface, and quantitating the released ATP and HMGB1 protein in 
the supernatant, as previously described (Diaconu et al. 2012). PC3-MM2 cells were mock-treated 
or treated in triplicates with 100 VP/cell of Ad5/3-∆24-GMCSF virus, and 12 h later treated 
with/without TMZ (c = 0.0025 mg/ml) and/or 4-HPCP (c = 0.00208 mg/ml). After 24 h, intact cells 
were harvested, washed and incubated in anti-calreticulin antibody (ab2907; Abcam, Cambridge, 
UK; 1:1000) for 40 min at 4 °C, and then similarly in secondary antibody Alexa fluor 488 (A21206; 
Invitrogen; 1:100). Calreticulin on surface of intact cells was analyzed by FACSAria flow cytometer 
(BD Biosciences, San Diego, CA), and FlowJo software (Tree Star, Ashland, OR). For extracellular 
ATP and HMGB1 analysis, supernatants of identically treated cells were collected on ice at 36 h 
post-treatment (12 h later than in calreticulin analysis), and analyzed with ATP Determination Kit 
(A22066; Molecular Probes/Invitrogen) and HMGB1 ELISA Kit (ST51011; IBL International, 
Hamburg, Germany) according to the manufacturer’s recommendations, and in the case of 
HMGB1, using a normal range procedure. 
 
 
3.4 Preclinical in vivo studies 
 
All animal experiments were approved by Experimental Animal Committee of the University of 
Helsinki and the Provincial Government of Southern Finland (ESAVI-2010-09782/Ym-23). The 
health of the mice was followed daily, and treatments and bioluminescence imaging were 
performed either in medetomidine-ketamine-0.9% saline (1:2:7) anesthesia or in isoflurane gas 
anesthesia. In study I, external beam radiotherapy was given as whole-body irradiation to avoid 
the need for prolonged anesthesia. Mice were euthanized according to the humane end-point 
guidelines. 
 
3.4.1 Animal models and efficacy experiments 
 
For subcutaneous prostate tumor models (I, III), male Nude/NMRI mice were used, provided by 
Scanbur BK (Sollentuna, Sweden) in study I, and by Taconic (Ejby, Denmark) in study III. Four (III) or 
five (I) million PC3-MM2 cells were inoculated into both flanks of the mice and tumor growth was 
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measured using the formula “length x width
2
 x 0.5”. When tumors reached injectable size (day 7 
post-implantation), mice were randomized, and treated with intratumoral injections of adenovirus 
or growth medium (total of 4 × 1 × 10
9
 VP/tumor in study I, and 2 × 2 × 10
10
 VP/tumor in study III). 
Fractionated external beam radiotherapy in study I was given every other day (4 × 2 Gy): Mice 
remained in standard plastic cages and received whole-body irradiation delivered by Clinac 600C/D 
linear accelerator. In study III, mice received intraperitoneal injections of metronomic low-dose 
cyclophosphamide (CP; 20 mg/kg in saline) or saline on days 0, 4, and 7, and low-dose pulse of 
TMZ (10 mg/kg in saline) or saline for five consecutive days starting on day 3 post-CP-treatment. 
Viruses used in study I were rAdE1B55K, rAdE4orf3, rAdE4orf6, Ad5(GL), and Ad300wt, and in 
study III Ad5/3-∆24-GMCSF. 
 
In study II, we established two intraperitoneal ovarian tumor models. Here, female C.B-17 SCID 
mice were used (Taconic) that were xenografted intraperitoneally with ten million SKOV3.ip1 cells 
in a survival experiment, or with five million SKOV3-Luc cells in a tumor volume follow-up model. 
In the survival experiment, mice were 10 days later injected intraperitoneally with 3 × 10
7
 VP of 
Ad5/3-∆24 virus or growth medium, and health of the mice was followed until guideline symptoms 
and then euthanized. Tumor masses in the peritoneal cavity were surgically collected on ice and 
snap-frozen to -80 °C for later analyses. In the tumor growth follow-up experiment, mice were 
treated on days 3, 7, and 10 intraperitoneally with 1 × 10
9
 VP of Ad5/3-∆24 virus or growth 
medium, and imaged noninvasively by bioluminescence imaging to monitor tumor growth: During 
isoflurane gas anesthesia, 150 mg/kg of D-luciferin (Promega, Madison, WI) was injected 
intraperitoneally and 10 min later imaged by IVIS 100 (Xenogen, Alameda, CA), as described 
(Hemminki et al. 2011). Images were overlaid with Living Image 2.50 (Xenogen). Total flux 
(photons/s) was measured by drawing regions of interest around the peritoneal area of the mice 
and background was subtracted. When treated tumors had relapsed on day 27, mice were 
euthanized, peritoneal tumors were surgically removed and two blocks of 0.3 cm
3
 intact tumor 
with stroma were freshly transplanted in laparotomy into anesthesized new SCID mice. In addition, 
two groups of new mice received five million naïve SKOV3-Luc cells intraperitoneally. Then the 
mice with transplanted (relapsed/mock-treated) or naïve tumors were treated on days 5, 8, and 11 
intraperitoneally with 1 × 10
9
 VP of Ad5/3-∆24 virus or growth medium, and again, imaged 
noninvasively for tumor growth.  
 
3.4.2 Determination of functional virus 
 
To determine the amount of functional adenovirus particles in tumor tissue in study II, control and 
virus-treated ovarian cancer xenografts were homogenized mechanically, freeze/thawed three 
times, and centrifuged to collect supernatants, which were used for a tissue culture infectious 
dose 50 (TCID50) assay: 293 cells seeded on 96-well plates at the density of 10000 cells/well were 
infected with supernatant in increasing ten-fold dilutions per row of wells, and the cytopathic 
effect (CPE) was recorded under a light microscope on day 10. Formula to determine the TCID50-
titer (TCID50/100 µl), and the converted pfu-titer ([TCID50×10]
-0.7
), was TCID50 = 10
1+d(S-0.5)
, where d = 
Log 10 of the dilution (= 1 for ten-fold dilutions), S = the sum of ratios (starting from the first 10
-1
 
dilution), with ratio meaning the number of CPE wells /total number of wells per dilution. Similar 
tittering was performed for all constructed adenoviruses to determine pfu-titers.  
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3.4.3 Gene expression and microarray analysis 
 
We investigated the gene expression patterns of adenovirus-treated relapsed SKOV3.ip1 tumors 
versus mock-treated tumors in study II. First, total cellular RNA of homogenized tumors was 
reverse-transcribed into cDNA using Qiagen QuantiTect Reverse Transcription Kit (205311; Hilden, 
Germany), including the genomic DNA wipeout procedure. Next, concentrations of the cDNAs 
were balanced by NanoDrop 2000 Spectrophotometer (Thermo Scientific, Waltham, WA), and 
samples were stored in -80 °C. We confirmed microarray results (see below) of certain 
differentially-expressed key genes both by semi- (described in original publication) and fully 
quantitative reverse transcriptase-PCR (described here): cDNA samples were amplified by 
LightCycler 480 real-time PCR with SYBR Green I Master mix (Roche, Mannheim, Germany) and 
using specific primers for human interferon α-inducible protein 16 (IFI16) (5-
ACTGAGTACAACAAAGCCATTTGA-3 and 5′-TTGTGACATTGTCCTGTCCCCAC-3′), interferon α-
inducible protein 27 (IFI27) (5′-ACCTCATCAGCAGTGACCAGT-3′ and 5′-ACATCATCTTGGCTGCTATGG-
3′), and Myxovirus resistance protein A (MxA) (5′-ACCTACAGCTGGCTCCTGAA-3′ and 5′-
CGGCTAACGGATAAGCAGAG-3′). Human β-actin (5′-TCACCCACACTGTGCCCATCT-3′ and 5′-
GTGAGGATCTTCATGAGGTAGTCAGTC-3′) was used for normalization to human genomic mRNA. 
ΔΔ-comparative threshold method was used to calculate the relative amounts of the indicated 
mRNA (Livak and Schmittgen 2001), and results were expressed as mean fold-change in expression 
levels.  
 
For microarray analysis, total RNA from xenografted tumors was extracted as described above. 
Microarray data obtained with Affymetrix GeneChip HG-U133A (Affymetrix, Santa Clara, CA) was 
pre-processed using Bioconductor in R (Durinck 2008). Hs133P_Hs_ENSG annotation library 
version 9 was used to bind the probes to transcripts. Normalization was performed by robust 
multiarray average normalization (Irizarry et al. 2003).  
 
3.4.4 Immunohistochemistry analyses 
 
Tissue level analyses in studies II and III concentrated on assessing protein levels of a proposed 
adenovirus resistance marker MxA and an established autophagy marker LC3B, respectively. MxA 
immunohistochemistry (II) was performed on five adenovirus-resistant, and five mock-treated 
frozen SKOV3.ip1 xenografts, together with normal SKOV3.ip1 cells as a control. Frozen sections 
were boiled in 10 mmol/l citrate buffer pH 6 for 30 min, covered with 3% hydrogen peroxide for 10 
min, and then treated with Protein Blocking Agent (Novocastra Laboratories, Newcastle, UK) for 10 
min. MxA antibody (sc-50509; Santa Cruz Biotechnology, Santa Cruz, CA; 1:1000) was applied for 
60 min at room temperature. After washing, sections were treated with NovoLink Polymer 
Detection System (Novocastra Laboratories) according to manufacturer’s instructions and 
counterstained with hematoxylin. Immunohistochemistry for microtubule-associated protein light 
chain 3 isoform B (LC3B) is widely used as a marker of autophagy for its involvement in the 
formation of autophagic vacuoles (autophagosomes), of which a punctate LC3B expression pattern 
is a strong indicator. PC3-MM2 xenografts were harvested on day 12 post-treatment (III), fixed 
with 4% paraformaldehyde, and embedded in paraffin. Cut sections were boiled in 10 mmol/l 
citrate buffer pH 6 for 15 min, covered with 3% hydrogen peroxide for 5 min, and stained with 
rabbit polyclonal LC3B antibody (ab48394; Abcam; 1:1500) in Dako Antibody Diluent (S0809; Dako, 
Carpinteria, CA) for 60 min at room temperature. Sections were then washed, treated with LSAB+ 
System-HRP Kit (K0679; Dako) according to manufacturer’s instructions, and counterstained with 
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hematoxylin. In both studies, slides were analyzed under a Leica DM LB microscope (Leica 
Microsystems, Wetzlar, Germany) and images were captured using an Olympus DP50 color camera 
(Olympus, Münster, Germany) and Studio Lite 1.0 software (Pixera, San Jose, CA). To determine 
the extent of autophagy (III), we calculated the average of five 40x visual fields of LC3B punctate-
positive cells (>3 dots/cell). 
 
3.4.5 Electron microscopy 
 
Electron microscopy was used to study autophagy in mouse xenografts and to confirm virus 
production (III). Immediately after euthanizing the mice, PC3-MM2 xenografts were surgically 
removed and fixed with 2.5% glutaraldehyde in 0.1 mol/l phosphate buffer pH 7.4. Samples were 
post-fixed with 2% osmium tetroxide for 1 h, dehydrated in series of ethanol, and embedded in LX-
112 resin. Ultra-thin sections were cut at 50–60 nm, and stained with uranyl acetate and lead 
citrate in Leica EMstain automatic stainer (Leica microsystems) according to manufacturer’s 
recommendations. Electron microscopy was performed by Jeol JEM-1400 (Jeol, Tokyo, Japan) at 80 
kV accelerating voltage, and digital microphotographs were captured using Olympus-Sis Morada 
digital camera (Olympus). 
 
 
3.5 Patient series 
 
3.5.1 Advanced Therapy Access Program (ATAP) 
 
Altogether 290 patients with advanced solid tumors refractory to conventional treatment 
modalities were treated with oncolytic adenoviruses in the context of an ISRCTN registered 
Advanced Therapy Access Program (ATAP) between Nov 2007 and Jan 2012 at Docrates Hospital, 
Helsinki, Finland (ATAP: a treatment for refractory cancer with oncolytic adenoviruses, ISRCTN: 
10141600). ATAP was regulated by Finnish Medicines Agency (FIMEA) as determined by the 
European Committee Regulation No 1394/2007 on advanced therapy medicinal products, 
amending Directive 2001/83/EC and Regulation No 726/2004. ATAP was in compliance with 
European Union and Finnish regulations and was evaluated by The Gene Technology Board and 
Medicolegal Department of the Finnish Ministry of Social Affairs and Health. All patients 
voluntarily contacted the clinic and the suitability of each patient was evaluated before treatment 
decisions. Inclusion criteria for ATAP were: advanced solid tumors progressing after and refractory 
to conventional therapies, and patients’ WHO performance score ≤ 3 at baseline. Exclusion criteria 
were: major organ dysfunction, organ transplant, known brain metastasis, HIV or other major 
immunosuppression, elevated bilirubin, alanine transaminase (ALT) or aspartate transaminase 
(AST) increased over x3 upper limit of normal, severe thrombocytopenia, and other severe disease. 
 
All patients gave a written informed consent after the principles of treatments, including possible 
side-effects were explained verbally and in writing. Treatments were performed according to Good 
Clinical Practice and based on Article 35 of the Helsinki Declaration of World Medical Association. 
ATAP was a personalized therapy program, not a clinical trial, and treatment decisions were based 
on individual characteristics of the patients, their tumors, and what had been learned from earlier 
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patients. After receiving treatments described in studies III and IV, patients were free to receive 
other cancer therapies, including additional virus treatments. All retrospective clinical-
epidemiological research conducted in this thesis including patient sample analyses (III, IV), have 
been approved by the Helsinki University Central Hospital Operative Ethics Committee (HUS 
62/13/03/02/2013). In addition, we obtained a separate permission, written informed consents 
from the patients and ethics committee approval (Dnro HUS 368/13/03/02/2009), for patient 
biopsies and biopsy analyses, since this data could be useful for developing more effective patient 
treatments. Data relating to these analyses are reported in the context of study II in this thesis. 
Clinical data for studies were collected from medical records and population registry. 
 
3.5.2 Patient selection, treatments and follow-up 
 
Patient selection criteria for our clinical-epidemiological analyses were based on the given ATAP 
treatments (III) or available baseline serum samples (IV). Particularly, study III focused on patients 
treated at earlier phase with the combination of oncolytic adenovirus and low-dose 
chemotherapeutics cyclophosphamide (CP) and temozolomide (TMZ) (N = 17). Study IV, in turn, 
included all patients with available non-hemolytic baseline serum sample for assessment of 
circulating HMGB1 level (N = 202). In addition in study III, nonrandomized matched control 
patients (N = 17) were selected in order to estimate the effect of TMZ adjuvant therapy on overall 
survival; these patients were treated similarly in the ATAP, but did not receive TMZ. Matching was 
based on known prognostic factors (percentage of successful matches in parenthesis): tumor type 
(100%), concomitant low-dose CP administration (yes/no 94%), exact same round of virus 
treatment (71%), treatment with the same oncolytic adenovirus (52%), WHO performance status 
at baseline (48%). Self-controls were not allowed. 
 
Patients received oncolytic adenovirus intratumorally (primary tumor and/or any injectable 
metastases) in ultrasound or CT guidance, when applicable. In case of a peritoneal or pleural 
disease, the intratumoral injection was performed intracavitary. Typically, one fifth of the virus 
dose was given intravenously in an attempt to achieve virus transduction of uninjectable lesions as 
well (Nemunaitis et al. 2001, Reid et al. 2002b). Some patients that lacked injectable lesions, 
however, received the whole virus dose intravenously. Viruses used in patient treatments are 
described in Table 3. Virus doses ranged from 1 × 10
10
 to 4 × 10
12
 VP in study III, and from 2 × 10
9
 
to 4 × 10
12
 VP in study IV. In the absence of contraindications, patients received low-dose 
cyclophosphamide in order to reduce regulatory T-cells (Lutsiak et al. 2005, Cerullo et al. 2011), 
which was administered perorally 50 mg daily in a metronomic manner starting one week before 
the virus treatment and continued until progression, or as a bolus infusion of 1000 mg 
intravenously on the day of the virus treatment, or as a combination of these (Cerullo et al. 2011). 
Both the metronomic oral and the intravenous infusion administration of CP have been shown to 
induce similar immunological effects (Cerullo et al. 2011). All patients in study III (excluding 
matched controls), and a subset of patients in study IV, received oral low-dose pulse of TMZ (100 
mg/day), which was administered according to three different dosing schedules, investigated in 
study III: 5 days before the virus (group 1), 5–7 days before and two weeks after the virus (group 
2), or 7–10 days after the virus treatment (group 3). Chemotherapeutic doses were adjusted for 
pediatric patients (N = 2 in III, and N = 5 in IV). 29 % of patients in study III, and 51 % in study IV, 
received the studied virotherapy as a serial treatment of three consecutive virus treatment cycles 
at 3-4 week intervals, due to emergence of evidence that multiple injections of oncolytic 
adenovirus could enhance immunologic responses (Kanerva et al. 2013).  
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Patient follow-up started on the day of the virus treatment. Patients were monitored for 24 h in 
the hospital and 4 weeks as outpatients, with intermittent recordings of clinical status and 
laboratory data. Adverse reactions (ARs) were reported according to Common Terminology 
Criteria for Adverse Events (CTCAE) v3.0 criteria. Pre-existing symptoms were listed only if 
worsened, and in that case they were scored according to final severity. In both studies (III, IV), 
ARs were further classified as either leading, or not leading, to patient hospitalization, 
malformation, life-threatening condition, or death; Any of these conditions constituted a serious 
adverse event (SAE), which were also reported, together with treatment results, to the FIMEA as 
requested. Of note, in study III we considered transient lymphocytopenia as an AR, whereas in 
study IV we excluded it from our analyses due to accumulating evidence indicating that it is 
compatible with lymphocyte redistribution, which is commonly seen after both virus infections and 
immunotherapy and does not appear as an actual adverse reaction but rather a phenomenon 
contributing to treatment efficacy (i.e. trafficking of lymphocytes) (Reid et al. 2002b, Brahmer et 
al. 2010, Kanerva et al. 2013, Hemminki and Hemminki 2014). 
 
 
Table 3. Adenoviruses used in thesis studies. 
 
 Used  in 
study 
Virus Transduct.  
targeting 
Transcript. 
targeting 
Transgene Source or 
reference 
O
n
co
ly
ti
c 
I Ad300wt 5 - - ATCC 
II Ad5/3-Δ24 5/3 Δ24 - Kanerva et al. 2003 
III, IV ICOVIR-7 5, RGD Δ24, E2F - Nokisalmi et al. 2010 
III, IV Ad5-Δ24-RGD-GMCSF 5, RGD Δ24 GMCSF Pesonen et al. 2012 
III, IV Ad5/3-Cox2L-Δ24 5/3 Δ24, COX2 - Pesonen et al. 2010 
III, IV Ad5-Δ24-GMCSF 5 Δ24 GMCSF Cerullo et al. 2010 
III*, IV Ad5/3-Δ24-GMCSF 5/3 Δ24 GMCSF Koski et al. 2010 
III, IV Ad5/3-hTERT-E1A-CD40L 5/3 hTERT CD40L Diaconu et al. 2012 
III, IV Ad3-hTERT-E1A 3 hTERT - Hemminki et al. 2011 
IV Ad5/3-E2F-Δ24-GMCSF 5/3 Δ24, E2F GMCSF Ranki et al. 2012 Mol 
Ther. Suppl.1 
IV Ad5/3-Δ24-hNIS 5/3 Δ24 hNIS Rajecki et al., 2012 
N
o
n
-r
e
p
lic
at
in
g 
I rAdE1B55K 5 - - Marcellus et al., 1996 
I rAdE4orf6 5 - - Querido et al., 1997 
I rAdE4orf3 5 - GFP Araujo et al., 2005  
I Ad5(GL) 5 - GFP, LUC Wu et al., 2002 
III Ad5Luc1 5 - LUC Krasnykh et al., 2001 
III Ad5lucRGD 5, RGD - LUC Kanerva et al., 2002b 
III Ad5/3Luc1 5/3 - LUC Kanerva et al., 2002a 
III Ad3Luc1 3 - LUC Fleischli et al., 2007 
* Virus was used both in preclinical experiments and in patient treatments. Other oncolytic viruses 
used in studies III and IV were only used in patient treatments, while non-replicating viruses (III) 
were used for neutralizing antibody titer determination of serum samples. 
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3.5.3 Response evaluation and survival analysis 
 
Tumor assessment in the ATAP was performed by contrast-enhanced computed tomography (CT), 
positron emission tomography-computed tomography (PET-CT), or magnetic resonance imaging 
(MRI), which was performed before and typically 3–6 weeks after a single treatment. In case of a 
serial treatment, post-treatment imaging was performed after the complete treatment series, 
typically 9-14 weeks after the first treatment. Response evaluations were performed by 
professional radiologists by applying modified Response Evaluation Criteria in Solid Tumors 
(RECIST) v1.1 for CT and MRI scans (Eisenhauer et al. 2009), and modified PET Response Criteria in 
Solid Tumors (PERCIST) for PET-CT as previously described (Koski et al. 2013a). Evaluations applied 
to overall disease status including injected and non-injected lesions, and the following 
classification was used: CR, complete response (disappearance of all tumors); PR, partial response 
(≥ 30% reduction in the sum of the longest diameters of all measured lesions); MR, minor response 
(MR, 10-29% reduction in the sum); PD, progressive disease (≥ 20% increase in the sum, or 
appearance of new metastatic lesions); SD, stable disease (tumor measurements not fulfilling the 
criteria for response or progression). For PET-CT, the same percentages were used, but evaluations 
based on [(18)F]-fluorodeoxyglucose activity within target lesions as published (Koski et al. 2013a). 
In addition in study III, we assessed tumor marker responses, if elevated at baseline, by applying 
the same percentages to the change between best response and baseline value. 
 
Baseline tumor load score assessment in study IV, was based on the whole-body radiographic 
evaluations of 95 patients: Tumor masses in lungs, liver, peritoneal cavity, bones, lymph nodes, 
and other sites were graded from 0 to 3 (none to high tumor burden), with bulky tumor at any 
location giving an additional 3 points, and the sum was calculated (possible range: 0-21 points). 
Presence of pleural/ascites effusion was also recorded, but it did not affect the solid tumor load 
score. Overall survival (III, IV) was calculated from the day of the first virus treatment (in study III: 
day of the first TMZ-combined treatment) until death or study conduction. Patient status 
(dead/alive information) was obtained from medical records and the population registry.  
 
3.5.4 Quantification of viral DNA in serum 
 
Patient blood samples were collected at normal hospital visits before and after virus treatments. 
Samples were centrifuged to separate clots, and the resulting serum (supernatant) and clots were 
stored at -20°C. As a surrogate of virus replication, we analyzed viral DNA in serum and blood clots 
at multiple timepoints by quantitative PCR (III, IV). Total DNA was extracted from serum using 
carrier DNA (polydeoxyadenylic acid; Roche) with QIAamp DNA mini kit (Qiagen, Hilden, Germany), 
which was then eluted in 60 μl nuclease-free water and measured by spectrophotometry to 
determine DNA concentration. Quantitative PCR using specific primers for serotype 5 oncolytic 
adenoviruses was performed as previously described (Cerullo et al. 2010, Escutenaire et al. 2011, 
Pesonen et al. 2012). For serotype 3 adenovirus, method and primers are described in the original 
publication (III) and reference (Hemminki et al. 2012). The viral loads were calculated using a 
regression standard curve based on serial dilutions of adenoviruses in normal human serum. 
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3.5.5 Protein analyses on patient samples 
 
Protein level analyses on patient samples included immunohistochemistry for LC3B protein on 
patient ascites samples (III), immunohistochemistry for MxA on patient tumor biopsy samples 
(reported in the context of study II), serum inflammatory cytokine measurements by cytometric 
bead array (III, IV), and serum HMGB1 protein measurements by human HMGB1 ELISA (III, IV).  
 
In order to study autophagy in patient ascites tumor cells, whole ascites samples were centrifuged 
to collect cells, which were then fixed with methanol and assessed for LC3B immunohistochemistry 
as described above. LC3B primary antibody (ab48394; Abcam; 1:1500) was applied for 120 
minutes. MxA immunohistochemistry analyses on patient tumor biopsies were performed as 
described for in vivo experiments in study II. Briefly, sections from paraffin blocks of tumor 
biopsies were cut on glass slides, assessed for MxA immunohistochemistry using anti-MxA 
antibody (sc-50509, Santa Cruz Biotechnology; 1:1000), and mounted under cover slips. Biopsy 
stainings were evaluated and scored (from 0+ to 3+) by an independent pathologist, who had no 
information about the pre-specified hypotheses. Hematoxylin eosin stainings were used as 
technical controls and for interpretation of tissue and cellular morphology. 
 
For serum cytokine analysis, 50 µl of serum sample was used for BD Cytometric Bead Array (CBA; 
BD Biosciences, San Diego, CA) performed using BD CBA Human Soluble Protein Master Buffer Kit 
and BD CBA Human IL-6, IL-8, IL-10, TNF-α, and GM-CSF Flex Sets (BD Biosciences, San Diego, CA) 
according to manufacturer’s instructions for serum samples on 96-well plates. BD FACSArray 
Bioanalyzer, BD FACS Array System software, and FCAP Array v1.0.2 software (BD Biosciences) 
were used for data analysis.  
 
Serum HMGB1 protein concentration was assessed by HMGB1 ELISA Kit (ST51011; IBL 
International, Hamburg, Germany) according to manufacturer’s instructions, using a high sensitive 
range protocol; Mircotiter plates were incubated with samples/controls for 23 h. Multipipetting 
was used when applicable, and the plates were analyzed immediately with spectrophotometer at 
450 nm. Hemolytic serum samples were considered unsuitable for analysis. An identical HMGB1 
ELISA protocol was used for ascites/pleural effusion samples. HMGB1 concentration was 
calculated from raw values plotted on the high sensitive range standard curve (standards on the 
same plate), and occasional negative values were considered as undetectable levels and regarded 
as zero. Change in serum HMGB1 (ΔHMGB1) was assessed by subtracting individual baseline 
concentration from post-treatment values. Since the same plate with same conditions was used 
for every sample of a respective patient, technical replicates proved unnecessary for serum ELISA 
and cytokine analyses due to negligible variance in readings.  
 
3.5.6 Neutralizing antibody titer determination 
 
Serum neutralizing antibody titer was determined by measuring serum-mediated blocking of gene 
transfer by a capsid-matched non-replicating adenovirus. First, 293 cells were seeded at 10000 
cells/well on 96-well plates and incubated overnight. Serum samples were incubated at 56°C for 90 
min to inactivate complement, and a four-fold dilution series was prepared in serum-free growth 
medium (1:1 to 1:16384). Non-replicating Ad5Luc1, Ad5LucRGD, Ad5/3Luc1, and Ad3Luc1 viruses 
were used for assessing serotype 5 capsid, RGD-modified serotype 5 capsid, 5/3-chimeric capsid, 
and serotype 3 capsid oncolytic viruses, respectively (see Table 3). Non-replicating virus was mixed 
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with the serum dilutions and incubated at room temperature for 30 min, followed by infection of 
293 cells at 100 VP/cell in triplicates. Growth medium with 10% FCS was added 1 h later, and 23 h 
later cells were lysed with 1x Reporter Lysis Buffer (Promega) and luciferase activity was measured 
using Luciferase Assay System (Promega) and TopCount Luminometer (Perkin-Elmer). Raw values 
were plotted relative to gene transfer achieved with the respective non-replicating virus alone, 
and the neutralizing antibody titer was determined as the lowest dilution that blocked gene 
transfer for over 80%. 
 
 
3.5.7 Enzyme-Linked ImmunoSpot (ELISPOT) assay 
 
Peripheral blood mononuclear cells (PBMC) were extracted from collected whole blood samples by 
Percoll gradient centrifugation, and PBMCs were immediately stored in CTL-CryoABC serum-free 
medium (Cellular Technology Ltd., Cleveland, OH) at -140°C. In studies III and IV, T-cell reactivity 
against a ubiquitous tumor-epitope Survivin was measured, while in study III, also adenovirus-
specific responses were studied by interferon-γ Enzyme-Linked ImmunoSpot (ELISPOT) assay. In 
order to avoid artificial or incorrect signals, we performed all ELISPOT assays without pre-
stimulation or clonal expansion of PBMCs, and thus results represent the actual frequency of these 
cells in blood. Since T-cell responses can take time to establish after immunotherapy, in study IV 
we analyzed PBMC samples following consecutive treatment cycles as well. Assays were 
performed according to manufacturer’s instructions using the h-INF-γ ELISPOT PRO 10 plate kit 
(MABtech, Stockholm, Sweden). To specify parts of protocol, viable cells were manually counted 
using Trypan Blue under a light microscope, and blocking medium contained 10% FCS as serum. 
For tumor-specific antigen responses, PBMCs were stimulated in triplicates with a tumor-
associated BIRC5 PONAB peptide Survivin (ProImmune, Oxford, UK), and for adenovirus-specific 
responses with human adenovirus serotype 5 penton or serotype 3 hexon peptide pools (HAdV-5 
or HAdV-3; ProImmune) for 20 h. Dried plates were analyzed with AID-ELISpot reader (Autoimmun 
Diagnostika, Strassberg, Germany), and the results were expressed as means of triplicates. In both 
studies, unspecific interferon-γ T-cell responses were also observed that might include T-cell 
reactivity against unknown tumor epitopes, and these were therefore not subtracted (Kanerva et 
al. 2013). We used a threshold of ≥ 20% change in spot forming colonies (SFC) from baseline 
together with an absolute count of ≥ 10 SFCs (per 1 million cells) as a true positive T-cell activity 
(induction/decrease), and otherwise considered it as anergy.  
 
 
3.6 Statistics and in silico analyses 
 
3.6.1 Preclinical statistics and pathway analyses 
 
Statistical analyses were performed using two-tailed Student’s t-test for in vitro data, and 
nonparametric Mann-Whitney U test, one-way analysis of variance repeated measures, and 
Kaplan-Meier method with Log-Rank test for in vivo data (SPSS 15.0 – 18.0, Chicago, IL). In order to 
determine synergism between adenovirus, TMZ, and 4-HPCP in study III, the cytotoxicity 
interactions were analyzed by CompuSyn software (ComboSyn, Paramus, NJ) using the Chou–
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Talalay median effect principle (Chou 2010). For microarray data in study II, the normalized pre-
processed raw data were analyzed with statistical tests in order to identify differentially expressed 
genes, which were deemed as such if the ratio of medians of normalized intensities of cases and 
controls were either less than 1/1.7 or greater than 1.7 and the standard deviation between all 
samples was at least 0.4. Data were next analyzed with two different in silico platforms: Ingenuity 
Pathways Analysis (IPA) (Ingenuity Systems, Mountain View, CA) and Moksiskaan analysis (Laakso 
and Hautaniemi 2010). In IPA, canonical pathway analysis was used to identify the most significant 
altered pathways according to the IPA library. The significance of the association between the data 
set and the canonical pathway was studied by ratio of data-set genes that map to a pathway 
divided by the total number of genes mapping to that pathway, and by Fisher’s exact test. 
Moksiskaan is a data integration platform containing gene, pathway and drug information 
obtained from Ensembl (Hubbard et al. 2009), Gene Ontology (Ashburner et al. 2000), KEGG 
(Kanehisa et al. 2010), SPIA (Tarca et al. 2009), SNPs3D (Yue et al. 2006), PathwayCommons 
(Cerami et al. 2006), PINA (Wu et al. 2009) and COSMIC (Forbes et al. 2010), which we used to 
identify connections between the differentially expressed genes, and related them to existing 
drugs, diseases, and known cancer mutations.  
 
 
3.6.2 Patient series statistics and multivariate analyses 
 
In study III, adverse reactions (ARs) were analyzed with two-tailed Student’s t-test, while in study 
IV ARs and imaging responses were compared by χ
2
 (chi-squared) test. Further in study IV, patient 
characteristics were compared by χ
2
 and Student’s t test, tumor load data was analyzed by linear 
correlation and Mann-Whitney U test, and the frequency of pleural/ascites effusion was compared 
by χ
2
 test. Overall survival data (III, IV) were analyzed by Kaplan–Meier method with Log-Rank 
tests. With regards to patient sample analyses, virus titers in blood were studied by Kruskal-Wallis 
test, serum cytokine data by Kruskal-Wallis test and one-way analysis of variance (ANOVA) with 
multiple comparison tests, and neutralizing antibody and HMGB1 serum data (III) with two-tailed 
Student’s t-tests. Correlations of serum HMGB1 with T-cell responses or survival were assessed by 
two-tailed Fisher’s exact test in study III, where only nine cases were evaluable. In contrast in study 
IV, correlations of baseline HMGB1 with survival or imaging responses were first studied by Log-
Rank or χ
2
 tests, respectively, and then verified in separate multivariate analyses (Cox proportional 
hazards and logistic regression models, respectively) using SPSS v.21.0 (SPSS, Chicago, IL). 
Assumption of proportional hazards for each factor (candidate confounding variables) was tested 
by evaluating parallelity of lines in log minus log survival plot, and for uncertain factors, by 
counting the Schoenfield's partial residuals and linearly regressing them against natural logarithm 
of survival time. To avoid overfitting, Cox and logistic regression models were also tested with 
fewer number of parameters, which rendered similar results. Predicted probabilities for each case 
were used to calculate a Receiver Operating Characteristic (ROC) and cross-validate the logistic 
regression model. Statistical analyses were performed using Microsoft Excel (Microsoft, Redmond, 
WA), GraphPad software (GraphPad Software Inc., La Jolla, CA) and SPSS software, all tests were 
two-sided, and values of P < 0.05 considered statistically significant.  
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3.7 Ethical considerations 
 
Patient samples and radiological evaluations in ATAP, which were used in our clinical-
epidemiological studies III and IV, were collected and performed for safety and response 
monitoring purposes. All patients gave written informed consent, which included permission for 
analysis of collected sample material and anonymous scientific publication of patient data. All 
clinical-epidemiological data and patient sample analyses in studies III and IV were approved by 
the local ethics committee (HUS 62/13/03/02/2013). Blood sample collection was intended for 
monitoring safety (e.g. liver transaminases) and treatment efficacy (e.g. tumor markers), causing 
additional but acceptable harm for patients. Ascites and pleural effusion samples were obtained 
during effusion removal in order to relieve patients’ symptoms. Tumor biopsies (in the context of 
study II), which were designed for development of patient treatments, caused additional but 
acceptable harm to patients, and were conducted after written informed consents, and approved 
by the local ethics committee (Dnro 368/13/03/02/2009). Radiological imaging with CT and PET-CT 
were used for monitoring treatment efficacy, which caused additional but acceptable ionizing 
radiation exposure, whereas MRI scanning caused no biological harm (used always for pediatric 
patients). Samples were analyzed and data was processed anonymously and used for intended 
purposes only. For ethical aspects regarding animal experiments, see preclinical in vivo studies. 
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4. RESULTS AND DISCUSSION 
 
4.1 Improving efficacy of radiotherapy by recombinant adenoviruses expressing 
radiosensitizing proteins 
 
Radiotherapy is widely used and important treatment of prostate, breast, and head and neck 
cancer, among other types. However, high irradiation doses carry the risks for side-effects to 
normal tissues, and thus lower curative doses would be desirable. One promising multi-modal 
approach is adenoviral cancer gene therapy combined to radiotherapy. While radiosensitizing 
transgenes such as p53 have been successfully utilized in combination treatments using 
replication-deficient adenovirus vectors (Pan et al. 2009, Yang et al. 2010), preclinical evidence 
indicates that cancer cells can be sensitized to irradiation by serotype 5 adenovirus replication per 
se (Kim et al. 2009, Rajecki et al. 2009), although the mechanisms behind this combinatorial 
benefit remain unknown. Data from cellular studies suggests radiosensitizing potential for innate 
adenoviral gene products: early region 1B 55-kDa (E1B55K) protein, and early region 4 proteins 11-
kDa (E4orf3) and 34-kDa (E4orf6). The normal function of these proteins is to maintain effective 
virus replication in the host cell by preventing cell cycle arrest, which is induced in response to the 
adenovirus genomes (viral double-stranded DNA is interpreted as DNA double-strand breaks 
[DSB]) (Lilley et al. 2007). Adenoviral proteins E4orf3 and E4orf6 interact directly with a MRN 
complex (Mre11, Rad50, and NBS1), which is crucial for DSB recognition (Williams et al. 2007), 
mislocalizing or targeting it for degradation (Stracker et al. 2002), while besides other functions 
E1B55K protein may enhance the activity of E4orf3 and E4orf6 in MRN complex inhibition (Lilley et 
al. 2007, Jayaram et al. 2008). To study these aspects and their applicability for cancer virotherapy, 
we assessed the radiosensitizing potential of replication-deficient adenoviruses expressing the 
proteins E4orf3, E4orf6, or E1B55K in vitro and in vivo, and revised the mechanisms behind the 
effect.  
 
4.1.1 Virus characterization and in vitro efficacy combined with radiotherapy 
 
Recombinant viruses rAdE4orf3, rAdE4orf6, and rAdE1B55K as well as wild-type control (Ad300wt) 
and replication-deficient control (Ad5[GL]) viruses transduced prostate cancer PC3-MM2 cells at 
over 90% rate (> 85% for rAdE1B55K) and showed high levels of transgene expression at 24 h post-
infection (Study I, Fig. 1). Combination treatment with each recombinant adenovirus followed 24 h 
later by radiotherapy was able to increase cancer cell killing as compared to combination 
treatment with Ad5(GL) control virus or radiotherapy alone. rAdE1B55K mediated the effect only 
in prostate cancer DU-145 cells, while rAdE4orf3 and rAdE4orf6 viruses increased killing of 
prostate cancer DU-145 and PC3-MM2, and breast cancer M4A4-LM3 cells, and rAdE4orf6 of also 
head and neck cancer UT-SCC8 cells (Study I, Fig. 2A). Furthermore, when combined with 
radiotherapy, rAdE4orf6 virus was the most potent of recombinant adenoviruses in mediating cell 
killing at 10-fold lower titer (Study I, Fig. 2B), and decreasing colony formation of PC3-MM2 cells 
(Study I, Fig. 4). Since molecular level studies suggest that E4orf6 and E1B55K (Stracker et al. 2002, 
Schwartz et al. 2008), as well as E4orf3 and E1B55K (Leppard and Everett 1999), might work in 
complexes to inhibit DSB repair, we studied the co-infections with multiple recombinant viruses 
together with radiotherapy in prostate, breast and head and neck cancer cells. Surprisingly, double 
or triple co-infections failed to improve cancer cell killing over the most effective virus component 
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alone in any tested cell line (PC3-MM2 shown in Study I, Fig. 3; M4A4-LM3 and UT-SCC8 not 
shown), suggesting that either E4orf6 or E4orf3 is sufficient in sensitizing a cancer cell to 
irradiation, and that E1B55K is not required for the synergistic effect. Of note, wild-type control 
virus Ad300wt, exhibiting oncolysis and expression of each studied protein (from inherent 
serotype 5 genes) mediated superior cell killing in all in vitro experiments (Study I, Figs. 1, 2, and 
4).  
 
4.1.2 Improved in vivo efficacy by combination therapy  
 
Efficacy of recombinant and control viruses together with or without fractionated radiotherapy 
was assessed in an aggressive model of prostate cancer PC3-MM2 subcutaneous xenografts in 
Nude mice. When combined with radiation, rAdE4orf3 was the most effective recombinant 
adenovirus in vivo, by virtually halting the tumor growth at the level of 400% from original and 
significantly inhibiting it as compared to Ad5(GL) control virus with radiation (P < 0.01; Study I, Fig. 
5). Similarly, rAdE4orf6 mediated significant tumor growth inhibition in combination with 
radiotherapy (P < 0.05, as compared to Ad5[GL] + radiation), whereas, consistent with our in vitro 
results, rAdE1B55K together with radiation failed to inhibit tumor growth. Also in line with in vitro 
data, the replicative control virus Ad300wt presented superior inhibition and halting of tumor 
growth when combined with radiotherapy (P < 0.001 as compared to Ad5[GL] + radiation), but not 
alone (data not shown). It should be noted that human wild-type adenovirus does not replicate in 
mouse cells, which renders the use of Ad300wt in our experimental setting as an “oncolytic” 
control virus, since only PC3-MM2 xenografts are of human origin allowing replication. 
Interestingly, if compared to Ad5(GL) alone or mock-treated animals, both of which developed 
rapidly growing tumors and had to be sacrificed by day 12, recombinant viruses showed some 
antitumor efficacy in the absence of radiotherapy (Study I, Fig. 5), which has been indicated by in 
vitro results of us and others (Brand et al. 1999).  
 
4.1.3 Persistent DNA damage in cancer cells after combination therapy 
 
Mechanisms behind radiosensitizing effects of recombinant and control adenoviruses were 
assessed in PC3-MM2 cells by studying the persistence of DSBs after irradiation. 
Immunofluorescence and Western blot against DSB-binding histone protein phospho-H2AX 
(gamma-form) was used to visualize DSBs at 30 min and 24 h after irradiation (Study I, Fig. 6). As 
expected from earlier reports indicating DSB repair inhibition as the main mechanism behind 
radiosensitizing effects of replicative adenoviruses (Stracker et al. 2002, Rajecki et al. 2009), wild-
type control virus Ad300wt infection prior to radiotherapy showed strong persistence of DSBs at 
24 h post-irradiation in both immunofluorescence and Western blot. Similarly, both rAdE4orf6 and 
rAdE4orf3 virus treatment prior to radiotherapy lead to inhibition of DSB repair as indicated by 
persistent γH2AX foci (in 40-50% of cells) and high protein levels still at 24 h. In contrast, 
rAdE1B55K treatment caused weak DSB repair inhibition since only ca. 25% of cells showed γH2AX 
foci at 24 h post-irradiation. As expected, the replication-deficient control virus Ad5(GL) prior to 
radiotherapy or radiotherapy alone, although inducing DSBs immediately after irradiation (at 30 
min timepoint), failed to inhibit DSB repair as seen at 24 h timepoint when the majority of the DNA 
breaks were repaired. 
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In summary, rAdE4orf6 and rAdE4orf3 viruses mediated strong inhibition of DSB repair, leading to 
radiosensitation and increased cancer cell killing in vitro and in vivo when combined with 
radiotherapy. Our results suggest that either E4orf6 or E4orf3 are sufficient in enhancing cancer 
cell killing by radiotherapy, whereas E1B55K does not significantly contribute to the effect. If 
comparing their relative radiosensitizing potentials, E4orf6 proved more effective in vitro, while 
E4orf3 seemed to have an upper hand in vivo, suggesting a more complex scenario in real therapy 
setting. Nevertheless, as indicated by the superior potency of the replicative “oncolytic” control 
virus Ad300wt, effective oncolysis combined to radiotherapy leads to improved antitumor efficacy, 
which cannot be achieved by gene transfer and DSB repair inhibition alone. This intrinsic ability of 
adenoviruses to sensitize cells to irradiation could be harnessed against cancer cells by selective 
targeting.  
 
Since the early phase of adenoviral cycle takes usually 6 – 8 hours, during which also DSB-repair 
inhibiting E4orf-proteins are expressed, it would be interesting to assess whether radiosensitation 
occurs optimally at this time. Nevertheless, for full combinatorial effects completion of oncolytic 
virus replication cycle would be desirable as well. On the other hand, also irradiated cells could be 
infected, followed by adenoviral gene expression and DSB repair inhibition, and as demonstrated 
by Rajecki et al. a schedule where radiotherapy was given 24 h prior to infection, provided optimal 
synergistic efficacy in their study (Rajecki et al. 2009).  
 
In addition to DSB repair inhibition, radiation-induced DSB damage mediates also other beneficial 
effects with regards to oncolytic immunotherapy: Nokisalmi et al. showed in several cell lines and 
using different adenoviruses that ionizing radiation induces increased production of mRNA and 
proteins, including adenoviral transgene products (Nokisalmi et al. 2012). This phenomenon may 
have accounted for improved efficacy in study I as well, although it remains controversial since 
Nokisalmi et al. also administered adenoviral gene therapy 24 h after irradiation. Recent evidence 
in radiobiology has proposed that ionizing radiation promotes immunogenic type of cell death 
(Apetoh et al. 2007, Golden et al. 2012). Moreover, autophagic cell death was observed as the 
primary mechanism underlying the synergy between radiotherapy and oncolytic adenovirus 
(Rajecki et al. 2009). Promotion of alternative cell death pathways that are immunogenic, by using 
the combination of oncolytic adenovirus and radiotherapy, may therefore further increase 
efficacy. This could lead to antitumor immune activations in an immunocompetent host: It is 
intriguing to speculate that such combinations could provide enough danger-signals and antigen-
spreading together with direct oncolysis to skew the immunosuppressive environment of human 
tumors, and mount tumor-specific immune responses. To this end, a multimodal study addressing 
the combination of adenoviral gene therapy, radiotherapy, and temozolomide (TMZ) in the 
treatment of glioma in vivo, demonstrated that such antitumor immune responses are achievable, 
and are dependent on HMGB1 release, which is a key DAMP molecule released in immunogenic 
cell death (Curtin et al. 2009). 
 
Emerging evidence thus suggests that combination benefits are mediated, at least, by intrinsic 
adenoviral proteins E4orf6 and E4orf3, increased transgene expression, and enhanced 
immunogenicity. As the study I and previous data demonstrate that replicative adenoviruses 
mediate superior radiosensitizing effects in vivo [Ad300wt in study I; (Rajecki et al. 2009)], an 
oncolytic adenovirus armed with either E4orf6 or E4orf3 as a transgene and delivered 24 h after 
radiotherapy, might mediate further enhanced antitumor efficacy. Alternatively, given the 
immunogenicity of cell death, an oncolytic adenovirus with intact intrinsic E4orf-genes armed with 
an immunostimulatory transgene, such as GMCSF, that would be administered 24 h after 
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radiation, could increase both cytotoxic synergy and adaptive antitumor immune responses. The 
combination treatment with radiotherapy and oncolytic immunotherapy is therefore a promising 
way to minimize the curative irradiation dose, consequently reducing the harmful side-effects, 
while increasing therapeutic efficacy and activating immune system to detect the cancer. 
 
 
4.2 Upregulation of interferon signaling mediates acquired tumor resistance to 
oncolytic adenovirus in vivo 
 
Preclinical and clinical data suggests that initially sensitive tumors can become resistant to 
virotherapy (Strauss et al. 2009, Koski et al. 2010, Kanerva et al. 2013), which is not surprising 
given the tremendous transforming capacity of advanced tumors. With regards to resistance to 
chemotherapy and targeted therapies, many resistance mechanisms have been identified, which 
has allowed development of countermeasures (Ross et al. 2009, Cathcart et al. 2012). For oncolytic 
adenoviruses, however, such data has been missing. Several mechanisms behind anti-adenoviral 
innate immunity have been identified in normal cells (Sung et al. 2001, Nociari et al. 2007, Zhu et 
al. 2007), while with regards to cancer, two human pancreatic cancer cell lines were found to 
entail different permissivity to adenoviral vectors and characterized by differential interferon gene 
signature and myxovirus resistance protein A (MxA) expression (Monsurro et al. 2010). The latter 
in vitro studies did not, however, assess the causality between actions of the virus and the 
upregulation of interferon pathways. In an attempt to identify underlying mechanisms and gain 
insights into developing countermeasures, we studied acquired tumor resistance against oncolytic 
adenovirus Ad5/3-∆24. We developed two orthotopic mouse models of acquired resistance using 
ovarian carcinoma SKOV3.ip1 and SKOV3Luc xenografts, where initially responding tumors gain 
resistance and relapse, and used them to investigate the phenomenon on mRNA, protein and 
tissue levels. 
 
4.2.1 Animal model of acquired resistance and characterization of virus-resistant phenotype 
 
We showed in mice that intraperitoneal ovarian carcinoma SKOV3.ip1 tumors treated with single 
intraperitoneal injection of oncolytic virus Ad5/3-∆24 are initially inhibited, but eventually relapse 
after a prolonged disease-free period of 120 days (Study II, Fig. 1A). The relapsed tumors were 
surgically removed, virus was extracted and used for replication assays, that revealed presence of 
functional virus (Study II, Fig. 1B). As comparison, also virus from naïve responding SKOV3.ip1 
tumors collected at day 4 post-infection was extracted and similarly assessed for functional 
tittering: Interestingly, the recurring 120-day old tumors showed even higher amounts of 
functional replicative virus, which had apparently been rendered ineffective by relapsing tumors. 
Next, we performed microarray analysis of five relapsed and five untreated tumors: More than 
hundred genes were found downregulated in the adenovirus-resistant tumors, whereas only a 
handful were significantly upregulated (Study II, Table 1 and Suppl. Table S1). Expression results 
regarding some of the key genes were further confirmed by semi and fully quantitative PCR (Study 
II, Fig. 3A and Suppl. Fig. S2). Two separate in silico analyses were performed on microarray data 
to investigate the gene expression signature: Moksiskaan analysis indicated activation of innate 
immunity in response to virus (Study II, Suppl. Fig. S1 and Suppl. Table S2), whereas Ingenuity 
Pathway analysis revealed upregulation of interferon signaling related genes in relapsed tumors 
(Study II, Fig. 2), suggesting tolerance on tumor microenvironment level.  
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4.2.2 Identification of potential therapeutic targets and a virus-resistance marker 
 
In addition to studying connections between differentially expressed genes, we used Moksiskaan 
analysis to relate them to existing drugs, diseases and known cancer mutations. This approach was 
aimed at finding novel druggable targets that could be utilized during oncolytic virotherapy as 
virus-sensitizers, or alternatively, as therapeutic targets after the emergence of virus resistance. 
Interestingly, we identified a downregulated gene in virus-resistant cells that might be an 
upstream molecule accounting for the resistant phenotype, which had existing agonists: nuclear 
receptor subfamily 3 group C member 2 (NR3C2) could be stimulated by desoxycorticosterone 
acetate, desoxycorticosterone pivalate, and desoxycortone (mineralocorticoids without 
glucocorticoid activity) (Study II, Suppl. Fig. S1c and Suppl. Table S1). This group of drugs are used, 
together with glucocorticoids, for replacement therapy of adrenocortical insufficiency and 
Addison's disease, and for treatment of salt-losing adrenogenital syndrome. Importantly, these 
drugs lack glucocorticosteroid activity that would be highly immunosuppressive and unfavourable 
for immunotherapy. We did not find any existing inhibitors for the upregulated genes, however, 
we identified several upregulated genes that code for membrane proteins (Study II, Table 2 and 
Suppl. Data), which could be useful targets for development of new drugs, i.e. monoclonal 
antibodies or small molecular inhibitors, for combination therapy with oncolytic adenoviruses.  
 
Myxovirus resistance protein A (MxA), a key downstream protein acting at an intersection of all 
interferon signaling pathways, was identified as one of the most significantly upregulated genes in 
virus-resistant tumors. Thus in line with previous studies, MxA seems to reflect the virus-resistant 
phenotype (Monsurro et al. 2010), and we hypothesized we could utilize it as a resistance 
biomarker. Unlike the in vitro results on the virus-resistant, MxA-positive pancreatic carcinoma cell 
lines by Monsurro et al. suggested, we found very low levels (5%) of in vitro MxA positivity in 
ovarian carcinoma SKOV3.ip1 cells, indicating virus permissivity. Indeed, after initially responding 
to virotherapy (Study II, Fig. 1), the relapsed tumors containing ineffective virus showed very high 
levels of MxA staining, while nontreated tumors retained the MxA-low phenotype (Study II, Fig. 
3B-C). Thus, we presume that killing of MxA-negative (virus-permissive) cells would result in 
selection of MxA-positive cells that would re-grow, eventually resulting in tumor relapse (Study II, 
Fig. 4). Alternatively, although not mutually exclusively, adenovirus treatment might also induce 
resistance and MxA-upregulation in initially sensitive cells which then cause relapse. Corroborating 
with the latter scenario, we showed in vitro that MxA expression can be induced in SKOV3.ip1 cells 
by infection with oncolytic adenovirus (Study II, Fig. 3D and Suppl. Fig. S3).  
 
Interestingly, an important pathogen recognition receptor, TLR-2 expression was found 
upregulated in the virus-resistant tumors (Study II, Table 2). Since there is evidence that majority 
of adenovirus-mediated immune responses are dependent on TLR-2 and 9 activation (Appledorn 
et al. 2008), it is possible that virus-resistant tumors feature constitutive activation of toll-like 
receptor signaling. TLR-2 mediates mainly interleukin production from immune cells, which is the 
other main arm of innate immunity. Thus, the upregulation of type I IFN and toll-like receptor 
signaling seem to complement the antiviral phenotype, although further experiments are needed 
to assess the role of TLRs. For example, it would be interesting to study if TLR-2 stimulation, similar 
to the observed IFN-α-receptor stimulation, would lead to MxA upregulation.   
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It is noteworthy that also favourable consequences of immunogenic cell death (see below) leading 
to activation of antitumor immunity may be connected to the antiviral innate immune responses 
triggered by oncolytic adenoviruses. For instance, an endogenous DAMP molecule HMGB1 has 
been shown to mediate antitumor immune responses in a glioma model exactly via TLR-2 on 
dendritic cells (Curtin et al. 2009). It is possible that TLR-2 upregulation observed in the virus-
resistant tumors could also reflect dendritic cell mediated DAMP signalling that is however 
attenuated in the SCID mice lacking effector T cells. Furthermore, an alkylating chemotherapeutic 
cyclophosphamide (CP), which is commonly used as an adjuvant drug, poses another example of 
potential benefits of the innate immune response: Standard dose chemotherapy with CP exerts 
activation of endogenous type I IFN response that can lead to increased dendritic cell activation, 
cross-presentation and antitumor efficacy (Schiavoni et al. 2011). Interestingly, these beneficial 
effects were synergized by co-administration of mouse type I IFNs. Nevertheless, low-dose CP 
mediates rather opposite immunological effects, and has not been linked to type I IFN response 
(Sistigu et al. 2011). Since low-dose chemotherapy has several favourable immunological effects 
over high-dose in the adjuvant setting with immunotherapy (Loven et al. 2013), current knowledge 
would not support promotion of type I IFN signalling, especially in the context of oncolytic 
adenovirus where antiviral innate immunity may dampen the oncolytic effect. Nonetheless, dual 
role of innate immunity should be considered when designing methods to counteract the antiviral 
resistance phenotype. For instance, it may be feasible to allow some degree of initial type I IFN 
response after oncolytic immunotherapy, which associates with danger-signaling and immune cell 
activations at the tumor site, and only later apply drugs that counteract emerging anti-viral state.  
 
4.2.3 Role of tumor stroma in maintaining resistance 
 
After showing that MxA expression can be induced in SKOV3.ip1 cells by virus infection per se, we 
evaluated whether it can be further boosted by external interferon stimulus. To simulate the effect 
of stromal cells, which are the major source of type I interferons in tumors, we pre-treated the 
SKOV3.ip1 cells with recombinant universal type I interferon-α: Virus infection after IFN-α 
treatment resulted in further upregulation of MxA expression at 1 h after infection (Study II, Fig. 
3D and Suppl. Fig. S3). Next we evaluated the impact of tumor stroma, and confirmed the 
emergence of virus-resistance, in another orthotopic ovarian cancer mouse model using SKOV3-
Luc cells. These cells allowed us to monitor growth of the intraperitoneal tumors by 
bioluminescence in vivo imaging. After three intraperitoneal injections of oncolytic adenovirus 
Ad5/3-∆24, tumors initially responded to treatment, but relapsed after two weeks suggesting 
acquired virus resistance (Study II, Fig. 5A). When tumors reached considerable size, mice were 
killed and both the untreated and the relapsed tumors were surgically removed and freshly 
transplanted, together with tumor stroma, into new SCID mice in laparotomy. Concurrently, two 
new groups of mice with naïve intraperitoneal SKOV3-Luc tumors were established. Then the mice 
were treated as previously, and tumor growth was again monitored: As expected, the naïve 
tumors initially responded to treatment followed by relapse. Of the surgically transplanted tumors, 
the previously untreated tumors responded to the virus treatment, whereas the previously virus-
treated tumors could not be inhibited (P < 0.001) (Study II, Fig. 5B). Importantly, replication assays 
demonstrated again the presence of functional virus in the resistant and relapsed tumors (average 
1.0 × 10
8
 pfu/g, not shown). Hence, the transplanted tumors retained the resistant phenotype 
when transferred together with tumor stroma into new mice. Interestingly, cancer cells derived 
from ascites of the untreated mice were able to grow and form colonies on cell culture plates, 
whereas cancer ascites cells from the relapsing virus-treated mice were instantly killed ex vivo 
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(data not shown). This further indicates the role for tumor stroma in maintaining resistance, 
because the relapsed cancer cells had become depend on their tumor microenvironment: While 
the whole-tumor transplantation was successful in naïve mice, single cell cultures failed to grow, 
probably due to retained susceptibility to latent virus or stress signals.  
 
In summary, we have identified an innate resistance mechanism that tumors can acquire to 
protect against oncolytic adenoviruses. Our data indicates that functional adenovirus is rendered 
ineffective by acquired resistance of ovarian tumors, which is characterized by upregulation of 
interferon signalling, as indicated by MxA protein expression, and involve crucial interactions with 
tumor stroma. Corroborating with our results, breast cancer initiating /stem cells have been found 
sensitive to oncolytic adenovirus due to their impaired toll-like receptor signalling and 
dysfunctional type I IFN response (Ahtiainen et al. 2010). Our microarray data and in silico analyses 
may help in developing countermeasures to reverse/counteract the virus-resistant phenotype, 
while MxA protein could be utilized as a simple biomarker correlating with the resistant phenotype 
(see below for preliminary translation into human data). 
 
Based on our results in study II indicating that acquired resistance against adenovirus in relapsed 
tumors is mediated by upregulation of type I interferon signalling, we have started to study 
chemical compounds that could reverse the antiviral phenotype. While our results are pending at 
this point, we have for instance tested a small-molecule inhibitor, termed virus-sensitizers 1 
(VSe1), which was identified as a potent enhancer of oncolytic vesicular stomatitis virus (VSV) 
mediated cancer cell killing in vitro and in vivo (Diallo et al. 2010). VSe1 has a narrow histone-
deacetylase inhibitor-like activity on gene expression representing closely to our adenovirus-
resistant SKOV3.ip1 gene expression signature, rendering it attractive to test in our models. 
Intriguingly, the “pharmacoviral” approach using small-molecular inhibitor VSe1 was shown to 
selectively enhance virus growth in tumor cells but not in normal tissues (Diallo et al. 2010). This 
type of potential safety issues are important to assess carefully given the central role of IFN 
responses for normal antiviral immunity as well. 
 
4.2.4 Translational data on identified virus-resistance marker MxA in cancer patients  
 
MxA protein expression was found a potentially useful marker correlating with the adenovirus-
resistant phenotype in vivo. To date, no direct evidence of acquired resistance against oncolytic 
adenovirus in human tumors exists, and also utility of antiviral resistance markers remains 
unknown. Therefore translation into patients would serve as valuable evidence and starting point 
for developing countermeasures and perhaps selecting patients for oncolytic adenoviral therapy. 
In a preliminary attempt to assess this, we received pre-treatment tumor biopsies from 15 patients 
with refractory solid tumors, who were thereafter treated with oncolytic adenoviruses in the 
context of the ATAP. Biopsies were taken shortly before the first oncolytic adenovirus treatment. 
In addition, two of these patients had available post-treatment tumor biopsies, which were used 
to study the acquired resistance against oncolytic adenovirus. We performed 
immunohistochemistry with MxA antibody, and correlated tumor staining scores with possible 
signs of treatment efficacy, in order to assess if MxA phenotype correlates with therapy outcome.  
 
We found that most of the 15 pre-treatment biopsies had missed the tumor tissue or proved 
otherwise unrepresentative for MxA assessment (e.g. necrotic tissue). As a result only nine 
biopsies were evaluable for scoring of MxA positivity and localization: four were scored as 3+, 
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other four as 2+, and one case as 1+. Patients with the highest MxA score (3+) showed a median 
overall survival of only 53 days, patients with MxA score 2+ had median survival of 204 days, and 
the one patient with MxA score 1+ showed survival of 123 days. When MxA scores 1+ and 2+ were 
grouped together, there was a trend for increased overall survival over the highest MxA score 3+ 
patients (P = 0.107, Log-Rank test). Since overall survival is an endpoint affect by multiple 
prognostic factors, we next assessed imaging and marker responses as possible signs of treatment 
benefit. However, only three cases were evaluable by these parameters. One metastatic breast 
cancer patient with cytoplasmic MxA staining scored as 2+ showed progressive disease in both 
post-treatment PET imaging and tumor markers. The other two interesting cases are discussed 
next in more detail. 
 
For the other two patient cases MxA immunohistochemistry could be applied on both pre- and 
post-treatment tumor biopsies. Moreover, facilitating comparison between these cases, both 
patients had ovarian carcinoma tumors progressing at baseline, both received their first oncolytic 
adenovirus treatment on the same week with Ad5/3-∆24-GMCSF virus together with metronomic 
cyclophosphamide as a serial treatment, and were imaged and biopsied again either on day 76 or 
78 post-treatment. Patient n:o 1 showed sustained intense nuclear MxA staining 2+, while 
presenting much less cytoplasmic MxA staining, in all biopsies (Figure 6A). Interestingly, this 
patient seemed to benefit from oncolytic adenovirus treatment, showing a minor metabolic 
response in PET imaging (-13.6% decrease), stabilization of Ca12-5 tumor markers, and 
improvement in symptoms. She had an overall survival of 336 days. On the contrary, the patient 
n:o 2 showed intense membranous (perinuclear) and cytoplasmic MxA staining 3+ in the pre-
treatment biopsy, and strong membranous/cytoplasmic MxA 3+ but progressive loss of nuclear 
staining in the post-treatment biopsy (Figure 6B). This patient showed a stable disease in PET 
imaging (+2.4% increase), but a progressive disease in Ca12-5 tumor markers accompanied with 
worsened symptoms, and had an overall survival of 101 days.  
 
Taken together, while based on only three case reports, there is room for speculation that 
membranous/cytoplasmic as opposed to nuclear MxA localization might indicate antiviral 
phenotype and poor therapy responsiveness. Especially the pattern of progressive loss of nuclear 
MxA and accumulation of cytoplasmic MxA, in the patient with relatively worse outcome is 
noteworthy (Figure 6B). Indeed, human MxA protein has been reported to mediate antiviral 
activities mainly in the cytoplasm, endoplasmic reticulum and perinuclear region, although its 
specific role in adenovirus infection has remained unknown (Haller et al. 2007, Wisskirchen et al. 
2011). Interestingly, as seen in Fig. 3C of study II, an almost identical cytoplasmic/perinuclear 
staining pattern that lacks nuclear MxA, can be observed in the virus-resistant recurrent ovarian 
carcinoma SKOV3.ip1 xenografts, as compared to the potentially virus-resistant patient biopsy 
(Figure 6B). The reason why MxA was highly expressed already in the pre-treatment biopsies is 
unknown. One explanation could be wild-type adenovirus infections during the course of tumor 
evolution, because tumor lesions can initially present fertile ground for replication but thereafter 
acquire resistance. Alternatively, MxA could be involved in other unknown tumor-promoting or 
resistance mechanisms as well.  
 
We set to study whether MxA positive or negative phenotype in patient tumors would correlate 
with signs of treatment efficacy, or lack thereof, following oncolytic virotherapy. Our preliminary 
analysis was hampered by several unrepresentative biopsies and lack of assessed endpoint 
parameters. Nevertheless, case reports of strong 3+ and cytoplasmic MxA expression in tumors 
were potentially associated with antiviral resistance and weaker efficacy, while nuclear MxA 
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staining 2+ linked to a patient case with promising signs of efficacy. Accordingly, patients with 
lower MxA staining scores trended for longer overall survival, although based on only nine cases. 
Therefore, corroborated by our preclinical data, these results of MxA as a candidate marker for 
adenovirus-resistance hint towards possible translational relevance, although further studies are 
needed to draw any conclusions. 
 
 
 
 
Figure 6. MxA immunohistochemistry on pre- and post-treatment tumor biopsies in two ovarian 
carcinoma patients. Two ovarian carcinoma patients were treated during the same time period 
with three consecutive intratumoral injections of oncolytic adenovirus Ad5/3-∆24-GMCSF (a serial 
treatment) together with metronomic cyclophosphamide. Tumor biopsies were taken before, and 
76 or 78 days after the first treatment of the series, in A and B, respectively. A) Patient n:o 1 
featured intense MxA staining in nuclei, scored as 2+, in both pre- and post-treatment biopsies. In 
addition, a third biopsy taken on day 98 after the first treatment showed similar nuclear staining 
pattern (not shown). Objective signs of possible benefit were observed for patient n:o 1: 
radiological PET evaluation showed minor response (MR) in total metabolic activity, tumor markers 
were stabilized, and symptoms were improved. B) Patient n:o 2 presented strong membranous, 
perinuclear MxA staining, scored as 3+, in both biopsies, but lacked nuclear staining especially in 
the post-treatment biopsy. Patient n:o 2 showed a stable disease in PET evaluation, but a 
progressive disease in Ca12-5 tumor markers and worsened symptoms. Hematoxylin eosin 
stainings were used as technical controls and for interpretation of cell and tissue morphology. 
Slides were scored by an independent pathologist. H&E, hematoxylin eosin staining; MxA, 
myxovirus resistance protein A; tx, treatment (Liikanen et al., unpublished data). 
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4.3 Combining oncolytic immunotherapy with low-dose temozolomide and low-
dose cyclophosphamide preclinically and in cancer patients 
 
Adenoviruses induce autophagic cancer cell death, which has been associated with increased 
oncolysis and virus replication (Ito et al. 2006, Jiang et al. 2011, Rodriguez-Rocha et al. 2011), and 
preclinical data suggests that autophagy-inducing therapies might enhance the efficacy of 
oncolytic adenoviruses (Rajecki et al. 2009, Tyler et al. 2009). While baseline autophagy is 
essentially considered as a survival process, mortal autophagic flux, characterized by increased 
turnover of cellular organelles leading to cell death, can be exploited in cancer therapy (Chen and 
Karantza 2011). Moreover, autophagy has recently been suggested a prerequisite for 
immunogenic cell death (ICD), a phenomenon useful or even necessary for induction of antitumor 
immunity (Hannani et al. 2011, Michaud et al. 2011, Martins et al. 2012). ICD is characterized by 
exposure of calreticulin on cell surface, and release of adenosine triphosphate (ATP) and a nuclear 
protein high-mobility group box 1 (HMGB1) to the extracellular space. These danger signals are 
recognized by dendritic cells, which respond by secreting interleukin-1b for the activation of 
cytotoxic T-cells.  
 
We studied therefore the combination of oncolytic adenovirus together with an autophagy-
inducing, alkyting chemotherapeutic temozolomide (TMZ). As a chemotherapeutic drug, TMZ is 
used in the treatment of e.g. melanoma, pituitary cancer, and various gliomas, and its autophagy-
inducing capacities have been regarded beneficial in the context of combination therapies (Gao et 
al. 2009, Palumbo et al. 2012). We hypothesized that combination of oncolytic adenovirus with 
low-dose TMZ could enhance efficacy via increased tumor autophagy and immunogenic cell death, 
leading to subsequent induction of antitumor immune responses. Since, tumors can evade 
antitumor T-cell responses at later stages by recruitment of immunosuppressive regulatory T-cells, 
we included low-dose cyclophosphamide in the treatments, which specifically decreases 
regulatory T-cells without compromising induction of antitumor immunity (Ghiringhelli et al. 2004, 
Ghiringhelli et al. 2007, Cerullo et al. 2011). We investigated the combinatorial effects of oncolytic 
adenovirus, low-dose temozolomide and low-dose cyclophosphamide preclinically, and the report, 
for the first time, safety, efficacy and immunological effects of the combination therapy in 17 
patients with metastatic solid tumors refractory to conventional treatments.  
 
4.3.1 Preclinical efficacy, autophagy induction and immunogenicity 
 
We assessed cytotoxicity of the combination therapy in prostate PC3-MM2 and breast MDA-MB-
436 cancer cells, by using an active metabolite of the prodrug cyclophosphamide (CP), i.e. 4-
hydroperoxycyclophosphamide (4-HPCP), oncolytic adenovirus Ad5/3-∆24-GMCSF, and TMZ in 
vitro: the triple combination as well as double combinations with either chemotherapeutic alone 
increased cell killing over oncolytic virus or chemotherapeutic agents alone (Study III, Fig. 1A and 
Suppl. Fig. S2). When drug combinations in PC3-MM2 cells were assessed for synergy using the 
median effect analysis developed by Chou and Talalay (Chou 2010), the triple combination showed 
synergism at the most relevant high fraction affected levels (Study III, Suppl. Fig. S2). Synergistic 
effect was the most pronounced with the combination of virus and TMZ, whereas virus with 
4HPCP showed only slight synergism or an additive effect, as expected for its purpose as an 
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immunomodulating agent mediated only in vivo (Cerullo et al. 2011). Next, we studied the ability 
of the combination therapy to induce immunogenic cell death. Treatment of PC3-MM2 cells with 
virus, TMZ, and 4-HPCP resulted in significant increase of all mediators of ICD, namely calreticulin-
positive cells, release of ATP, and secretion of HMGB1, when compared with control cells (Study 
III, Fig. 1B).  
 
To assess the in vivo efficacy, subcutaneous prostate cancer PC3-MM2 xenograft bearing mice 
were treated with Ad5/3-∆24-GMCSF or growth medium twice intratumorally, followed by 
concomitant treatment with TMZ (10 mg/kg) or saline, and CP (20 mg/kg) or saline 
intraperitoneally. Subtherapeutic doses of chemotherapeutic drugs were used as to mimic low-
dose administration, which thus showed no efficacy alone (Study III, Fig. 1C). However, oncolytic 
virus combined to TMZ showed enhanced tumor growth inhibition (P < 0.05), and the effect was 
further enhanced when CP was added to the regimen (P < 0.01, both over control). We performed 
electron microscopy and immunohistochemistry on PC3-MM2 tumors to study autophagy 
induction, which has previously been reported as a key cell death mechanism in glioma 
virotherapy in vivo (Tyler et al. 2009). Electron microscopy revealed autophagic vacuoles in 
combination- and virus-treated tumor cells, together with evidence of progressive autophagic flux 
and virus progeny inside some of the combination treated dying tumor cells (Study III, Fig. 1D). To 
determine the extent of autophagy, we further performed immunohistochemical staining for LC3 
protein isoform B (LC3B), a widely used marker of autophagy due to its involvement in the 
formation of autophagic vacuoles. Combination treated tumors presented a significantly higher 
frequency of LC3B punctate-positive cells as compared to control tumors (Study III, Fig. 1D and 
Suppl. Fig. S3). 
 
4.3.2 Safety and biological virus activity in patients 
 
We studied safety, efficacy and immunological data of 17 patients with metastatic solid tumors 
progressing after conventional therapies, who were treated with the combination therapy (1–6 
treatment cycles) in the context of the ATAP. Patients had a WHO performance score ≤ 3 at 
baseline, and were heavily pre-treated with a median of 2 previous chemotherapy regimens and 1 
surgery (Study III, Suppl. Tables S1 and S2). Combination treatments were sub-grouped according 
to administration of low-dose pulse of TMZ: Group 1 received TMZ (100 mg/day) for 5 days before 
virus treatment, group 2 for 5–7 days before and 2 weeks after the virus, and group 3 for 7–10 
days following virus treatment. All but two patients received also low-dose CP, either 
concomitantly per os (50 mg/day) or as an intravenous infusion on the day of virus treatment 
(1,000 mg), as reported (Cerullo et al. 2011). Chemotherapeutic doses were adjusted for the two 
pediatric patients. Treatments appeared well-tolerated with mostly grade 1–2 adverse reactions 
(flu-like symptoms, fever, fatigue, nausea and pain), and no grade 4–5 clinical ARs. Laboratory ARs 
included grade 1–2 transient hemoglobin decreases, liver transaminase increases, and 
thrombocytopenia (Study III, Table 1). In addition, transient lymphopenia was commonly observed 
(88% of treatments), and accounted for majority of the grade 3, and the only grade 4 laboratory 
AR, that were observed (Table 4). In fact, accumulating evidence indicates that transient 
lymphocytopenia seen after virus treatment is likely to reflect redistribution of lymphocyte subsets 
from blood to the target tissues of infection, i.e. tumors, as suggested for potent 
immunotherapeutics and viruses (Reid et al. 2002b, Brahmer et al. 2010, Kanerva et al. 2013, 
Hemminki and Hemminki 2014). Moreover, observed transient lymphopenia did not appear to 
translate into clinical symptoms: First of all, none of the patients were reported to suffer from 
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clinical infections as AR. Second, as very expected, fever was observed after majority of the virus 
treatments (75,6%), but this did not correlate with lymphocytopenia, as both patient groups had 
fever: 75% (27/36) of patients with lymphopenia, and 80% (4/5) without lymphopenia. Transient 
lymphopenia after oncolytic immunotherapy may not therefore be an actual “adverse” reaction 
but rather a phenomenon contributing to efficacy, which was regarded later in study IV (see 
below). 
 
When comparing to patient treatments given in the same therapy program but using oncolytic 
adenoviruses and low-dose CP (Cerullo et al. 2011), ARs did not appear increased by the addition 
of low-dose pulse of TMZ overall, although grade 2 nausea seemed slightly more common, as 
expected for TMZ therapy (22% vs. 11%, not significant). Interestingly, when compared between 
the TMZ administration subgroups, group 3 receiving TMZ for 7–10 days after the virus treatment 
seemed to exhibit less laboratory ARs, especially liver transaminase increases, than group 1 
receiving TMZ for 5 days before the virus (grade 1 and 2 lab ARs recorded in 94 and 83% of 
treatments in group 1, and in 75 and 50% in group 3, respectively [P < 0.05]). One potentially 
treatment-related adverse reaction, grade 3 ileus in a cholangiocarcinoma patient, led to patient 
hospitalization and was therefore classified as a serious adverse event, while the other two clinical 
grade 3 ARs were alleviated by blood transfusions and antibiotics as outpatients.  
 
To study biological viral activity in patients, we assessed inflammatory cytokines, neutralizing 
antibodies, and adenovirus genomes in blood (as a surrogate of virus replication). Patient serum 
titers for pro-inflammatory interleukin (IL)-6, and anti-inflammatory IL-10 showed transient 
increases at day 1 (P < 0.05 and P < 0.0001, respectively). In line with the differences seen in AR 
profiles between the TMZ administration subgroups, the most pronounced inflammatory cytokine 
changes were observed in patients receiving TMZ before the virus (group 1; Study III, Suppl. Fig. 
S4). Injected virus is rapidly cleared from the blood stream, and therefore extended presence of 
circulating specific adenovirus genomes is indicative of virus replication (Galanis et al. 2005). We 
observed prolonged (≥ day 3 up to day 74 post-treatment) circulating virus genomes in blood after 
14 out of 30 evaluable treatments, and after 28 out of 38 treatments overall (when including 
earlier time-points; Study III, Suppl. Table S3). Circulating neutralizing antibody titers against 
specific adenovirus-capsid antigens showed gradual elevations during the first 1–5 weeks post-
treatment (Study III, Suppl. Table S4). As expected, patients receiving their first oncolytic 
adenovirus treatment showed significantly lower titers at baseline and at 1 week post-treatment 
as compared to subsequent treatment cycles (P < 0.05, both time-points), followed by elevations 
to the overall median. In summary, treatments were well-tolerated and the addition of low-dose 
pulse of TMZ did not seem to essentially alter the safety profile. Since there were no differences 
between the TMZ administration subgroups in circulating adenovirus genomes or neutralizing 
antibody titers but the cytokine response and laboratory adverse reactions appeared more 
pronounced in patients receiving TMZ before the virus (group 1), our biological and safety data 
supports the administration of temozolomide after the virus treatment. 
 
4.3.3 Evidence of autophagy, immunogenicity and immune responses in patients 
 
We obtained pre- and post-treatment ascites tumor cell samples from two combination-treated 
patients and assessed them for LC3B-immunohistochemistry to study autophagy induction. In both 
cases, the assay revealed clear increase in LC3B punctate-positive tumor cells in one week post-
treatment samples (Study III, Fig. 2D). To our knowledge, this is the first evidence of autophagy 
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induction in patients treated with oncolytic viruses. We also assessed the immunogenicity of 
patient treatments by measuring serum HMGB1 titers and antitumor T-cell responses in blood. 
Induction of tumor-specific T-cells in blood after combination treatment was seen in 8 out of 15 
evaluable patients (Study III, Fig. 3A). Intriguingly, the immunogenic HMGB1 protein levels in 
serum showed corresponding changes, and trended for correlation with the antitumor T-cell 
responses even in this small patient analysis (P = 0.0833; Study III, Fig. 3B). Thus, our 
immunological results suggested activation of antitumor immunity in majority of the combination 
treated patients, and provided data to postulate that serum HMGB1 might be a candidate 
predictive marker for antitumor immune responses after oncolytic immunotherapy.  
 
Of note, additional immune cell subtype analyses would have been required to address the overall 
immunological effects of the combination therapy. Effector T-cells can be inactivated by 
immunosuppressive subtypes, such as regulatory T-cells and myeloid-derived suppressor cells 
(MDSCs) that hamper antitumor T-cell functions also at later stages (Lindau et al. 2013). Low-dose 
CP was included in the treatments, because it has been shown to selectively inhibit regulatory T-
cells (Ghiringhelli et al. 2004, Lutsiak et al. 2005), and further to mediate similar effects in 
combination treatments with oncolytic adenoviruses when administered either metronomically or 
intravenously (Cerullo et al. 2011). In addition, emerging evidence suggests that low-dose CP can 
also induce immunogenic type of cell death in vivo, very similar to low-dose TMZ and oncolytic 
adenoviruses (Sistigu et al. 2011). Despite these favourable effects, low-dose CP might on the 
other hand promote production of chronic inflammatory mediators, as reported in a model of ret 
transgenic mice (Sevko et al. 2013). The authors found that low-dose CP treatment lead to 
accumulation of immunosuppressive MDSCs that coincided with decreased effector cell activity in 
both tumor-bearing and chronic inflammation models. Interestingly, low-dose CP induced higher 
production of several inflammatory mediators of Th2 type response in tumors, including GMCSF, 
IL-1β, IL-5, IL-10, IFN-γ, and TNF-α. In contrast, cytokine profile involved in innate immune 
response triggered by oncolytic adenovirus is an acute response towards Th1 type (Tuve et al. 
2009, Hendrickx et al. 2014), Indeed, the combination of low-dose CP and oncolytic adenovirus 
coding for CD40L shifted the inflammatory profile towards Th1-type response in majority of the 
cancer patients (Pesonen et al. 2012). Hence, current evidence still indicates beneficial effects 
using this combination in cancer patients. Nonetheless, evidence of MDSC induction and their 
immunosuppressive role requires attention. In fact, considerable progress has been done to design 
chemotherapeutic regimens and small-molecule inhibitors for their selective inhibition as well 
(Alizadeh and Larmonier 2014). 
 
4.3.4 Clinical responses and survival 
 
Patients treated in the context of the ATAP were radiologically imaged and assessed for tumor 
markers because, in addition to safety data, the local regulatory agency FIMEA requires reporting 
of all treatment responses and outcomes (for assessment of the risk-to-benefit ratio). As the 
patient treatments were not conducted in a context of a prospective clinical trial, especially the 
patient efficacy data described in this thesis and reported in studies III and IV must be regarded 
with caution and conclusions should await confirmation from ongoing and future clinical trials. 
Nevetheless, besides obliged to report data from all experimental therapies according to 
Declaration of Helsinki article 35, we also felt that the observed possible signs of treatment 
efficacy would be of interest to the scientific community, since some of the treatments in the ATAP 
represent novel empirically supported approaches and drug combinations.  
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In study III, radiological tumor responses (by CT, PET-CT or MRI imaging), and tumor markers were 
studied to evaluate signs of efficacy after the combination treatments. Since patients were 
progressing prior to oncolytic virus treatments, disease stabilization or better was regarded as 
treatment benefit (disease control). Overall, objective evidence of antitumor efficacy was 
observed in 67% of evaluable treatments in imaging, and in 4 out of 9 treatments by tumor 
markers (Study III, Table 2). Specifically with regards to imaging, one treatment response was 
classified as a minor response (Study III, Fig. 2A-C), twelve as stable diseases, and seven as 
progressive diseases. In addition, one pediatric patient with neuroblastoma responded in 
ultrasound imaging that could not be classified due to unconventional imaging method, but the 
same patient showed a partial response in tumor marker levels. Considering that patients were 
progressing after all conventional treatment modalities, several interesting cases of radiological 
disease control together with unusually long survival were reported in each TMZ administration 
subgroups: An endometrial sarcoma patient in group 1, with an overall survival of 951 days, 
showed clinical response to three rounds of combination treatment by experiencing a 15% 
decrease in the total tumor diameters at best, observed after the second treatment, and a minor 
response in tumor markers, seen after all three combination treatment rounds (Study III, Fig. 2A-C 
and Table 2). A mesothelioma patient in group 2 seemed to benefit from two rounds of 
combination treatment with stabilization of the disease and decrease in pleural effusion, together 
with an unexpectedly long survival of 779 days. A heavily pre-treated patient with malignant 
fibrous histiocytoma (a subtype of sarcoma) in group 3 showed disease stabilization that lasted for 
three rounds after initiation of the combination treatment and although progressing thereafter, 
had an overall survival of 553 days. Finally, at the end of follow-up (time of submitting the study III 
article: last updated in Jan 2013) one sarcoma patient receiving combination treatments first 
according to group 1 and then group 3 and showing sustained stabilization of the disease, was still 
alive with an ongoing survival of 1459 days. Interestingly, possible signs of clinical benefit 
(imaging/marker responses together with prolonged survival) were observed in all age groups as 
the aforementioned five patients were 6, 45, 65, 67, and 17 years old at baseline, respectively.  
 
Overall survival is an endpoint affected by many prognostic and predictive factors, including tumor 
type, performance score, age, previous and following therapies, and comorbidities. While 
acknowledging this, however, survival is also the most relevant endpoint in cancer therapy 
research, and thus we wanted to examine the overall survival data of patients treated with 
oncolytic adenoviruses together with or without low-dose pulse of TMZ. Therefore, matched non-
randomized control patients (n = 17) treated in the same therapy program, but without TMZ, were 
selected according to known prognostic factors. A Kaplan-Meier comparison between the 
treatment groups suggested a trend for improved survival in favour for combination-treated 
patients, with a median overall survival of 269 days in combination-treated versus 170 days in non-
TMZ treated control patients (not significant; Study III, Fig. 4). It should be noted, however, that 
patients treated in the ATAP were thereafter allowed to receive other treatments, including other 
oncolytic adenovirus treatments. In fact, 3 out of 17 combination-treated patients and 4 out of 17 
matched control patients were later treated with one or more additional cycles of virotherapy, 
which may have impacted the overall survival. To study whether immune activations would result 
in improved outcome, we studied correlations of immunological parameters to therapy responses. 
While T-cell responses or serum HMGB1 changes failed to correlate with disease control as 
assessed by imaging and/or tumor markers, a correlation between HMGB1 response (increase/ no 
increase post-treatment) and overall survival at median cutoff was observed even in this small 
patient series (P = 0.0119, Fisher’s exact test). In other words, combination-treated patients who 
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experienced serum HMGB1 increase after treatment seemed to have a longer overall survival. We 
postulated that release of HMGB1 into circulation as a consequence of immunogenic cancer cell 
death triggered by combination therapy, could lead to activation of antitumor immunity as 
suggested by antitumor T-cell inductions observed in blood, which in turn would be reflected into 
long-term overall survival. However, these preliminary data were regarded as hypothesis forming, 
and lead us to investigate the role of serum HMGB1 in detail in study IV.   
 
To conclude, our results demonstrate the safety of the combination treatment with oncolytic 
adenoviruses, low-dose TMZ and low-dose CP in cancer patients. Adverse reaction profile and liver 
enzyme elevations suggested that the low-dose TMZ pulse is optimally administered after the virus 
treatment. In addition, we provide important insights into mechanistic and immunological effects 
of the combination. Our findings are corroborated by earlier reports, suggesting that both agents, 
TMZ and oncolytic adenoviruses alone, can induce autophagy and immunogenic cell death 
preclinically (Kanzawa et al. 2004, Ulasov et al. 2009, Jiang et al. 2011, Diaconu et al. 2012). 
Interestingly, one study has also reported on combination of another adenoviral approach, called 
suicide gene therapy, together with TMZ and radiotherapy in the treatment of glioma in vivo 
(Curtin et al. 2009). The authors found that combination therapy as well as monotherapies 
resulted in HMGB1 release, and that HMGB1 binding to TLR-2 receptor on dendritic cells, as an 
endogenous danger signal, mediated effective antitumor immune responses. These results are 
compatible with our findings, and suggest further benefit by including also radiotherapy, which 
was under investigation in our study I. As an extension to the preclinical data, we report for the 
first time, evidence of the autophagy and immunogenic HMGB1 release after the combination 
therapy in patients, possibly in conjunction with the observed antitumor T-cell activations. In 
summary, autophagy induction and HMGB1 release together with signs of antitumor efficacy in 
both preclinical and clinical therapy setting indicates analogous effects at bench and patients’ 
bedside. Adding the good safety and antitumor T-cell activity observed in patients, our 
translational findings encourage for clinical trials using oncolytic adenoviruses in combination with 
low-dose TMZ and CP.  
 
 
4.4 Serum High-mobility group box 1 (HMGB1) protein is a predictive and 
prognostic biomarker for oncolytic immunotherapy in cancer patients 
 
Emerging preclinical and clinical evidence by us and others suggest that extracellular HMGB1 
protein plays a central role in both immunosuppression and immune activation, the former being 
relevant for tumor progression and the latter dominating in therapeutic setting. HMGB1 is a 
nuclear chromatin protein and a key cytokine in local inflammation. Under autophagic or necrotic 
cell death, HMGB1 is released from dying cells, acting as a damage-associated molecular pattern 
(DAMP) molecule that, in conjunction with other DAMP signals, stimulate dendritic cells and 
increase antigen-presentation (Apetoh et al. 2008, Martins et al. 2012, Guo et al. 2013). However, 
HMGB1 is also actively secreted by monocytes, macrophages and dendritic cells, and this chronic 
production has been linked to carcinogenesis, tumor progression and immunosuppression through 
chronic inflammation (Liu et al. 2011b, Kang et al. 2013, Li et al. 2013b). In study III, we observed a 
preliminary correlation between post-treatment HMGB1 surge in serum and survival, a tantalizing 
finding given that no specific prognostic or predictive biomarkers for oncolytic viruses exist. In fact, 
there is an urgent need for biomarkers for immunotherapy since it would facilitate planning of 
clinical trials and selecting the right patients for each therapy. 
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These aspects encouraged us to investigate the role of circulating HMGB1 in oncolytic 
immunotherapy in more detail. Given the two opposing roles of extracellular HMGB1, we 
hypothesized that serum HMGB1 level is an indicator of immunosurveillance status: High baseline 
values would indicate prior immunological detection of the tumor, which has subsequently 
resulted in local immunosuppression reflected by the chronic production of HMGB1. In contrast, 
low baseline levels coupled with HMGB1 surge after therapy could indicate lack of extensive 
baseline immunosuppression and therapeutic responses, representing immunologically naïve 
tumors that would be susceptible to immunogenic immunotherapy. We studied the role of serum 
HMGB1 in a large cohort of 202 cancer patients treated with oncolytic adenoviruses in the context 
of the ATAP. In order to rigorously assess the prognostic and predictive value of HMGB1, we 
considered possible confounding factors in multivariate analyses and performed additional 
correlative analyses to study the biological impact of serum HMGB1 status. Our clinical-
epidemiological report sets the stage for, and helps in planning of, prospective biomarker studies 
and may eventually help in selecting the right patients for each therapy, thus sparing costs and 
human suffering. 
 
4.4.1 Serum HMGB1 baseline levels, patient characteristics and treatments 
 
The study population consisted of 202 patients with advanced solid tumors progressing after 
conventional therapies, who had available baseline serum samples for assessment of HMGB1 
concentration by ELISA. Since normal physiological range of serum HMGB1 levels are unknown for 
advanced cancer patients, we used the overall median concentration at baseline (0.512 ng/mL) as 
a cutoff for dividing patients into low and high HMGB1-baseline groups. With regards to HMGB1 
change, as assessed by subtracting individual baseline level from post-treatment values (total n = 
172), patients experiencing HMGB1 increase, or surge, after treatment were considered as 
responders and otherwise deemed as non-responders. Our multivariate analyses focused on the 
HMGB1-baseline comparison where significant differences in therapy outcome were seen, and 
thus the HMGB1 change is discussed later and more shortly. Patient characteristics of the HMGB1 
baseline groups were evenly distributed with regards to gender, age, tumor type and previous 
therapies (Study IV, Table 1). Patients were heavily pretreated with a median of 1 previous surgery 
and 3 chemotherapy regimens in both groups. The most common tumor types included colorectal, 
breast, pancreatic and ovarian cancer. Only WHO performance status at baseline showed mild 
discrepancy, with six more WHO performance score 3 (poor performance) patients in the high-
baseline group (not significant), which was taken into account, similar to all other possible 
confounding factors, later in multivariate analyses. Of note, all five pediatric patients had low 
HMGB1 baselines (average of 0.382 ng/mL +/- 0.049 [SEM]). This is well in accord with our 
hypothesis, because pediatric tumors often develop more rapidly than adult tumors, and thus may 
feature less prior immunosurveillance, evasion and suppression (Vakkila et al. 2006).  
 
Similar to patient demographics, the first oncolytic adenovirus treatments given to 202 cancer 
patients were well-balanced between the HMGB1-baseline groups (Study IV, Table 2). Most of the 
treatments featured adenoviruses armed with immunostimulatory transgenes, i.e. granulocyte-
macrophage colony stimulating factor (GMCSF) or CD40-ligand (CD40L) (Koski et al. 2010, Pesonen 
et al. 2012). Low-dose CP, used for the selective reduction of immunosuppressive regulatory T-
cells (Cerullo et al. 2011), and low-dose TMZ, intended to increase immunogenicity of the 
treatments (study III), were used in 66% and 13% of treatments overall, respectively. Virus types 
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were evenly distributed, while concomitant low-dose CP, serial treatment and intratumoral 
administration were slightly more frequent in the high-baseline group (none significantly), all of 
which were again later taken into account as possible confounding factors. It is important to note 
that HMGB1 baseline level was unknown at the time of treatment decision and follow-up, 
rendering clinical decision making and radiological response evaluation in our experimental setting 
unbiased. Furthermore, since none of the relevant characteristics or treatments correlated with 
the retrospectively analyzed HMGB1 status, we conclude that clinical aspects did not influence the 
biomarker findings in study IV. 
 
4.4.2 Independent prognostic and predictive value of HMGB1 baseline status 
 
Serum HMGB1 concentration at baseline showed an inverse correlation to overall survival (Study 
IV, Fig. 1A). When survival was examined using the median HMGB1 concentration as a cutoff, 
overall survival in the low HMGB1-baseline group was 151 days at median (95% CI 120 – 181 days), 
and in the high HMGB1-baseline group 102 days at median (95% CI 89 – 115 days), a significant 
difference as assessed by Log-Rank test (P = 0.008; Study IV, Fig. 1B). We next studied the 
radiological tumor responses of all 50 and 65 evaluable cases in the high and low HMGB1-baseline 
groups, respectively, and noticed a corresponding correlation: disease control (disease stabilization 
or better in previously progressing patients) was achieved in 49.2% of patient treatments in the 
low HMGB1-baseline group, whereas only 30.0% showed disease control in the high HMGB1-
baseline group (P = 0.038, chi-squared test). Moreover, 18.5% of evaluable patients in the low-
baseline group experienced tumor regression (minor response or better), including 6 complete 
responses, while none of the high-baseline patients had complete response and only 8.0% showed 
tumor regression (Study IV, Table 2).  
 
Outcome variables, especially overall survival, are influenced by a number of prognostic and 
predictive factors that, if not adjusted for, can adversely affect the relation between the 
independent variable and the dependent outcome variable. Therefore we adjusted our findings for 
known confounding factors in two adequate multivariate models, Cox proportional hazards model 
for overall survival, and logistic regression model for radiological disease control. Importantly, both 
observations held in multivariate analyses (Study IV, Table 3): First, the prognostic value (overall 
survival) of the baseline HMGB1 status remained significant in the Cox model (P = 0.006), and 
second, the HMGB1 baseline status emerged as the only independent predictive factor for disease 
control in the logistic regression model (P = 0.049). With regards to prognostic impact of the 
HMGB1-baseline status, the hazard ratio (HR) was 0.638 (95% confidence interval at 0.462-0.881) 
and the adjusted survival and hazard functions appeared even more separated (Study IV, Suppl. 
Fig. S1A-B). Meanwhile in the logistic regression model, the odds ratio (OR) for predicting disease 
control by HMGB1-baseline status was 2.618 (95% confidence interval at 1.004-6.827). Overall, our 
logistic regression model showed fair to good predictive power, i.e. sensitivity and specificity, as 
suggested by the area under the receiver operating characteristic (ROC) curve value of 0.776 (+/- 
0.043 SE; Study IV, Suppl. Fig. S1C). 
 
With regard to prognostic factors, WHO performance status and tumor type were expectedly 
identified as other independent prognostic factors, whereas the third additional significant factor 
that emerged was less obvious: treatment with oncolytic adenovirus armed with GMCSF. This 
observation is in line with our previous reports suggesting that patients with GMCSF-susceptible 
tumor types may benefit from oncolytic immunotherapy with GMCSF-armed adenoviruses. In fact, 
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several clinical trials with GMCSF-armed oncolytic viruses are ongoing, and the first positive phase 
3 trial results in the Western countries were recently reported with an oncolytic herpes simplex 
virus coding for GMCSF. 
 
Considering predictive factors, the strong impact of the HMGB1-baseline status in predicting 
therapy outcome is underlined by the fact that even WHO performance status, which is considered 
as one of the most important parameters for clinical decision making in oncology (Ando et al. 
2001), failed to reach statistical significance in this analysis (P = 0.055). Oncologists use the 
performance scores in planning anticancer treatments and selecting doses. Classically, physical 
condition/activity of the patient is considered to reflect the stamina to withstand heavy 
chemotherapeutic, surgical or radiotherapeutic regimens aimed at direct cell killing and reduction 
of tumor burden, thus predicting also responses to conventional therapies (Ando et al. 2001). In 
contrast, as the lack of clinically relevant predictive factors for cancer immunotherapy suggests, 
this is not directly applicable, or at least sufficient, in predicting responsiveness to immunotherapy, 
where patient’s own immune system is ultimately responsible for antitumor responses. Hence, 
regarding the sole significance of the baseline HMGB1 as a predictive factor, these aspects may 
further increase the impact and potential clinical relevance of our finding. Considering that the 
WHO performance status did not correlate with HMGB1 status, these two parameters do not 
appear mutually exclusive and could in theory be utilized in parallel in planning of 
immunotherapeutic regimens for each patient. In summary, serum HMGB1 baseline status proved 
to be an independent prognostic and a tentative predictive biomarker for oncolytic 
immunotherapy, and it was the most strongly predictive factor of treatment efficacy.  
 
4.4.3 Safety assessment and comparison between the patient cohorts  
 
In study III, we specifically studied safety profile of the combination therapy using oncolytic 
adenoviruses, low-dose TMZ, and low-dose CP (see above), whereas in study IV, we studied overall 
safety of the first oncolytic adenovirus treatments given to a large cohort of cancer patients with 
or without concomitant therapies; Here we wanted to examine whether the safety profile differs 
between the HMGB1-low and HMGB1-high cancer patients, given their differential responsiveness 
to the therapy. In theory, poor therapy outcome could be due to premature therapy 
discontinuation after encountered adverse reactions. This was not the case, however, as oncolytic 
immunotherapy was equally well-tolerated in both groups (Study IV, Suppl. Table S1), and the 
adverse reaction profiles (most commonly grade 1–2 fever, fatigue, pain, transient anemia and 
electrolyte disturbances) were in line with previous reports (Koski et al. 2010, Cerullo et al. 2011, 
Pesonen et al. 2012). Most adverse reactions were self-limiting, however, 11 and 9 treatments in 
low and high HMGB1 groups, respectively, were associated with grade 2-4 serious adverse event 
(SAE) leading to patient hospitalization (Study IV, Suppl. Table S1). To conclude, the adverse 
reaction profiles did not differ between the HMGB1 groups, and therefore frequent therapy 
discontinuation in high baseline group seemed unlikely.  
 
Safety of the oncolytic immunotherapy, with or without low-dose TMZ and CP, reported in studies 
III and IV was good throughout. In an attempt to compare between studies/groups, frequencies of 
ARs by grades in different patient cohorts are summarized in Table 4. Mild to moderate clinical 
grade 1 and 2 ARs were encountered both at a median of 2 per treatment in study IV, and all but 
one patient out of total 202 patients experienced one or more clinical AR. Meanwhile in study III, 
clinical grade 1 ARs were slightly more frequent (median of 3 per treatment), whereas the grade 2 
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ARs in turn were slightly less frequent (median of 1). Importantly, there were no treatment related 
deaths (grade 5), and only one grade 4 clinical AR emerged: pulmonary embolism was diagnosed in 
a colon carcinoma patient that led to patient hospitalization and was thus classified as a serious 
adverse reaction (SAE, see below). Thus, the frequency of symptomatic clinical ARs did not 
significantly differ between treatment regimens or any patient groups, and treatments appeared 
well-tolerated overall. 
 
Table 4. Adverse reactions (AR) after oncolytic immunotherapy in studies III-IV. 
Of note, there were 5 patient treatments that were included both in study III and in study IV (4 in 
high and 1 in low HMGB1 group), which were thus counted only once in the total number of 
treatments, resulting in total N = 238. Adverse reactions (ARs) were reported according to 
Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria, and the follow-up time for 
ARs in both studies was 28 days after the virus treatment. Pre-existing symptoms were recorded 
only if worsened, and in these cases were scored according to final severity.
 
†
 In order to reliably compare laboratory ARs between the groups, the TMZ-combined treatments 
of study III are also shown here without taking lymphocytopenia into account. Same applies to the 
Total % of the laboratory ARs. 
‡ 
ARs were classified as potentially treatment-related serious adverse reactions leading to patient 
hospitalization, malformation, life-threatening condition, or death (any of these constituting a 
“serious adverse event, SAE”), or not. 
 
 
Interestingly with regards to laboratory ARs, when lymphocytopenia was retrospectively omitted 
from AR analysis of study III, as suggested by accumulating evidence (see above), the laboratory AR 
profile still showed more mild to moderate (grade 1 and 2) ARs in study III than in study IV (P < 
0.001 and P < 0.05, respectively; see Table 4). In contrast, grade 3–4 laboratory ARs were 
explained by the transient lymphocytopenia. One explanation for the more frequent grade 1–2 
laboratory ARs could be the liver transaminase increases, commonly seen in the study III subgroup 
that received TMZ before the virus. Liver enzyme elevations were indeed slightly more frequent in 
study III than in study IV overall (39% versus 32%, not significant), while even more so as compared 
to low HMGB1-baseline patients of study IV (39% versus 25%, P = 0.096; all chi-squared tests). The 
 Study N Cohort Gr.1 Gr.2 Gr.3 Gr.4 Gr.5 
Clinical AR III 41 TMZ-combined (%) 93 83 7 0 0 
 IV 101 Low HMGB1 (%) 89 83 12 1 0 
 IV 101 High HMGB1 (%) 93 89 14 0 0 
         
 III-IV 238 Total (%) 91 86 11 0 0 
Laboratory AR III 41 TMZ-combined (%) 88 71 49 2 0 
 III 41 TMZ-comb. (%), no lymph.
†
 88 56 15 0 0 
 IV 101 Low HMGB1 (%) 48 30 11 4 0 
 IV 101 High HMGB1 (%) 58 43 15 1 0 
         
 III-IV 238 Total (%)
†
 59 39 13 2 0 
Serious ARs
‡
 III 41 TMZ-combined  (n) 0 0 1 0 0 
 IV 101 Low HMGB1 (n) 0 0 10 1 0 
 IV 101 High HMGB1 (n) 0 1 7 1 0 
         
 III-IV 238 Total (n) 0 1 18 2 0 
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laboratory ARs in study III were nevertheless asymptomatic or alleviated by outpatient care, as 
only one serious adverse reaction leading to hospitalization occurred (grade 3 ileus). 
 
In clinical cancer research as well as in oncology practice, serious adverse reactions deserve special 
attention since these may constitute clinical or laboratory conditions potentially hazardous for 
patients. As a commonly used definition, serious adverse event (SAE) was defined as a potentially 
treatment-related serious adverse reaction leading to patient hospitalization, malformation, life-
threatening condition, or death. Including safety data from studies III and IV, SAE was reported 
after 8,0% of all 238 treatments (two treatments resulted in two separate SAE reports), with 
altogether 21 SAE reports of grades 2–4 (see Table 4). One marginally more common SAE was 
grade 3 dyspnea. At least in 2 out of 3 occasions it was associated with pleural effusion, and might 
have been due to accumulation of effusion either caused by virus activity in lung/pleural lesions or 
because of tumor progression. Notably, close to a third (6 out of 21) of SAE reports were due to 
grade 3 ileus. These possibly treatment related SAEs might have been caused by virus-induced 
inflammation in cancer lesions residing on the gut lining, resulting in gut distension and paralysis, 
which is supported by the fact that 4/6 were ovarian carcinoma and 1/6 was a cholangiocarcinoma 
patient, both of which typically feature disseminated intraperitoneal diseases in advanced stage. 
One of these ovarian carcinoma patients was imaged by CT at 69 days post-treatment (over a 
month after the ileus), and had a minor response of 12% reduction in the total tumor diameters. 
She also experienced a 25% decrease in tumor markers (Ca12-5), also scored as a minor response. 
Moreover, circulating viral genomes (959 VP/ml) of the treatment virus Ad5/3-cox2L-∆24 were 
detected in serum at day 4 post-treatment, suggestive of virus replication. These observations 
support the previous hypothesis that ileus may in fact relate to the replicative and inflammatory 
effects of the adenovirus, and should be taken into consideration when planning treatments and 
clinical trials for patients with peritoneally disseminated disease.  
 
Of note, our analyses in study IV only included safety assessments done after the first oncolytic 
adenovirus treatment, and thus the impact of possible consecutive treatments on patient safety 
cannot be evaluated here. However, as previously reported and supported in study III, mounting of 
antiviral immune responses and induction of neutralizing antibodies is often observed soon after 
the first treatment, which are expected to protect the patient from inflammatory ARs of the 
consecutive treatments.  
 
4.4.4 Correlative analyses of potential mechanistic factors 
 
Another clinical variable besides ARs, which could account for the observed HMGB1 baseline 
status, was tumor burden at baseline, because tumor cells and the associated immune cells are 
regarded as the dominant source of HMGB1. In fact, we showed with available samples that 
HMGB1 levels in serum seemed to correlate with tumor-associated ascites/pleural effusion 
HMGB1 levels (Study IV, Fig. 1C). Thus, we speculated that the quantity of tumor cells releasing, 
and the amount of associated immune cells actively secreting HMGB1, might dictate the baseline 
HMGB1 level in serum. To address this, we studied the patient’s tumor burden at baseline (pre-
treatment whole-body imaging) and correlated the data with serum HMGB1-baseline levels. 55 
patients from low and 40 from high baseline group were evaluable for assessment of tumor load 
correlation: The median tumor load score was 6 in both low and high HMGB1 groups (possible 
range: 0-21), with no statistical difference and lack of linear correlation (Study IV, Suppl. Fig. S4), 
indicating that serum HMGB1 levels are not directly dependent on tumor burden. Interestingly, 
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however, when only very high tumor loads (score >10) were studied, a significant linear correlation 
was observed (r
2
=0.8662, P < 0.0001). Reason behind this correlation might be that very large, 
typically necrotic tumors are associated with rapid tumor cell turn-over. Alternatively, although 
not mutually exclusively, large bulky tumors often represent highly evolved immunosuppressive 
environments featuring lots of immune cells chronically producing HMGB1. Interestingly, when we 
further looked at the disease distribution pattern, presence of pleural/ascites effusion was 
observed significantly more frequently in low (27.3%) as compared to high HMGB1 baseline 
patients (10.0%) (P = 0.038, chi-squared test). When examined in more detail, none of the low 
HMGB1 patients with effusion (n = 15) had large tumor burden (median score of 6), while 3 out of 
4 high HMGB1-baseline patients who had effusion, showed very high tumor loads (median score of 
12.5). Hence, we postulated that large bulky tumor masses, as opposed to disseminated 
peritoneal/pleural disease, would be more prone to develop a highly evolved immunosuppressive 
tumor microenvironment, characterized by chronic HMGB1 production. Alternatively, these 
tumors might feature vast necrotic areas as a source of continuous HMGB1 shedding (Scaffidi et al. 
2002). Finally, the amount of tumor-associated immunosuppressive cells, mediating also chronic 
production of HMGB1, has been identified as an independent prognostic factor (Tanchot et al. 
2013), and may not directly depend on the tumor size. Tumor biopsies would have been required 
to assess this. 
 
We further studied correlations of HMGB1-baseline status with relevant biological variables, such 
as classical virotherapy parameter virus replication: Circulating adenovirus genomes did not 
present greater virus replication in the low HMGB1-baseline patients, as could be expected for 
improved outcome. In fact, even a slight opposite trend towards higher replication in the high 
HMGB1-baseline group was noted. Nevertheless, a similar transient increase was observed in both 
groups after treatment, suggesting equal replication capacity in both patient groups (Study IV, 
Suppl. Fig. S2). Second, we studied inflammatory cytokines that may relate to antiviral immunity, 
antitumor immune activation, and immunosuppression as well. We used a panel of five relevant 
anti- and pro-inflammatory cytokines, IL-6, IL-8, IL-10, TNF-α, and GMCSF that was also used as a 
transgene in majority of the virus treatments: No significant differences between the HMGB1 
groups emerged, but interestingly, HMGB1-high group showed a trend for higher total amount of 
IL-6 (Study IV, Suppl. Fig. S3). In addition to this, HMGB1-high patients presented a trend for 
higher increase in post-treatment GMCSF levels. Overall trends toward acute phase increase in IL-6 
and a late increase in TNF-α were observed in both groups.  
 
Our correlative analyses did not reveal mechanistic links to classical virotherapy parameters. There 
was, however, slight variation between the groups: high HMGB1-baseline patients showed a trend 
for higher virus replication, GMCSF production and acute phase IL-6 production, while featuring 
the highest tumor loads (score >10) that linearly correlated with increasing HMGB1 levels. These 
parameters may be connected because large bulky tumors that can be intratumorally injected, are 
optimal grounds for initial virus replication, coupled with efficient transgene expression (GMCSF), 
and antiviral cytokine response (IL-6). As discussed, however, these tumors also feature extensive 
immunosuppression, limiting their responsiveness. As a potential sign of this, the total amount of 
IL-6 was greater in the high-HMGB1 patients, which has been linked to advanced 
immunosuppressed tumors, and poor outcome after immunotherapy, mediated for example via 
chronic Stat3 activation (Burdelya et al. 2005, Zarogoulidis et al. 2013). 
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4.4.5 Evidence of immunological mechanisms underlying the HMGB1 status 
 
We hypothesized that HMGB1 baseline level could distinguish between immunologically naïve 
responding patients and immunologically inert/suppressed non-responding individuals. Therefore, 
we analyzed antitumor T-cell activity in peripheral blood of 129 evaluable patients, and correlated 
the data with outcome variables and HMGB1 status. 49,6% of patients in total featured antitumor 
T-cell inductions, and the frequency was similar in both HMGB1-baseline groups, suggesting that 
the amount of T-cell inductions after oncolytic immunotherapy is not altered. However, when T-
cell data was correlated to survival inside the HMGB1-groups, only the patients with low-HMGB1 
baseline seemed to benefit from T-cell activations (Study IV, Fig. 2): The median survival of low-
HMGB1 patients who featured T-cell inductions was 221 days (95% CI 113 – 329 days) versus 111 
days (95% CI 101 – 121 days) in the high-HMGB1 group with T-cell inductions (not significant). 
Moreover, when also a decrease in antitumor T-cell counts, which is compatible with trafficking of 
T-cells from blood into tumors, was studied together with T-cell inductions, low-HMGB1 patients 
showed significantly improved survival over high-HMGB1 patients (P = 0.043), and importantly, 
over the remaining low-HMGB1 patients (P = 0.038).  
 
Next, we assessed the more specific endpoint for therapy responsiveness, radiological responses. 
Again, we observed that in patients with T-cell induction, low-HMGB1 group showed a trend for 
further increased disease control rate over high-HMGB1 group (55.0% versus 27.3%; P = 0.068), 
and when trafficking was taken into account, a significantly improved response rate was observed 
(66.7% versus 20.0%; P = 0.040). Thus, we have identified the most immunologically active, best-
responding subgroup, using HMGB1 and T-cell analyses: This subgroup features low-HMGB1 
baseline levels, responds to oncolytic immunotherapy by showing induction and trafficking of 
antitumor T-cells in blood, and results in highest rate of objective signs of possible efficacy, both in 
tumor imaging and survival.  
 
In addition to T-cell data, also the aforementioned trend for higher total IL-6 levels in the high-
HMGB1 patients fits together with the proposed immunosuppression. Moreover, virus arming with 
the GMCSF cytokine, which has proven as a useful immunostimulatory adjuvant especially in the 
context of oncolytic viruses (Andtbacka et al. 2013), was observed to mediate the best signs of 
therapeutic efficacy in the low-HMGB1 patients (Study IV, Fig. 3): While the median survival was 
nearly doubled in the low-HMGB1 group over the high-HMGB1 patients (P = 0.004), the most 
notable improvement was seen in the long-term survival, which is well in line with the proposed 
immunological response profile, reported for other immunotherapeutic agents as well (Hodi et al. 
2010, Hoos et al. 2010).  
 
4.4.6 Post-treatment changes in serum HMGB1 and outcome parameters 
 
Chronic production of HMGB1 by immune cells mediates several immunosuppressive actions (Liu 
et al. 2011b, Li et al. 2013a, Li et al. 2013b), whereas its acute release from immunogenically dying 
tumor cells is essential for immune activation (Scaffidi et al. 2002, Apetoh et al. 2007, Guo et al. 
2014). Therefore, we hypothesized that these phenomena might have different circulation 
kinetics, and analyzed post-treatment serum HMGB1 levels, subtracted the individual baseline 
values, and correlated the data with outcome variables. Surprisingly, however, post-treatment 
HMGB1 increase in serum did not associate with improved outcome at any given time point after 
therapy (Study IV, Suppl. Fig. S5). On the contrary, late time point increase in HMGB1 (at 15 – 28 
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days post-treatment) trended towards shorter median survival (138 days versus 212 days in “no 
increase” group; not significant). Interestingly, this trend was due to low HMGB1-baseline patients, 
since HMGB1 elevation trended towards poor prognosis only in this baseline group (P = 0.098). 
Therefore, the low-baseline patients who maintained the low serum levels of HMGB1, especially at 
late time points after treatment, seemed to survive the longest. Accordingly with regards to 
treatment efficacy, the sustained low-HMGB1 patients showed an impressive disease control rate 
of 66.7% (2 complete responses, 1 partial response, 1 minor response, 6 stable diseases, and 5 
progressive diseases), a much higher rate than in high-baseline patients (30.0%, P = 0.011) or in 
high-baseline patients with HMGB1 decrease post-treatment (26.1%, P = 0.013), but did not reach 
statistical significance as compared to low-baseline patients with HMGB1 increase post-treatment 
(43.9%, P = 0.131). These findings suggest that sustained low serum levels of HMGB1 associate 
with treatment benefits, but perhaps due to lack of multiple post-treatment samples and 
heterogeneity in treatments, predictive conclusions could not be drawn here.  
 
These results are rather surprising given the preclinically well-established role of HMGB1 as an 
immunogenic DAMP molecule, also in the context of oncolytic viruses (Guo et al. 2014). Even 
though we observed an association between tumor-related ascites/pleural effusion and serum 
HMGB1, the absolute levels were constantly higher locally. Thus, it might be that a transient local 
release of HMGB1 is sufficient in activating dendritic cells – a spatiotemporal phenomenon that 
could not be recorded in serum, but only at the tumor site. The observed trend for poor outcome 
in patients with late time point HMGB1 elevation, on the other hand, could indicate harmful 
immunosuppression emerging. It should be noted that immunogenic cell death is mediated in 
conjunction with other DAMP signals as well (Guo et al. 2014), particularly calreticulin exposure 
and ATP release, that were not studied here. In contrast, our results in study III and previous data 
suggest that oncolytic adenoviruses, with or without low-dose chemotherapy, can induce 
immunogenic cell death (Diaconu et al. 2012). In study III, calreticulin exposure was observed at 24 
h post-treatment, followed by ATP and HMGB1 release at 36 h post-treatment, while in study by 
Diaconu et al. using CD40-L coding oncolytic adenovirus, calreticulin, ATP, and HMGB1 were 
observed at 12 h, 18 h, and 24 h post-treatment, respectively. This suggests that dynamics of 
immunogenic cell death depend on the treatment agent and cell type, further complicating 
assessment in vivo, let alone in human biopsies. Nevertheless, the pivotal role of HMGB1 is 
important to take into account when designing novel treatments and biomarkers. 
 
4.4.7 Potential clinical relevance of the biomarker 
 
Effective responses seen after cancer immunotherapy, while often durable in nature due to 
immunological memory, can take time to mount and remain difficult to foresee, which complicates 
selection of appropriate immune-based treatments for each patient and slows down the progress 
in clinical trials. Therefore predictive biomarkers are urgently needed for cancer immunotherapy 
that would optimally, not only indicate biological activity of the drug, but also discriminate 
between immunologically responding and non-responding patients for each immunotherapeutic 
application. Good examples of the latter are immune checkpoint modulating antibodies that 
directly act on the immune system: programmed death-1 (PD-1) pathway, among others, mediates 
tumor-induced immunosuppression and monoclonal antibodies against PD-1 receptor or its 
ligands, such as nivolumab, are showing promise in the treatment of e.g. melanoma, lung, and 
renal cancer. Importantly, clinical data suggests that only patients with PD-L1-positive tumors 
seem to respond to antibody treatment, although warranting for confirmation in prospective 
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biomarker trials (McDermott and Atkins 2013). This would be logical since these patients feature 
strong PD-1 mediated immunosuppression that could be combated by pathway blocking 
antibodies releasing the specific breaks of the immune system.  
 
For immunogenic immunotherapy, aimed at inducing antitumor immune responses rather than 
releasing the existing suppressive breaks, however, no such predictive biomarkers exist yet. Tumor 
lytic adenoviruses belong to this class, by featuring a strong immunostimulatory anticancer 
component via release of danger signals and tumor-associated antigens, which can be further 
boosted by immunogenic transgenes and/or adjuvant therapies. Interestingly, a very recent phase 
II randomized multicenter immunotherapy trial using chemotherapy together with or without 
oncolytic reovirus for the treatment of relapsed or metastatic pancreatic cancer failed meet its 
main endpoint of progression-free survival (PFS) in the total patient population, but instead 
showed a trend for improved PFS (39% increase in median PFS) in a sub-analysis where only KRAS-
mutated patients were included (ClinicalTrials.gov Identifier: NCT01280058). Importantly, this 
subgroup analysis was based on previous preclinical and clinical reports suggesting that the 
oncolytic reovirus was mostly active in cancer cells with an activated RAS pathway (Thirukkumaran 
and Morris 2009). This predefined biomarker assessment was thus implied to have a major clinical 
significance, suggesting therapeutic benefit only in a subtype of pancreatic cancer, although the 
overall survival data remains to be seen. Unlike the optimal biomarker arsenal, however, the KRAS-
mutation status as studied here only seems to predict biological activity of the drug (virus 
replication), thus ignoring the immunological aspects of the patient and tumor.  
 
Closer to this end, a smaller pilot study focusing on oncolytic vaccinia virus treated melanoma 
patients recently investigated potential immunological biomarkers by gene expression analyses on 
peripheral blood T-cells. The authors identified immunoglobulin-like transcript 2 (ILT2) expression 
on immunosuppressive subset of CD8+ T-cells (CD8+FoxP3+ILT2+) as a candidate predictive 
biomarker of vaccinia virus immunotherapy outcome. Although not as straightforward to assess as 
serum HMGB1 and pending for further validation in large-scale studies, these findings are 
compatible with our results: In both studies, the overall frequency of (activated) CD8+ T-cells did 
not differ between responders and non-responders, but the antitumor T-cell activity reflected to 
improved outcome only in patients with low HMGB1 baseline, and the same was observed in 
vaccinia virus treated patients with low immunosuppressive CD8+FoxP3+ILT2+ T-cell population. It 
would be interesting to assess if these observations are connected by studying suppressive ILT2-
positive T-cell populations in our patient series, and vice versa.  
 
In a previous report by our group we studied if germline differences in the immunological 
mechanisms of patients, in particular, single nucleotide polymorphisms in Fc gamma receptors 
(FcgRs), could predict survival or disease control after oncolytic immunotherapy (Hirvinen et al. 
2013). In that study we focused on FcgRs because of their central role in the immune defense 
against infections and potential impact on cancer therapy (van Sorge et al. 2003, Mellor et al. 
2013). Blood samples of 235 patients treated with oncolytic viruses in the context of the ATAP 
were studied, with the Ethics Committee approval because receptor polymorphisms might also 
impact safety or efficacy of the treatments, and genotyped for two different Fc gamma receptor 
polymorphisms, FcgRIIa-H131R and FcgRIIIa-V158F. Comparisons between allotypes revealed that 
one particular genotype combination, FcgRIIIa-VV + FcgRIIa-HR, differed from others and was 
predictive of poor overall survival after virotherapy, but since only 10 patients carried this 
genotype, multivariate and further correlative analyses could not be performed. Nevertheless, our 
results suggested that genotypic differences in immunological charateristics may also have some 
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impact on the responsiveness to oncolytic immunotherapy, although predictive significance of 
FcgR polymorphisms remained to be evaluated. 
 
In study IV, we have extended our attempt in identifying patients that possibly benefit from 
oncolytic immunotherapy. We have identified serum HMGB1 protein as an independent 
prognostic and predictive biomarker for oncolytic immunotherapy that may potentially 
discriminate between immunologically responding and non-responding patients. It would be 
interesting to study some of the aforementioned putative predictive factors together with our 
findings. In theory, this could further increase the sensitivity and specificity, similar to what we saw 
with regards to predictive impact of antitumor T-cell activations. Potentially, our findings could 
also apply to other immunogenic immunotherapy approaches including other oncolytic viruses, 
adoptive T-cell therapy, and cancer vaccines. Further mechanistic and prospective clinical studies 
using predefined levels of HMGB1 as a putative biomarker are warranted. Identifying novel 
predictive factors for emerging cancer immunotherapies is crucial not only for the individual 
patient benefit, but also to improve cost-effectiveness of these often expensive therapies 
(Geynisman et al. 2014). Ultimately, our results may help in selecting the right patients for each 
therapy, thus reducing costs and human suffering. 
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5. CONCLUSIONS AND FUTURE PROSPECTS 
 
Cancer immunotherapy has recently provided several success stories, and is gradually meeting its 
expectations as a potent form of cancer therapy. CTLA-4 blocking antibody ipilimumab was shown 
to mediate durable antitumor responses and approved for treatment of metastatic melanoma 
(Hodi et al. 2010, Robert et al. 2011). A therapeutic cancer vaccine Sipuleucel-T was approved for 
treatment of castration-resistant prostate cancer (Kantoff et al. 2010). Anti-CD19 CAR T-cell 
therapy rendered pediatric leukemic patients into remission even after exhausting all other 
treatment options (Grupp et al. 2013). Most recently, oncolytic immunotherapy for treatment of 
metastatic melanoma, using an oncolytic herpes virus coding for GMCSF (T-VEC), met its primary 
endpoint in a phase III clinical trial, and is expected to receive marketing approval in the United 
States (Andtbacka et al. 2013). Owing to these advancements, the field was rightfully selected as 
the breakthrough therapy of the year by a leading scientific journal (Couzin-Frankel 2013).  
 
Despite the evident progress, numerous immunotherapy trials have failed due to low efficacy. 
Cancer is the number one cause of death worldwide and incidence is rising. There are many tumor 
types still lacking curative treatments despite the advancements in conventional therapies. The 
aim of this thesis was to improve efficacy while maintaining favorable safety by combining 
oncolytic immunotherapy with conventional treatment modalities. We found that inherent 
potential of adenoviruses to sensitize infected cancer cells to radiotherapy is mediated by two 
proteins that inhibit DSB repair inhibition, and demonstrate the combination efficacy in vivo. 
Furthermore, we demonstrate that combination therapy of oncolytic adenovirus with low-dose 
TMZ and CP can mediate immunogenic cancer cell death and enhanced tumor regression in mice, 
and was well-tolerated with promising signs of possible efficacy in patients with advanced solid 
tumors, refractory to conventional therapies. 
 
In addition, we aimed to identify acquired resistance mechanisms against oncolytic adenovirus, 
and novel predictive and prognostic biomarkers for oncolytic immunotherapy, which could 
ultimately lead to development of countermeasures, and better patient selection. Cancer entails 
enormous transforming capacity that renders each tumor individual and complicates planning of 
treatments. Nonetheless, also common growth promoting pathways and resistance mechanisms 
have been identified, which has allowed design of counteracting drugs and biomarkers, many of 
which are in clinical use. For immunotherapy in general, and oncolytic viruses in particular, 
predictive biomarkers are urgently needed, since it appears obvious that not all tumors respond to 
a given immunotherapeutic modality. To this end, we first identified a tentative 
immunohistochemical biomarker that correlated with the acquired antiviral phenotype 
preclinically, and provide here preliminary data on potential translation into cancer patients. 
Second, we propose a novel clinical prognostic and predictive biomarker for oncolytic adenoviral 
immunotherapy, which may distinguish between immunologically inert and reactive patients. 
Important for its utility, a simple serum sample could dictate between responsive and non-
responsive cancer patient. 
 
We used several methods in this thesis to study oncolytic immunotherapy, proceeding from bench 
to patients’ bedside. In studies I and II we conducted basic research assessing molecular 
mechanisms behind treatment effects of oncolytic adenoviruses when combined with 
radiotherapy, and studied mouse models of acquired tumor resistance against oncolytic 
virotherapy. In this thesis we provide a translational extension of study II, by assessing the 
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potential antiviral resistance marker in available samples of advanced cancer patients treated with 
oncolytic adenoviruses. Study III was a translational study, addressing the underlying mechanisms 
and efficacy of oncolytic adenovirus with low-dose chemotherapy preclinically, and studying safety 
and possible signs of efficacy and immunological activity in cancer patients with solid tumors 
refractory to conventional treatments. Finally, in study IV, we evaluated the value of a novel 
prognostic and predictive biomarker, serum HMGB1, for oncolytic adenoviral immunotherapy in a 
large cohort of advanced cancer patients.  
 
Both of our clinical-epidemiological reports (III, IV) serve as pilot research for future studies: First, 
they demonstrate safety and possible signs of efficacy of oncolytic adenovirus treatments in a 
heterogeneous group of cancer patients. Second, our reports suggest a feasible treatment 
combination, potential signs of immunological activity, and propose a novel prognostic and 
predictive biomarker. Hence, studies III and IV set the stage for clinical trials in specific groups of 
cancer patients. In particular, the promising combination of oncolytic adenovirus with low-dose 
TMZ and CP, must be evaluated in selected tumor types. On the contrary, serum HMGB1 would be 
expected to serve as a pan-tumoral biomarker, given the proposed immunological mechanism 
behind the predictive value. However, further mechanistic studies and prospective trials are 
warranted to confirm this. 
 
Interestingly, when integrating the results between studies and reflecting them to research 
published by others, several aspects reappear in different contexts. For instance, besides the 
studied DSB repair inhibition (study I), synergy between oncolytic immunotherapy and 
radiotherapy is also mediated via autophagy and immunogenic cell death, which is analogous to 
the observed effects with low-dose temozolomide (study III). Moreover, HMGB1 protein, acting as 
a central cytokine for all lymphoid and innate immune cells, plays a key role in each of our studies: 
it is involved in autophagy and immunogenic cell death triggered by both combinatorial 
approaches (studies I and III), in innate antiviral immunity as an endogenous enhancer of danger-
signaling (study II), and in tumor immunosuppression by activating regulatory T-cells and myeloid-
derived suppressor cells (study IV). In fact, this congruence is beginning to emerge in all platforms 
of immunotherapy, which is an imminent indicator that the field has come of age: Developed far 
from the empirical times of Dr. William Coley, to the concept of immunosurveillance, and gradual 
understanding of the underlying tumor immunology and capacity of the human immune system, 
cancer immunotherapy may finally offer a remarkable addition to the standard care of many 
malignancies.  
 
Nonetheless, many challenges lie ahead to achieve this. One major hurdle in the development of 
immunotherapeutics is the ever increasing costs. Considering an estimation that development of 
an approved drug will take approximately 20 years and cost over half a billion euros, it is not 
surprising that novel immunotherapeutics like ipilimumab and sipuleucel-T cost ninety-five and 
eighty-thousand euros per treatment, respectively (Couzin-Frankel 2013). Since academia is hardly 
to have the resources, collaboration with pharmaceutical companies at an early phase is 
imperative. Alternatively, fund raising or crowdfunding could provide means to proceed with drug 
development. One key element in improving the cost-effectiveness of the expensive cancer 
immunotherapies is to identify predictive biomarkers for better patient selection (Geynisman et al. 
2014), which we have addressed in this thesis as well. The increasing costs raises also ethical and 
socio-economic questions of using expensive therapeutics that sometimes only transiently prolong 
patient survival. Another problem in drug development is the continuously increasing bureaucracy 
and the amount of regulations, which on one hand serve to ascertain scientific rigor, but on the 
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other hand slow down the progress and decrease availability of novel promising treatments. A 
balance between proper administration and urge to fill the unmet medical need should therefore 
be found. The United States Food and Drug Administration (FDA) Fast Track program is a 
refreshing attempt to this direction, which facilitates and prioritizes development of drugs that 
treat serious or life-threatening conditions.  
 
In the near future, immunotherapy is likely to reach standard care in the treatment of many more 
malignancies. With non-overlapping safety profiles combination with conventional treatment 
modalities seems feasible. Oncolytic immunotherapy combined with standard or low-dose 
chemotherapy and radiotherapy holds promise, especially when moving to less 
immunosuppressed earlier patients. Specifically, oncolytic viruses could be utilized in earlier stage 
disease together with surgery, chemo- and radiotherapy, to boost the immune system to detect 
cancer and develop potent immunological memory, thus perhaps preventing many relapses. Along 
with improved diagnostics and personalized treatments, fewer tumors will advance and spread. 
However, occasionally also these highly resistant cases emerge, which could be treated with 
combination of different immunotherapeutics, such oncolytic immunotherapy and checkpoint 
blocking antibodies, that would increase immunogenicity, provide danger signals, and combat 
tumor immunosuppression. As an intriguing preliminary example of this, a very recent phase Ib 
trial using oncolytic T-VEC together with ipilimumab reported durable responses in 10 out of 18 
(56%) evaluable patients, with 33% being complete responses, and no dose-limiting toxicities from 
the combination (Puzanov et al. 2014). Furthermore, along with longer life-spans, more 
immunocompromised patients will develop cancer. In these cases, an optimal combination of 
immunotherapy could be using oncolytic adenoviruses together with adoptive T-cell therapy given 
in specialized centers. Treatment with armed oncolytic adenoviruses would first provide danger-
signals and tumor-antigens, distort the tumor microenvironment, and produce immunostimulatory 
molecules, followed by adoptive T-cell therapy, where patients’ adaptive immune activation occurs 
ex vivo, thus surpassing patients’ weak inherent immunity and creating enough potency to 
eradicate the remaining tumor cells. 
 
The rapidly growing repertoire of targeted cancer treatments and improved methods to 
characterize individual tumors creates prospects for more personalized targeted medicine. Success 
of modern oncology, however, originates from well-designed clinical trials and evidence-based 
medicine, which ultimately either substantiate a given treatment as more beneficial than standard 
therapy, or not. Novel targeted strategies, in particular immunotherapy, must be evaluated with 
the same principles but with adapted criteria, that will take its specific features such as tumor 
swelling, long-term survival statistics, and specific side-effects into account when evaluating 
responses and adverse reactions. Also definitive judgements on utility should be held back until 
these specific characteristics are identified and tested for, which are based on comprehensive 
understanding of the underlying tumor-, virus- and immunobiology, together with human 
physiology and oncology. With regards to immunotherapy, time has come to encompass these 
features, as demonstrated by the vast number of ongoing clinical trials and formed clinical 
consortia. Ultimately, the emerging scientifically-proven immunotherapeutic approaches can 
change the way how we see and treat cancer: hopefully to a more optimistic direction. 
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